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General introduction and outline of the thesis
Giving a patient immunosuppressive medication is creating an environment in which 
a transplanted organ will be accepted and rejection will be prevented. Unfortunately, 
the use of immunosuppression is complicated by serious side effects. After deal-
ing with acute rejection in solid organ transplantation and reducing the incidence of 
infections in the early days of transplantation, other serious complications became 
more and more clear. The development of, for example, cardiovascular disease, 
diabetes mellitus, nephrotoxicity and malignancies after solid organ transplantation is 
a well known problem for every transplant clinician. 
Cardio vascular disease
For many years now, cardiovascular disease is the leading cause of death with a 
functioning graft and the most common cause of transplant failure. 
Many chronic renal disease patients already have a history of cardiovascular disease 
before transplantation and the prevalence of the traditional risk factors for  
cardiovascular complications is high in this patient group (1-2). On top of this,  
patients suffer from non-traditional risk factors related to poor kidney function such 
as altered calcium-phosphate metabolism, hyperparathyroidism, chronic inflam-
mation, anaemia, microalbuminuria, homocysteinemia and volume overload (3-4). 
Moreover, hypertension, diabetes, dyslipidemia, obesity, CMV infection and  
hyperhomocysteinemia are risk factors for cardiovascular disease which are exacer-
bated by the use of immunosuppression after transplantation (5)-(6).
So, the reported mortality rate of cardiovascular disease in patients with end stage 
renal disease (ESRD) is between 10 till 20 times higher then in the general population 
(4, 7). The mortality rate increases with duration of dialysis, but even after transplan-
tation it remains high (4, 7-8). Ojo et al, described in 2006 an annual risk of a fatal 
or non-fatal CVD event of 3.5 to 5% in kidney transplant recipients which is 50-fold 
higher than the general population(9). 
Malignancies
In all reports from different sides of the world, the incidence of almost all tumour 
types, skin and non-skin, is increased after solid organ transplantation compared 
with the general population. Cancer is currently the second or third highest cause 
of death in renal transplant recipients (10-12). Skin cancer is the most commonly 
observed type of de novo malignancy after transplantation with a reversed ratio of 
basal cell carcinoma (BCC) to squamous cell carcinoma (SCC) compared with the 
general population, in which basal cell carcinoma is the most common (13-16). Given 
the relationship between sun exposure and skin malignancies, it is not surprising 
that the incidence of skin malignancies in the Australian and New Zealand transplant 
population is high. Ramsay et al reported a cumulative incidence of skin cancer in the 
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Queensland renal transplant population of 82% after more than 20 years of exposure 
to immunosuppression (17). However, even in areas with less sun exposure, like the 
United Kingdom, the cumulative incidence is still high with numbers of 61%  20 years 
after renal transplantation, while 64% of the patients had multiple lesions(18). Studies 
in the Dutch and Norwegian transplant recipients, both populations with moder-
ate sun exposure, showed that SCC occurred 65-250 times and BCC 10 times as 
frequently as in the general population (19-20) with a high risk of subsequent non-
melanoma skin cancer (21). Sixty-four to 74% of this transplanted patients with non-
melanoma skin cancer had multiple lesions, with a maximum reported cumulative 
number of skin lesions of 50 in one patient. Almost 4% of the patients who  
developed a non-melanoma skin cancer died due to metastatic disease (21).
As with skin cancer, transplanted patients are at elevated risk for almost all de novo 
solid tumor types. Overall, the standardised incidence ratio (SIR), defined as the ratio 
of the observed number of tumors in the transplanted population to the expected 
number of tumors in the general population, matched for age, gender and occurring 
in the same calendar year, is approximately 2.5-4 times higher (22-24). The cumula-
tive risk of developing at least one malignancy (excluding nonmelanoma skin can-
cer) while the graft continued to function reaches 30% after 20 years. The relative 
risk varies by cancer site, with some risk on solid tumor types only moderately and 
others seriously elevated compared with the general population, depending on age, 
gender, race, primary cause of ESKD, racial background, prior malignancy and con-
tinued graft function. This excess relative risk is not constant but is inversely related 
to age: the greatest relative risk is experienced by younger recipients of both sexes. 
For example, an analysis of the Australian and New Zeeland population by Webster 
et al showed us a cancer rate for a 25 year-old female renal transplant recipient 
equivalent to that of a 55 year-old woman in the general population. With increasing 
age, this risk declines towards that experienced by the general population, although 
the risk for developing cancer for recipients over the age of 65 years is still 2-3 times 
above that of the general population(23). This results in a different distribution of ma-
lignancies in the transplanted population compared with the general population, and 
therefore not all existing screening programs are applicable in this patient group. 
The pathogenesis of cancer in organ transplant recipients is complex because of the 
multiple pathogenetic factors in these patients.  
The incidence of cancer increases over time and besides the known risk factors for 
cancer in the general population like age, gender, smoking habits, genetic predispo-
sition, etc., there is interplay of several immunological and non-immunological factors 
after transplantation which increases the cancer risk in this specific population. For 
instance, the overall or cumulative exposure to immunosuppressive agents is closely 
correlated with the cancer risk. The use of immunosuppression disrupts antitumor 
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immunosurveillance and anti viral activity, but some agents promote carcinogenesis 
independent of their immunosuppressive effects (25-28) and/or may potentiate the 
carcinogenic effects of other agents (29). To prevent rejection, transplanted patients 
uses combinations of different immunosuppressive drugs. This makes it is difficult to 
asses the impact on cancer risk of each individual immunosuppressive agent. How-
ever, among non-transplant patients who use one specific immunosuppressive agent 
it has been described that, prednisone increases the risk of developing SCC, BCC, 
Kaposi sarcoma and non-Hodgkin lymphoma (NHL)(30-33). This is not an uniform 
finding: others reported that, in patients with polymyalgia rheumatica and temporal 
arteritis treated with high cumulative doses corticosteroids, this risk on NHL was not 
increased (34). Patients with psoriasis treated with cyclosporine have an increased 
risk on non-melanoma skin cancer (NMSC), especially SCC, as well as NHL(35-37). 
The use of azathioprine in patients with multiple sclerosis and rheumatoid arthritis 
is associated with a progressive rise in their risk on malignancy depending on the 
duration of treatment, although none of these increased risks were statistically signifi-
cant.(38-39). A meta-analysis has demonstrated an increased risk on lymphoma in 
patients with inflammatory bowel disease treated with azathioprine or mercaptopu-
rine(40).  So it seems that immunosuppression per se results in a higher incidence of 
cancer.
An increased susceptibility to (viral) infections after transplantation, also implicates 
an increased risk to some malignancies. Certain viral infections clearly are linked with 
post transplant malignancies, including Epstein Barr virus (EBV) with PTLD(41-42), 
hepatitis B virus and hepatitis C virus with hepatocellular carcinoma (43-45), human 
herpes virus-8 with Kaposi’s sarcoma(46-48) and papillomaviruses with SCC, oro-
pharyngeal carcinoma and cervical cancer(49-51). 
Another possible predisposing factor for developing cancer may be prolonged 
uremic status before transplantation and with graft failure. Chronic uraemia may be 
considered as a state of immunodeficiency. In particular, lymphomas and carcinomas 
of the kidney, bladder, prostate, liver and uterus show an enhanced prevalence in 
patients with impaired renal function, compared with the general population (52-54).
Finally, the chronic antigen stimulation by the transplanted organ, combined with an 
inadequate cytotoxic T cell activity due to the chronic use of immunosuppression, 
may also represent an important cause of the tendency to form malignancies after 
transplantation.
Considering the above observations, minimization of immunosuppression whenever 
possible, as a strategy to reduce the incidence of post transplant malignancies, 
seems to be warranted. This thought is supported by the fact that the risk of de 
novo cancers, which are not related to ESRD, like thyroid, bladder and urinary tract, 
returns to pretransplant levels after graft failure and return to dialysis (55).
14
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Figure 1. 
(Left) Scanning electron micrograph of an afferent arteriole (AA) and glomerular tuft from a 
control animal.
(Right) From a similar animal after 14 d of cyclosporine treatment.
Reprinted from English J, Evan A, Houghton DC, Bennett
WM: Cyclosporine-induced acute renal dysfunction in the rat:
Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44(1): 
135–141, 1987 (reference 29), with permission.
Nephrotoxicity
The clinical introduction of the calcineurin inhibitors (CNI) cyclosporine (CsA) and 
tacrolimus (Tac) has dramatically reduced the incidence of acute rejection and thus 
improved the short time graft survival. However, the long-term results have not 
improved to a similar degree over the last few decades(56). An important contribut-
ing factor of this later observation is CNI induced nephrotoxicity. Nephrotoxicity after 
solid organ transplantation, but also in patients treated with CNIs for autoimmune 
diseases, can be distinguished in an acute and chronic form. The acute form of CNI 
induced nephrotoxicity was first described by Calne et al in the first publications of 
the clinical use of cyclosporine in human renal transplant recipients (57-58), whereas 
prior animal studies had not observed this important side effect (59-61).  Acute 
CNI induced nephrotoxicity may manifest with variable severity and is character-
ised by a rise in serum creatinine levels with or without an oligoanuric syndrome. It 
usually starts several days after the introduction of CNI’s.  Pathophysiologically it is 
characterised by vasoconstriction of the afferent glomerular arteriole, leading to a 
decreased perfusion of the corresponding glomeruli and finally a decrease in glo-
merular filtration rate (GFR)(Figure 1)(62). Non-specific morphological tubular abnor-
malities also characterize acute CsA nephrotoxicity, including giant mitochondria, 
isometric vacuolization and microcalcification. 
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The giant mitochondria tend to predominate in the convoluted section of the proxi-
mal tubule, whereas isometric vacuolization is mainly limited to the thick descending 
limb of the loop of Henle. More severe nephrotoxicity is often associated with arte-
riolopathy, characterised by focal myosite necrosis in the media of small arteries, in 
the absence of intimal changes, or trombotic microangiopathy. These changes are 
not pathognomonic for CNI induced nephrotoxicity, although they are particularly 
frequent in patients treated with CsA or Tac, and can be focal or even absent in the 
presence of clinical nephrotoxicity (63). For most patients, both the morphologic and 
functional changes are rapidly and completely reversible when dose reduction or 
withdrawal of the CNI has taken place (64-66). If not, other causes for renal dysfunc-
tion, like acute rejection, need to be excluded (67).
In 1984, Myers et al, were the first to describe an irreversible renal functional deterio-
ration as a result of the long-term use of cyclosporine in heart transplant recipients, 
called “chronic CNI nephrotoxicity” (68). This chronic CNI induced nephrotoxicity is 
characterised by a slow, progressive decline of renal function, which may progress 
to end stage renal disease, and sometimes mild to moderate proteinuria. In addition 
most patients have hypertension. Later, these nephrotoxic effects of long-term use 
of cyclosporine and tacrolimus were confirmed by many others, and has been seen 
after all types of transplantation (69-72), but also after chronic treatment with CNI for 
auto-immune diseases (73-75). In 2003. Nankivell et al described a cohort of kidney-
pancreas transplant recipients, treated with CsA, which they prospectively followed 
for up to 10 years after transplantation. Protocol kidney biopsies were obtained 
regularly after transplantation. Ten years after transplantation, the cumulative inci-
dence of histological changes in the kidney, indicative of chronic CNI related ne-
phrotoxicity, was nearly 100%(76). Although this result is impressive, we should note 
that this study did not contain a control group, so the influence of other causes like 
aging, hypertension etc. remains unknown. In 2002 Bagnis et al described a group 
of patients treated with CsA for uveitis. Among the 41 patients, the GFR decreased 
from 102 mL/min/1.73m2 at the start of treatment to 88 mL/min/1.73 m2 after 2 years 
of CsA therapy. Renal biopsies, taken before and 2 years after starting treatment 
with CsA, showed important histological changes over time with significant increases 
in glomerular sclerosis, thickening of Bowman’s capsule, and tubular atrophy and 
interstitial fibrosis(77). 
Histologically, al parts of the kidney can be affected by CsA or Tac treatment. Diag-
nostic pathological criteria for chronic CNI nephrotoxicity include arteriolar hyalinosis, 
glomerular sclerosis and thickening of Bowman’s capsule, tubular atrophy (TA), and 
interstitial (striped) fibrosis (78-80). However, the non-specificity of most of these 
lesions makes the differential diagnosis very difficult and includes, for example, ag-
ing, diabetes mellitus, hypertension and, in renal transplantation, pre-existing donor 
injury or chronic (humoral) rejection. Besides this differential diagnosis, these are all 
conditions which may coexist with chronic CNI nephrotoxicity (80). The mechanisms 
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responsible for this chronic nephropathy are not completely elucidated.  A combina-
tion of hemodynamic changes leading to ischemia, direct toxic effects of CNI on the 
tubules, and an increased expression of the profibrotic transforming growth factor-ß 
(TGF- ß) are considered important etiologic factors. TGF- ß expression of tubular cells 
is directly upregulated by CsA as well as by Tac (81-86). TGF- ß promotes interstitial 
fibrosis by decreasing the degradation and increasing the production of extracellular 
matrix proteins (87-88). In addition, TGF- ß induces epithelial mesenchymal transi-
tion, in which renal tubular epithelial cells lose their epithelial phenotype and acquire 
new characteristic features of mesenchyme. This transition is recognized as a major 
mechanism contributing to renal interstitial fibrosis (89-93).  Although the persistent 
use and a higher doses of CNIs seems to be contributing factors to chronic CNI 
nephrotoxicity (94-95), there are recent studies who describe an individual suscep-
tibility to CNI nephrotoxicity, depending on individual variation of the organ donor or 
recipient in drug transporters (for example ABCB1, formerly known as permeability 
glycoprotein or P-gp), drug-metabolizing enzymes (for example CYP3A) or other 
polymorphically expressed genes, such as, TGF- ß(96-97), vascular endothelial 
growth factor(98), and caveolin-1(99). 
In contrast with acute CNI nephrotoxicity, renal function and histological changes in 
chronic CNI nephrotoxicity improves only little, if at all, after minimization or withdraw-
al of CNIs. So, better insight in the mechanisms responsible for CNI nephrotoxicity 
may guide us to develop preventing strategies for CNI toxicity.    
Despite the negative aspects of organ transplantation mentioned above, renal trans-
plantation is still the treatment of choice for most patients with ESRD, as it results 
in better patient survival and quality of live compared with dialysis (100). Given this 
knowledge, we have to search for an opportunity to minimize the immunosuppres-
sive load to prevent long term complications and to improve patient’s quality of live, 
although an adequate combination of various kinds of immunosuppressive drugs 
is needed to prevent acute rejection in the early post-transplant period. To assess 
at what time after transplantation immunosuppression can be safely reduced or 
stopped, the use of a proper biomarker that measures antidonor reactivity is helpful. 
For example, van der Mast et al and van Besouw et al have shown that conversion 
from CNI to mycophenolate mofetil (MMF) or azathioprine( AZA) in stable renal trans-
plant recipients is a safe procedure when helper T-cell reactivity and donor specific 
cytotoxic T-lymphocyte precursor frequency is low (101-102). Besides the identifica-
tion of patient’s who can be weaned of immunosuppression, biomarkers could help 
us to predict and diagnose acute rejection before irreversible injury has occurred 
during these weaning protocols which would make these protocols easer to perform 
and ethically more acceptable. However, to understand more which mechanism 
leads to tolerance we need to study the influence of immunosuppressive medication 
on both immune activation cascades as in the immune suppressive counter mecha-
nisms.  
17
introduction and outline
1
Aim of this thesis
In this thesis, the incidence of long-term side effects, such as CNI induced renal in-
sufficiency and malignancies, and the influence of these complications on patient and 
graft survival in Dutch heart and renal transplant recipients were analysed. Knowing 
the negative influence of immunosuppression on these complications, we studied the 
possibilities to taper the immunosuppressive load after transplantation and analysed 
the effects of this minimization in stable renal transplant recipients on both clinical 
and immunological parameters. This knowledge will help us understand the influence 
of immunosuppressive medication on immunological processes leading to tolerance 
or rejection of the graft which will help us to develop a more efficient immunosup-
pressive treatment strategy which is tailored to individual patient characteristics.
18
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Abstract
Background: Nephrotoxicity is a major side effect of calcineurin inhibitors (CNI). 
Earlier we reported 8% of our heart transplant recipients reaching end-stage renal 
failure (ESRF). Now, with an extended follow up of 20 years, we re-evaluated the de-
velopment of ESRF and studied its influence on survival and the impact of polymor-
phisms in codon 10 and 25 of the promoter region of TGF-ß on the risk of ESRF.
Methods: 465 patients were transplanted between 6/84 and 6/05. All were on 
maintenance CNI treatment. Development of ESRF was studied in the 402/465 
(86.5%) patients surviving at least one year. Their median follow up was 8 years, total 
observation time of 3414 years. TGF-ß polymorphisms in codon 10 (Leu to Pro) and 
codon 25 (Arg to Pro) were analyzed with real time PCR in a cohort of 237 patients, 
with an observation time of 2329 years. 
Results: Ten years survival of patients surviving at least one year was 58.5%. 
Seventy-three patients (18.2%) developed ESRF. Dialysis free survival was 60% at 15 
years. 
The RR for ESRF in Pro10 carriers was 2.9 (CI 1.5-5.8) compared to patients with 
the Leu/Leu10 genotype (p=0.002), while Pro25 carriers had a RR of 2.6 (CI 1.4-4.8) 
compared to the Arg/Arg25 genotype (p=0.002). 
Survival of patients with ESRF was 1.5 years (median).
Conclusion: We found a highly significant association between TGF-ß polymor-
phisms and CNI induced ESRF after heart transplantation (HTx). Pro carriers of either 
codon 10 or 25 had a 2.6 to 2.9 times increased risk of developing ESRF. As ESRF 
after HTx results in high mortality rates these patients should no longer receive CNI-
based immunosuppression.
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Introduction
With improved results and longer survival after heart transplantation, we are confront-
ed with the complications of long-term use of immunosuppressive medication. After 
the introduction of calcineurin inhibitors (CNI), the median survival of heart transplant 
recipients now exceeds 10 years(1). Apart from complications of immunosuppres-
sion in general, chronic treatment with CNI’s more specifically may result in renal 
failure. The prevalence of renal dysfunction in heart transplant recipients, varies from 
0 to 20 % in different studies (2-12). The disparity in reported prevalence’s is due 
to differences in the definition of renal failure as well as in the duration of follow-up 
after transplantation in the different studies. Identification of patients at risk for renal 
dysfunction or finally end stage renal failure (ESRF) could contribute to prevention of 
this complication by adjustment of the therapeutic regime. Possible risk factors for 
the development or progression of renal dysfunction after heart transplantation such 
as older age at heart transplantation (HTx), pre- and post-transplant hypertension, 
pre- and post-transplant diabetes mellitus, male gender, immediate post HTx renal 
function have been mentioned(13-15). 
Independent of the primary cause of renal dysfunction, fibrosis is a typical histological 
feature of progression to ESRF and transforming growth factor- ß1 (TGF-ß1) seems 
to play a central role in this process (15). Because, TGF-ß1 levels are associated with 
gene polymorphisms in the TGF-ß1 promoter region, we wondered about the effect 
of TGF-ß1 gene polymorphisms on the risk for developing ESRF(16-18)
Now, with an extended follow of 20 years, we studied the development of the 
ultimate consequence of CNI nephrotoxicity: end stage renal failure (ESRF) and its 
influence on patient survival. Moreover we analyzed the impact of polymorphisms in 
codon 10 and 25 of the promoter region of TGF-ß1 on the risk of ESRF.
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Materials and methods
Patients
Between June 1984 and June 2005, 468 heart transplantations were performed in 
465 patients in our centre. Their clinical characteristics were as follows: 368 (79%) 
patients were male, 100 (21%) female; their median age was 50 (range 2-71); their 
primary heart disease was ischemic heart disease (IHD) in 244 (52%) patients, 
dilated cardiomyopathy in 201 (43%) patients and primary valvular disease or other 
in 23 (5%) patients. Only patients with a creatinine clearance of more then 30 ml/min 
were accepted for cardiac transplantation. Sixty-six patients had a follow-up of less 
than 1 year. Thirteen of them were recently transplanted, 53 patients died within this 
first year. The causes of death were primary graft failure in 19 (36%), acute rejection 
in 10 (19%), peri-operative complications in 7 (13%), infection in 8 (15%), malignancy 
in 5 (9%) and 4 (8%) patients died of various other causes.  None of them had been 
on dialysis. Development of ESRF was studied in the 402/465 (86.5%) patients 
surviving at least one year. ESRF was defined as the need to start renal replacement 
therapy. Follow up of all patients was performed in our outpatient clinic. During these 
visits, clinical and laboratory data were collected. The diagnosis of renal failure due to 
calcineurin inhibitor toxicity was made by exclusion of other causes, mainly by ultra-
sonography and urine analysis. A renal biopsy was done in only 5 patients. Histology 
of all these biopsies showed marked CNI nephrotoxicity. 
Immunosuppression
In 21 years of heart transplantation, several immunosuppressive regimens have 
been used in our heart transplantation centre. All were based on CNI with or without 
induction treatments with OKT3, ATG and anti-CD20 antibody (19). All patients used 
CNI as early post-operative and as maintenance CNI treatment in combination with 
azathioprine or mycophenolate mofetil and prednisone. The majority of patients used 
cyclosporine as CNI, but since the year 2000 tacrolimus was introduced in a small 
group of 21 patients. In none of the patients CNI’s were discontinued. 
TGF-ß1 gene polymorphisms
TGF-ß1 polymorphisms in codon 10 (Leu to Pro) and codon 25 (Arg to Pro) were 
analyzed in a cohort of 237 HTx recipients transplanted between June 84 and  
January 99. 
DNA isolation, amplification and detection of TGF-ß1 gene polymorphisms were per-
formed as described before (20). In brief, the studied TGF-ß1 polymorphisms (+869, 
Leu10 → Pro and +915, Arg25 → Pro) were determined by dot blot hybridization. Two 
biotinilated oligonucleotide probes were used to determine each polymorphism. Two 
ml PCR product was spotted onto Hybond™-N+ membrane (Amersham Pharmacia, 
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Buckinghamshire, UK) and treated with 0.5 mol/liter NaOH and 1.5 mol/liter NaCl for 
5 minutes to separate double-stranded amplified DNA, followed by a neutralization 
step with 1.5 mol/liter NaCl and 0.5 mol/liter Tris, pH 7.5, for 1 minute. The mem-
branes were baked in a microwave for 5 minutes, and DNA was immobilized onto 
the membranes by cross-linking with ultraviolet for 1 minute. Thereafter blots were 
incubated in 10 ml of hybridization buffer containing 5X SSC, 0.5X Denharts solution, 
0.2 mol/liter EDTA, 0.5% sodium dodecyl sulphate (SDS), and 0.1 ml sonicated her-
ring sperm (Promega, Madison, Wisconsin, USA) at 42.5°c for 30 minutes. We added 
400 ng of specific biotinilated oligonucleotide probe and allowed it to hybridize for 90 
minutes at 42.5oc. The membranes were washed twice with 5X SSC and 0.1% SDS 
at room temperature for 5 minutes, followed by stringency washing with 1X SSC and 
0.1% SDS at 58°c (1869, Leu10 3 Pro) and 61°c (1915, Arg25 3 Pro) for 30 minutes. 
Before visualizing the hybridized probes, the membranes were washed in 0.15 mol/
liter NaCl and 0.1 mol/liter Tris buffer, pH 7.5, for 1 minute and treated with 0.5% 
blocking agent (Roche Diagnostics, Almere, The Netherlands) for 30 minutes. Sub-
sequently, the membranes were incubated with a streptavidine horseradish labeled 
peroxidase conjugate (Amersham Pharmacia) for 30 minutes at room temperature 
before detection by chemoluminiscence using the ECL™ system (Amersham  
Pharmacia).
We determined TGF-ß1 genotypes in 2 replicate experiments.
Statistical methods
Data for this study were obtained by retrospective patient chart analysis. Survival 
curves were made using the Kaplan-Meier method and the log-rank test was used 
to compare the survival rates. Continuous variables are reported as means ± SD and 
tested by Student’s t-test. Data that did not follow a normal distribution are presented 
as medians and tested by Mann-Whitney U test. Qualitative variables are reported as 
percentages and were tested by the Pearson’s chi-squared test. 
Potential associations with dialysis free survival and with patient survival were studied 
by means of univariable analysis and the multivariable Cox proportional hazards 
analysis. Dialysis free survival was censored for death; patient survival was censored 
for ESRF. Variables included in this study were: age, gender, primary heart disease, 
serum creatinine levels before transplantation, total cholesterol and triglycerides at 
one year, cyclosporine levels at one year, coronary artery disease at one year and 
TGF-ß1 polymorphisms in codon 10 and codon 25.  The SSPS statistical package 
version 12.0.1 was used. P-values <0.05 were considered significant
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Results
The median follow up of the 402 patients with at least one year follow up was 8 
(range 1-20) years with a total observation time of 3.414 years. The mean serum cre-
atinine level of the study group just before and one year after HTx was 107±31 and 
139±46 µmol/l respectively. After Htx 72% of the patients developed hypertension, 
which was treated with calcium-antagonists for initial therapy. Patients with treated 
hypertension were equally divided between the group with and without ESRF. 
At the time of observation, 73 of 402 (18.2%) patients with more than one year follow-
up developed ESRF. The median time after HTx of developing ESRF was 92 months 
(range 11-239). Sixty percent of these 402 heart transplant patients were free from 
dialysis after 15 years (figure 1). The mode of renal replacement therapy was haemo-
dialysis in 37 patients, peritoneal dialysis in 28 patients, unknown in 6 patients and 2 
patients died just before dialysis could be started. Seven patients (4 of a deceased 
and 3 of a living donor) received a kidney transplant after they started dialysis. At 
time of observation 33 (89%) of the haemodialysis, 24 (86%) of the peritoneal dialysis 
patients and 5 (71%) of the kidney transplant recipient’s had died. 
No differences in age, gender, primary heart disease, serum creatinine level, lipid 
profile or diabetes mellitus pre HTx were found between patients who did (ESRF +) or 
did not (ESRF -) develop ESRF (table 1). However, cyclosporine through levels were 
significantly lower in the ESRF + group. 
In the univariable analysis and the multivariable Cox proportional hazards analysis 
none of the previously mentioned factors significantly influenced the risk of develop-
ing ESRF.  
perioperative complications in seven (13%), infection in eight
(15%), malignancy in five (9%), and four (8%) patients died of
various other causes. None of them had been on dialysis.
Development of ESRF was studied in the 402/465
(86.5%) patients surviving at least one year. ESRFwas defined
as the need to start renal replacement therapy. Followup of all
patients was performed in our outpatient clinic. During these
visits, clinical and laboratory data were collected. The diag-
nosis of renal failure due to calcineurin inhibitor toxicity was
made by exclusion of other causes, mainly by ultrasonogra-
phy and urine analysis. A renal biopsy was done in only five
patients. Histology of all these biopsies showed marked CNI
nephrotoxicity.
Immunosuppression
In 21 years of heart transplantation, several immunosup-
pressive regimens have been used in our heart transplantation
center. All were based on CNI with or without induction
treatments with OKT3, antithymocyte globulin (ATG), and
anti-CD20 antibody (19). All patients used CNI as early post-
operative and asmaintenance CNI treatment in combination
with azathioprine ormycophenolate mofetil and prednisone.
The majority of patients used cyclosporine as CNI, but since
the year 2000 tacrolimus was introduced in a small group of
21 patients. In none of the patients were CNIs discontinued.
TGF-1 Gene Polymorphisms
TGF-1 polymorphisms in codon 10 (Leu to Pro)
and codon 25 (Arg to Pro) were analyzed in a cohort of 237
HTx recipients transplanted between June 1984 and Janu-
ary 1999.
DNA isolation, amplification, and detection of TGF-1
gene polymorphisms were performed as described before
(20). In brief, the studied TGF-1 polymorphisms (869,
Leu103 Pro and 915, Arg253 Pro) were determined by
dot blot hybridization. Two biotinylated oligonucleotide
probeswere used to determine each polymorphism. Twomil-
liliter polymerase chain reaction (PCR) product was spotted
ontoHybond-Nmembrane (Amersham Pharmacia, Buck-
inghamshire, UK) and treated with 0.5 mol/L NaOH and 1.5
mol/L NaCl for five min to separate double-stranded ampli-
fied DNA, followed by a neutralization step with 1.5 mol/L
NaCl and 0.5 mol/L Tris, pH 7.5, for 1 min. The membranes
were baked in a microwave for five min, and DNA was im-
mobilized onto themembranes by cross-linking with ultravi-
olet for one min. Thereafter, blots were incubated in 10 ml of
hybridization buffer containing 5 SSC, 0.5 Denharts so-
lution, 0.2 mol/liter ethylenediamine tetraacetic acid (EDTA),
0.5% sodium dodecyl sulfate (SDS), and 0.1 ml sonicated
herring sperm (Promega,Madison,WI) at 42.5°C for 30min.
We added 400 ng of specific biotinylated oligonucleotide
probe and allowed it to hybridize for 90 min at 42.5°C. The
membranes were washed twice with 5 SSC and 0.1% SDS at
room temperature for five min, followed by stringency wash-
ing with 1 SSC and 0.1% SDS at 58°C (1869, Leu10 3 Pro)
and 61°C (1915, Arg25 3 Pro) for 30 min. Before visualizing
the hybridized probes, the membranes were washed in 0.15
mol/L NaCl and 0.1 mol/L Tris buffer, pH 7.5, for one
min and treated with 0.5% blocking agent (Roche Diagnos-
tics, Almere, the Netherlands) for 30 min. Subsequently, the
membranes were incubated with a streptavidine horseradish
labeled peroxidase conjugate (Amersham Pharmacia) for 30
min at room temperature before detection by chemolumi-
nescence using the ECL system (Amersham Pharmacia). We
determined TGF-1 genotypes in two replicate experiments.
Statistical Methods
Data for this study were obtained by retrospective pa-
tient chart analysis. Survival curves were made using the
Ka lan-M iermethod and the log-rank test was us d to com-
pare the survival rates. Continuous variables are reported as
meansSD and tested by Student’s t test. Data that did not
follow a normal distribution are presented as medians and
tested by Mann-Whitney U test. Qualitative variables are re-
ported as percentages and were tested by the Pearson’s chi-
squared test.
Potential associations with dialysis-free survival and
with patient survival were studied by means of univariable
analysis and the multivariable Cox proportional hazards
analysis. Dialysis-free survival was censored for death; patient
survival was censored for ESRF. Variables included in this
study were: age, gender, primary heart disease, serum creati-
nine levels before transplantation, total cholesterol and trig-
lycerides at one year, cyclosporine levels at one year, coronary
artery disease at one year, and TGF-1 polymorphisms in
codon 10 and codon 25. The SSPS statistical package version
12.0.1 was used. P values0.05 were considered significant.
RESULTS
The median follow up of the 402 patients with at least
o e year of follow upwas eight (range 1–20) years with a total
observation time of 3.414 years. The mean serum creatinine
level of the study group just before and one year afterHTxwas
10731 and 13946mol/L, respectively. After Htx, 72% of
the patients developed hypertension, which was treated with
FIGURE 1. Kaplan-Meier curve of the cumulative free-
dom from dialysis censored for death in the one-year sur-
vivor heart transplantation group (n402).
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Figure 1. Kaplan-Meier curve of the  
cumulative freedom from dialysis censored  
for death in the one-year survivor heart  
transplantation group (n=402).
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Table 1. 
Demographics of patients with (ESRF +) and without (ESRF -) end stage renal failure 
after heart transplantation.
ESRF + ESRF - p-value*
Number of patients 73 (18.2%) 329 (81.8%) -
Male: Female 64:9 256:73 n.s.
Age (years, median, range) 49(15-64) 50 (4-71) n.s.
Primary heart disease:
    -Ischemic heart disease
    -Cardiomyopathy
    -Valvular disease or other
39 (53.4%)
28 (38.4%)
6 (8.2%)
167 (50.8%) 
147 (44.7%)
15 (4.6%)
n.s.
n.s.
n.s.
Creatinine level pre HTx
(mmol/l, median, range) 105(69-232) 103 (36-282)
n.s.
CsA level at 1 year 
(ng/ml, median, range) 104 (45-420) 180 (31-610) p=0.001
Triglycerides at 1 year (mmol/l, median, 
range) 2.22 (0.56-6.20) 2.11 (0.17-9.39) n.s.
Total cholesterol at 1 year (nmol/l, 
median, range) 6.8 (2.6-10.9) 6.4 (1.1-15.5)) n.s.
Diabetes Mellitus pre HTx  (n, %)
1 (1.4%) 13 (3.9%) n.s.
* Mann Whitney test and Pearson’s chi-squared test
The median patient survival time of the study group was 11.3 years (range 1–19.9). In 
the univariable analysis, increasing patient age at transplantation (p=<0.001), male 
gender (p=0.02), or presence of coronary artery disease at one year after transplan-
tation (p=0.05) significantly influenced the death risk. Besides, primary heart disease 
significantly influenced this risk (p=0.003). In comparison to cardiomyopathy, is-
chemic heart disease had a relative risk (RR) of 1,6 (CI 1.2-2.2, p=0.002) and primary 
valvular disease had a RR of 2.2 (CI 1.2-4.1, p=0.013). Multivariable Cox proportional 
hazards analysis revealed that age was the only independent predictor of death 
(p=<0.001). There was a significant difference in the median survival between the 
ESRF + versus the ESRF- group, 9.50 versus 12.08 years respectively (p=0.0001). 
After reaching ESRF, the median survival time was only 1.5 years (range 0-14.7). 
TGF-ß1 gene polymorphisms 
The median follow up of the 237 patients of whom TGF-ß1 gene polymorphisms 
were analyzed was 9 years (range 1-20 years) with a total observation time of 2.329 
years. 
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Table 2. 
Distribution of TGF-ß genotypes between patients without (ESRF -) and with (ESRF 
+) ESRF for codon 10 and 25 in a cohort of 237 HTx recipients.
The distribution of the TGF-ß1 gene polymorphisms, for codon 10 and 25 in patients 
with and without ESRF is shown in table 2. For codon 10, 82.5% in the ESRF + 
group versus 56.1% in the ESRF – group were Pro-carriers (p=0.0003). For codon 
25, 24.6% in the ESRF + group versus 10% in the ESRF – group were Pro-carriers 
(p=0.008).  None of the patients who were homozygote for leucine at codon 10, 
were pro-carriers at codon 25. 
Fifty percent of the Pro10 carriers were free from dialysis after 14.7 years compared to 
19 years in patients with the Leu/Leu10 genotype (p=0.001). Patients who were Pro25 
carriers, 50% are free from dialysis after 13.3 years versus 18.5 years in the patients 
with the Arg/Arg25 genotype (p=0.01)(figure 2A and B). 
In the univariable analysis both polymorphisms of TGF-ß1 thus were strongly associ-
ated with development of ESRF: Pro10 carriers had a RR of 2.9 (CI 1.5-5.8, p=0.002) 
for developing ESRF compared to patients with the Leu/Leu10 genotype, while Pro25 
carriers had a RR of 2.6 (CI 1.4-4.8, p=0.002) compared to patients with the Arg/
Figure 2A: Freedom of dialysis censored for 
death in heart transplant patients with and without 
a TGF-ß1 gene polymorphism for codon 10.
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Arg25 genotype. Multivariable Cox proportional hazards analysis revealed that only 
Pro10 carriers (RR 3.4, CI 1.7-6.7, p=0.001) and older age per year (p=0.01) were 
independent predictors of developing ESRF after HTx.
Discussion
In this retrospective analysis, with an extended follow-up of 20 years, the prevalence 
of ESRF (18.2%) proved to be higher then the 8% reported earlier from our center 
(9). This reflects the problems that we face with longer patient survival after cardiac 
allograft transplantation and the associated long-term use of CNI. 
In contrast with other studies, in our heart transplant recipients, no significant differ-
ences in age, gender, primary heart disease or lipid profile were found between the 
patients with and without ESRF(13-15).
Cyclosporine through levels were significantly lower in the ESRF + group, probably 
due to tapering of the CsA dose when renal dysfunction occurs. Indeed most stud-
ies in literature do not find a correlation between high CNI dose or through levels in 
patients who do develop ESRF compared with patients who don’t (2-5, 7-12). This 
suggests an individually determined susceptibility for the nephrotoxic effect of CNI’s.
Factors responsible for CNI related nephrotoxicity are not completely understood. 
Immunohistochemistry has shown that kidneys with CNI induced morphologic ab-
normalities express the cytokine transforming growth factor TGF-ß1 (21-24). Further-
more, stimulation of the TGF-ß1 production in vivo after the use of CNI, has been de-
scribed by several groups. So, TGF-ß1, with its profibrogenetic properties, seems to 
play a central role in CNI induced nephropathy. Polymorphism in the signal sequence 
genetically control the production of TGF-ß1 (16, 25, 26). Association between these 
TGF-ß1 gene polymorphisms and for instance progression of IgA nephropathy, reflux 
Figure 2B: Freedom of dialysis censored for 
death in heart transplant patients with and without 
a TGF-ß1 gene polymorphism for codon 25.
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  nephropathy, atherosclerosis, hypertension, myocardial infarction, cardiomyopathy 
and accelerated graft vascular disease after HTx have been described (20, 27-32).  
We already reported the finding of an association between TGF- ß1 codon 10 (Leu-
cine to Proline) gene polymorphism and CNI induced renal insufficiency in HTx re-
cipients in 2000 (18). Now, with an extended follow up and a larger cohort, we found 
a highly significant association between TGF-ß gene polymorphisms and, the final 
consequence of CNI induced renal insufficiency, ESRF after heart transplantation. 
Pro carriers of either codon 10 or 25 had a 2.6 to 2.9 times increased risk for devel-
oping ESRF in univariable analysis. Also older age is an independent variable predict-
ing ESRF as it is in the general population.
Survival of ESRF patients on renal replacement therapy was extremely poor with a 
median of only 1.5 years. This poor survival rate explains our underestimation of this 
very high prevalence of ESRF after heart transplantation: we actually see only 3 to 4 
patients on renal replacement therapy at the same time.
In conclusion, after 21 years of cardiac allograft transplantation we found a high  
prevalence of ESRF and a highly significant influence of TGF-ß polymorphisms on 
CNI induced ESRF after heart transplantation in univariable analysis. In the multi-
variable analysis the influence of TGF- ß1 codon 10 gene polymorphism remained 
significant. The implications of our findings are that maintenance immunosuppressive 
regimens of cardiac allograft recipients with a TGF- ß1 codon 10 and probably also 
25 gene polymorphism should no longer contain CNI, particularly because ESRF 
after heart transplantation results in extremely high mortality rate.
37
TGF-beta gene polymorphism and end stage renal failure
2
References
1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International  
Society for Heart and Lung Transplantation: twenty-second official adult heart 
transplant report--2005. J Heart Lung Transplant 2005; 24 (8): 945.
2. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a 
 nonrenal organ. N Engl J Med 2003; 349 (10): 931.
3. Satchithananda DK, Parameshwar J, Sharples L, et al. The incidence of end-
stage renal failure in 17 years of heart transplantation: a single center  
experience. J Heart Lung Transplant 2002; 21 (6): 651.
4. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D.  
Cyclosporine-associated end-stage nephropathy after cardiac transplantation: 
incidence and progression. Transplantation 1997; 63 (5): 664.
5. Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: 
retrospective analysis of 133 consecutive patients in a single center. Clin 
Transplant 1997; 11 (1): 1.
6. Al Aly Z, Abbas S, Moore E, Diallo O, Hauptman PJ, Bastani B. The natural 
history of renal function following orthotopic heart transplant. Clin Transplant 
2005; 19 (5): 683.
7. Goral S, Ynares C, Shyr Y, Yeoh TK, Johnson HK. Long-term renal function in 
heart transplant recipients receiving cyclosporine therapy. J Heart Lung  
Transplant 1997; 16 (11): 1106.
8. Gonwa TA, Mai ML, Pilcher J, et al. Stability of long-term renal function in heart 
transplant patients treated with induction therapy and low-dose cyclosporine. 
J Heart Lung Transplant 1992; 11 (5): 926.
9. van Gelder T, Balk AH, Zietse R, Hesse C, Mochtar B, Weimar W.  
Renal insufficiency after heart transplantation: a case-control study. Nephrol 
Dial Transplant 1998; 13 (9): 2322.
10. Zietse R, Balk AH, vd Dorpel MA, Meeter K, Bos E, Weimar W. Time course of 
the decline in renal function in cyclosporine-treated heart transplant recipients.  
Am J Nephrol 1994; 14 (1): 1.
11. Senechal M, Dorent R, du Montcel ST, et al. End-stage renal failure and  
cardiac mortality after heart transplantation. Clin Transplant 2004; 18 (1): 1.
12. Herlitz H, Lindelow B. Renal failure following cardiac transplantation. Nephrol 
Dial Transplant 2000; 15 (3): 311.
13. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation.  
Am J Transplant 2006; 6 (4): 671.
14. Lindelow B, Bergh CH, Herlitz H, Waagstein F. Predictors and evolution of re-
nal function during 9 years following heart transplantation. J Am Soc Nephrol 
2000; 11 (5): 951.
38
Chapter 2
15. Garrido IP, Crespo-Leiro MG, Paniagua MJ, et al. Independent predictors of 
renal dysfunction after heart transplantation in patients with normal pretrans-
plant renal function. J Heart Lung Transplant 2005; 24 (9): 1226.
16. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. 
Genotypic variation in the transforming growth factor-beta1 gene: association 
with transforming growth factor-beta1 production, fibrotic lung disease, and 
graft fibrosis after lung transplantation. Transplantation 1998; 66 (8): 1014.
17. Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P. TGF-beta1 DNA 
polymorphisms, protein levels, and blood pressure. Hypertension 1999; 33 (1 
Pt 2): 271.
18. Baan CC, Balk AH, Holweg CT, et al. Renal failure after clinical heart  
transplantation is associated with the TGF-beta 1 codon 10 gene  
polymorphism. J Heart Lung Transplant 2000; 19 (9): 866.
19. Wabbijn M, Balk AH, van Domburg RT, et al. Ten-year follow-up of recipients of 
a kidney or heart transplant who received induction therapy with a monoclonal 
antibody against the interleukin-2 receptor. Exp Clin Transplant 2004; 2 (1): 
201.
20. Holweg CT, Baan CC, Niesters HG, et al. TGF-beta1 gene polymorphisms in 
patients with end-stage heart failure. J Heart Lung Transplant 2001; 20 (9): 
979.
21. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis.  
N Engl J Med 1994; 331 (19): 1286. 
22. Pankewycz OG, Miao L, Isaacs R, et al. Increased renal tubular expression of   
transforming growth factor beta in human allografts correlates with cyclo-
sporine toxicity. Kidney Int 1996; 50 (5): 1634.
23. Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth 
factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998; 65 
(3): 313.
24. Nicholson ML, Bicknell GR, Barker G, Doughman TM, Williams ST, Furness 
PN. Intragraft expression of transforming growth factor beta1 gene in isolated 
glomeruli from human renal transplants. Br J Surg 1999; 86 (9): 1144.
25. Yamada Y, Miyauchi A, Goto J, et al. Association of a polymorphism of the  
transforming growth factor-beta1 gene with genetic susceptibility to osteopo-
rosis in postmenopausal Japanese women. J Bone Miner Res 1998; 13 (10): 
1569.
26. El-Gamel A, Awad MR, Hasleton PS, et al. Transforming growth factor-beta  
(TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 
1999; 18 (6): 517.
27. Wang XL, Sim AS, Wilcken DE. A common polymorphism of the transforming 
growth factor-beta1 gene and coronary artery disease. Clin Sci (Lond) 1998; 
95 (6): 745.
39
TGF-beta gene polymorphism and end stage renal failure
2
28. Syrris P, Carter ND, Metcalfe JC, et al. Transforming growth factor-beta1 gene 
polymorphisms and coronary artery disease. Clin Sci (Lond) 1998; 95 (6): 659.
29. Lim CS, Kim YS, Chae DW, et al. Association of C-509T and T869C polymor-
phisms of transforming growth factor-beta1 gene with susceptibility to and 
progression of IgA nephropathy. Clin Nephrol 2005; 63 (2): 61.
30. Solari V, Owen D, Puri P. Association of transforming growth factor-beta1 gene  
polymorphism with reflux nephropathy. J Urol 2005; 174 (4 Pt 2): 1609.
31. Holweg CT, Baan CC, Balk AH, et al. The transforming growth factor-beta1 
codon 10 gene polymorphism and accelerated graft vascular disease after 
clinical heart transplantation. Transplantation 2001; 71 (10): 1463.
32. Di Filippo S, Zeevi A, McDade KK, Bastien O, Webber SA. Impact of TGFbeta1 
gene polymorphisms on acute and chronic rejection in pediatric heart trans-
plant allografts. Transplantation 2006; 81 (6): 934.
40
Chapter 3
41
Survival after cancer in renal transplant recipients
3
Chapter 3
Patient survival after the  
diagnosis of cancer in  
renal transplant recipients:  
a nested case control 
study
Transplantation 2010; 90: 1542–1546
Jacqueline van de Wetering1, Joke I. Roodnat1, Aline C. Hemke2, 
Andries J. Hoitsma2 and Willem Weimar1,2.
Erasmus MC, University Hospital Rotterdam, Internal Medicine and Transplantation1, 
Rotterdam, Dutch Transplant Foundation2, Leiden, 
The Netherlands
42
Chapter 3
Abstract
Introduction
Malignancy is a well-known complication after renal transplantation. We studied the 
influence of cancer on patient survival in the Dutch renal transplant population in a 
nested case controlled analysis.
Methods
Between March 1966 and May 2008 15,227 renal transplantations in 12,805  
recipients were registered in the Netherlands Organ Transplant Registry database. 
Total follow-up was 89,651 person years. We performed an analysis of patient and 
graft survival both from the day of transplantation and the diagnosis of cancer in re-
cipients with invasive cancer. Recipients without invasive cancer, matched for gender, 
age and year of transplantation, served as a control group. For the survival analysis 
after the diagnosis of cancer, the matched control group consisted of patients with a 
functioning graft at the moment the index patient was diagnosed with cancer.
Results
Cancer had been registered in 908 (7.1%) patients, 630 (69%) of them died with 
functioning kidney, 510 (81%) due to their malignancy (at 8.2 years after transplanta-
tion, median). The median patient survival after transplantation was 11.9 versus 16.8 
years in the study and control group respectively (p <0.001). The median patient 
and graft survival, after the diagnosis of cancer was 2.1 versus 8.3 (p<0.001) and 25 
versus 22.4 (p<0.001) years in the study and control group respectively. 
Conclusion
Mortality due to cancer is observed at a significantly later time after transplantation 
compared to mortality due to the other main lethal complications. It significantly  
affects life expectancy and carries a poor prognosis with a limited survival after  
diagnosis. 
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Introduction
The management of renal transplant recipients is changing over the years. Prevention 
of acute rejection has been our main concern in the early years, but with the devel-
opment of better immunosuppressive medication, the increasing age of the trans-
planted population, and better patient and graft survival, the incidence of other com-
plications increased in frequency. Currently, developing malignancies is a well-known 
and feared complication (1-7). The incidence of cancer increases over time and the 
relative risk of almost al tumor types are higher in the transplant recipients compared 
to the general population(8). Skin cancer is the most commonly observed type of 
malignancy with a reversed ratio of basal cell carcinoma (BCC) to squamous cell car-
cinoma (SCC) compared with the general population (2, 9-11). Studies in Dutch and 
Norwegian transplant recipients, a population with moderate sun exposure, showed 
that SCC occurred 65 to 250 times, BCC 10 times as frequently as in the general 
population (12-13) with a high risk of subsequent nonmelanoma skin cancer (14) .
An analysis of 13,000 renal transplants performed in Australia and New Zealand 
showed a cumulative risk for developing at least one malignancy (excluding non-
melanoma skin cancer) of approximately 30% after 20 years (15). 
Relative and absolute risk differ across patient groups and depending on patients’ 
age, gender, primary cause of end stage kidney disease, race, prior malignancy, 
and graft survival. Better graft survival implies a higher cumulative dose of immuno-
suppression and thus a higher risk of cancer (5-6, 8).  The use of immunosuppres-
sion and the possible limitation of treatment options in renal transplant recipients 
may have its influence on patient survival after the diagnosis of cancer (16). Studies 
describing patient survival after the diagnosis of cancer are scarce. Miao Y. et al 
performed a study for several common cancers, which showed that renal transplant 
recipients are diagnosed at a younger age and later stage of disease and have a 
significant worse outcome after the diagnosis of cancer compared with the general 
population (17). We studied the influence of developing cancer on patient survival in 
the Dutch renal transplant population. As a control group we did not use the general 
population but a nested case control group of renal transplant recipients with com-
parable other risk factors, in example cardiovascular disease and infection. 
Materials and methods
Patients
After transplantation all renal transplant recipients were seen in the outpatient clinic of 
their transplant center. During every visit to their outpatient clinic, history was record-
ed and laboratory tests and urine analysis was performed. An electrocardiogram, 
chest X-ray and a cervical smear was performed once a year and on indication. On 
indication, more specific investigations were done (if there were abnormal findings in 
history, physical examination or other test results). For every transplanted organ, the 
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NOTR database form is completed yearly until the transplant fails or the patient dies.  
For this study, we retrospectively checked the medical records of the 15,227 re-
nal transplantations in the NOTR database to identify recipients with a first post-
transplant malignancy. Non-melanoma skin cancers and malignancies before 
transplantation were not included in this analysis. All malignancies were confirmed 
by pathological examination. We performed an analysis of patient survival from the 
day of transplantation in recipients developing their first post-transplant invasive 
cancer (‘cases’, non-melanoma skin cancer excluded). Subsequent malignancies 
in a different organ system, not considered as metastasis from the primary tumor, 
were counted separately. Recipients not diagnosed with invasive cancer, matched for 
gender, age and year of transplantation, served as a control group. 
Furthermore we performed a survival analysis after the diagnosis of malignancy. In 
this analysis the control group, matched for gender, age and year of transplantation, 
consisted of patients with a functioning graft at the moment the index patient was 
diagnosed with cancer. The requirement for informed consent from patients was 
waived because the researchers received only anonymous data.
Immunosuppression
From 1966 until 1984 the standard immunosuppressive treatment for renal trans-
plantation in the Dutch transplantation centers consisted of prednisolone (Pred) 
combined with azathioprine (AZA). Cyclosporine (CsA) was first registered in the 
NOTR as one of the immunosuppressive drugs after renal transplantation in 1979. 
From1984 the preferred immunosuppressive regimen for new renal transplant recipi-
ents was a combination of Pred and CsA, with or without AZA. 
In 1992 mycophenolate mofetil (MMF) was first registered in the NOTR database as 
used in a renal transplant recipient as one of the immunosuppressive drugs. From 
1996 onwards, the preferred immunosuppressive regimen for de novo renal trans-
plant consisted of triple therapy with Pred, MMF and a calcineurine inhibitor, first CsA 
and later tacrolimus (Tac). 
Induction therapy with anti-thymocyte globulin (ATG), OKT3 or anti-CD25 was not 
common practice, but only used as part of controlled clinical trials. 
In case of acute rejection, patients were treated with methylprednisolone. If there was 
no response to methylprednisolone and/or in a T-cell mediated rejection with arteritis 
(type II rejection, Banff classification), ATG was given. Humoral rejection was treated 
with a combination of methylprednisolone, intravenous immunoglobulin’s (IvIg), plas-
mapheresis and Rituximab.
Statistical methods
Survival curves were made using the Kaplan-Meier method and the log-rank test 
was used to compare the survival rates. Data that did not follow a normal distribution 
are presented as medians and tested by Wilcoxon signed rank test.  
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The SSPS statistical package version 15.0 (®SPSS Benelux BV, an IBM Company) 
was used. P-values <0.05 were considered significant
Table 1: 
Different types of cancer with patient survival censored for failure
Cancer site
Number 
of RTx
with  
cancer
Median 
time from 
RTx to can-
cer Dx
(years)
Number of  
patients 
died after 
cancer Dx
Patient 
survival 
rate (%)
Median 
patient 
survival 
after RTx
(years)
Median 
patient 
survival af-
ter the Dx 
of cancer
(months)
Primary brain tumors 11 4.5 6 45% 10.6 54
Tractus respiratorius 67 6.2 59 12% 8.1 5
Lip, oral cavity and 
pharynx
31 7.3 17 45% 14.3 69
Esophagus 15 16.5 9 40% 21 7
Stomach 13 10.2 12 8% 10.8 5
Colorectal 68 9.3 45 34% 14.7 15
Gall bladder & liver 18 9.7 16 11% 10.7 1
Pancreas 5 0.8 5 0% 0.8 2
Breast 48 6.5 21 56% 17 49
Gynecological tumor 35 5.4 14 60% 19 304
Prostate 41 3.8 11 73% 30 114
Kidney 29 7.3 12 59% 21.2 77
Urinary tract and 
bladder
48 3.6 21 56% 18.1 91
Melanoma 15 4.5 8 47% 15.3 39
Non-Hodgkin lym-
phoma
81 4.8 45 44% 11.6 26
Hodgkin lymphoma 10 7.0 3 70% 24 205
Leukemia 45 6.3 29 36% 9.6 10
Other malignancies 67 5.5 36 46% 13.7 24
Patients registered as 
died due to cancer of 
unknown primary site
261 unknown 261 0% 9.9 unknown
Total number 908 630 31%
RTx=renal transplantation, Dx=diagnosis.
The median graft survival, censored for death, after the diagnosis of cancer was 
25 (range 0-29) versus 22.4 (range 0-25) years in the cases versus the controls 
(p<0.001) (Figure 2).
The cause of death in patients diagnosed with cancer specified for the different types 
of cancer are shown in table 2. 
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Results
Between March 1966 and May 2008 15,227 renal transplantations, (12,060 de-
ceased and 3167 living donor kidneys), in 12,805 recipients, (5163 female and 7642 
male), were registered by the 7 Dutch transplantation centers in the Netherlands 
Organ Transplant Registry (NOTR) database of the Transplant Society (NTS). Total 
follow-up was 89,651 person years. The median age at transplantation of the total 
group was 44 (range 1-80) years. The median patient survival, censored for graft 
failure, was 18.9 (range 0-39) years. The median graft survival, censored for death, 
was 21.2 (range 0-39) years. The median overall uncensored graft survival was 9.3 
(range 0-39) years.
Deceased patients and the causes of death:
In total 3173 patients died with a functioning graft. In 505 (16%) patients the cause of 
death was registered as due to an infection (at 3.5 years after RTx, median), in 161 
(5%) patients a gastrointestinal complication (at 5.2 years after RTx, median), in 1117 
(35%) patients cardiovascular disease (at 6.2 years after RTx, median) and 880 (28%) 
patients died of other causes. Malignancy was registered as cause of death in 510 
(16%) patients (at 8.2 years after RTx, median). 
Mortality due to cancer was observed at a significantly (p<0.001) later time after 
transplantation compared to mortality due to infection, gastrointestinal complications 
and cardiovascular disease.
Patients diagnosed with cancer:
At time of observation, a first post transplant malignancy was registered after 908 
(7.1%) transplantations in 906 recipients. Of these 906 patients, 630 (70%) died with 
functioning kidney, 510 (56%) due to their malignancy. The median patient sur-
vival censored for failure after transplantation in these 906 renal transplant patients 
registered with a malignancy was 11.9 versus 16.8 years in renal transplant patients 
without malignancy (p <0.001). The results of patient survival for the different types of 
malignancies are shown in table 1.
Survival analysis after the diagnosis of cancer
The median patient survival, after the diagnosis of cancer was 2.1 (range 0-25) 
years in the study versus 8.3 (range 0-29) years in the control group without can-
cer (p<0.001) (Figure 1). In this last analysis the control group, matched for gender, 
age and year of transplantation, consisted of patients with a functioning graft at the 
moment the index patient (case) was diagnosed with cancer. The results of patient 
survival after the diagnosis of cancer, specified for the different types, are shown in 
table 1.
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Table 2: Cause of death in renal transplant patients, with the diagnosesis of cancer. 
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Figure 1: Patient survival, censored for failure, after the diagnosis of cancer. 
Patients with cancer (cases) versus the control group. The control group, matched 
for gender, age and year of transplantation, consisted of patients with a functioning 
graft at the moment the index patient was diagnosed with cancer.
Median patient survival, cases versus controls, was 2.1 (range 0-25) versus 8.3 
(range 0-29) years, p<0.001.
Figure 2: Graft survival, censored for death, after the diagnosis of cancer.
Patients with cancer (cases) versus the control group. The control group, matched 
for gender, age and year of transplantation, consisted of patients with a functioning 
graft at the moment the index patient was diagnosed with cancer. Median graft  
survival, cases versus controls, was 25.0 (range 0-29) versus 22.4 (range 0-25) 
years, p<0.001.
p<0.001
p<0.001
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Discussion
Most studies in transplantation, describing patient survival after developing cancer, 
compare their results with the general population, showing a significant worse sur-
vival for the transplanted population. However, the vast majority of the general popu-
lation is not at risk for the other known lethal side effects of immunosuppression, 
such as infection and cardiovascular disease. Our study shows that even compared 
with other renal transplant recipients, matched for gender, age, time after and year 
of transplantation, developing cancer after renal transplantation significantly affects 
life expectancy and carries a poor prognosis with a limited patient survival after the 
diagnosis. Moreover, the mean follow-up of our patients is shorter than the time to 
the diagnosis of cancer, which implicates that a higher number of patients will be 
diagnosed with cancer in future. Furthermore, we are not informed about the cancer 
risk after transplant failure, which also may contribute to patient survival in a negative 
way (18).
In patients with types of cancer with relative good prognosis, mortality tends to shift 
to other causes of death, (e.g. cardiovascular disease). For instance, nearly all pa-
tients who died and had a history of cancer of the esophagus (89%), stomach (83%) 
or pancreas (100%), died from their malignancy. In contrast, this proportion was 
smaller in patients with cancer of the prostate (36%), urinary tract and bladder (53%)
(Table 2). However, in due time, patients surviving cancer have a comparable death 
risk and risk for graft failure as the control group, as can be deducted from the paral-
lel slopes of the curves in figure 1 and 2, after apparently 8 years.
When patient survival is curved (Figure 1) the sharp early decrease in survival can 
easily be explained by the complications of cancer. Moreover, a certain reluctance 
to treat renal transplant recipients with nephrotoxic agents might lead to a further 
reduction in survival after the diagnosis of cancer. The significant difference between 
cases and controls in graft survival, censored for death, is probably the result of 
censoring.
We also noted that mortality due to cancer is observed at a significantly later time af-
ter transplantation compared to mortality due to the other main lethal complications. 
Nevertheless, cancer is the 2nd most frequent cause of death after renal transplanta-
tion. Besides genetic predisposition, race, age, environment, duration of uremia and 
chronic antigen stimulation, the higher risk of cancer after transplantation is partially 
due to an impaired immune surveillance, a higher incidence of viral infections and an 
impaired capability to repair DNA damage. The last three factors can be attributed to 
the chronic use and cumulative dose of immunosuppression. Early minimization of 
the immunosuppressive load could therefore be successful in the prevention of this 
late complication after kidney transplantation.
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Abstract
Background
Tapering of immunosuppressive medication is indicated to prevent long-term side 
effects. Recently, we have shown that renal transplant recipients can safely be con-
verted from calcineurin inhibitors to MMF or AZA when their donor specific cytotoxic 
T lymphocyte precursor frequencies (CTLpf) are below 10/106 PBMC. We wondered 
whether a low CTLpf also had predictive value when immunosuppressive medication 
was reduced in patients only on MMF or AZA and steroid medication.
Methods
Renal transplant recipients with stable renal function, at least two years after trans-
plantation and with low (<10/106 PBMC) CTLpf were included. Their MMF or AZA 
dose was reduced to 75% at 4 months and to 50 % of the original dose at 8 months 
after inclusion.  Endpoint of the study was 12 months after inclusion or developing 
acute rejection.
Results 
Forty-five patients have reached the one-year follow up endpoint. Their median time 
after transplantation was 4.2 years (range 2.0-15.5 years). Acute rejection was seen 
in one patient only, who had discontinued all his medication.
Conclusion
In patients with low CTLpf long after kidney transplantation a 50% reduction of im-
munosuppression is safe and further decreasing their immunosuppressive load is the 
obvious next step. 
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Introduction
Despite the fact that early graft survival in renal transplant recipients has been mark-
edly improved there are still a lot of problems to solve. The long-term outcome of 
renal transplantation is influenced by the occurrence of chronic allograft nephropa-
thy and side effects of the immunosuppressive medication such as nephrotoxicity, 
cardiovascular disease and malignancies. Of all deaths after renal transplantation, 16 
to 36% are the results of accelerated cardiovascular mortality and 9 to 12% of early 
malignancy (United States Renal Data System 1999). Evidently, tapering of the im-
munosuppressive load is indicated to prevent these side effects and to improve the 
long-term survival of these patients, provided that no rejection will occur. To reduce 
the risk of developing rejection, it is very important to select a patient group on im-
munological grounds in which tapering of immunosuppressive medication is safe.  
Finding a reliable immunological assay that makes it possible to make this selection 
is an important goal in organ transplantation.
Recently, we performed a study with renal transplant recipients who were at least 
one year after transplantation and had a stable renal function, in whom their immu-
nosuppressive medication was converted from calcineurin inhibitors and prednisone 
to mycophenolate mofetil (MMF) or azathioprine (AZA) and prednisone. This conver-
sion was safe, without developing acute rejection, if their donor specific cytotoxic 
T-lymphocyte precursor frequency (CTLpf) was low (<10 per million PBMC’s) (1). We 
wondered whether further reduction of the immunosuppressive load in patients not 
on calcineurin inhibitors and with a low donor specific CTLpf was possible too. 
Patients and methods
Forty five renal transplant recipients who were at least two years after transplantation 
with stable renal function, no proteinuria, without acute rejection in the last 6 months 
and with low (< 10 per million PBMC’s) donor specific cytotoxic T-lymphocyte precur-
sor frequencies (CTLpf) before reduction of their immunosuppressive medication 
were included in this prospective study. HLA identical transplantations were exclud-
ed. Donor spleen cells of a deceased donor or living donor PBMC had to be available 
to measure CTLpf. CTLpf was measured using a limiting dilution assay as described 
before (1). All patients had a high CTLpf against third party. At time of inclusion (T0) 
all patients were treated with AZA 2 mg/kg/day or MMF 2 gr/day in combination with 
prednisone 10 mg/day. The AZA or MMF dose was reduced to 75% at 4 months (T4) 
and to 50% of the original dose at 8 months after inclusion, reaching maintenance 
treatment of AZA 1 mg/kg/day or MMF 1 gr/day combined with prednisone 10 mg/
day. Endpoints of the study were end of follow up at 12 months after inclusion (T12), 
death, graft loss or developing acute rejection. The diagnose of acute rejection was 
made on clinical grounds (rising creatinine, proteinuria, oliguria, fever and/or graft 
tenderness) and confirmed by core needle biopsy. Acute rejection was treated with 
methyl prednisolone 1 gram i.v. a day for 3 consecutive days.
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Statistical analysis 
Numerical data were compared using paired t-test or the Wilcoxon signed rank test.
The results are reported as the mean with standard deviation or the median with 
range. A two-tailed P-value of <0.05 was considered to be significant.
Results
The baseline characteristics of the patients at time of inclusion are shown in table 1.  
Thirty-seven patients ( 82%) have reached T12. One patient (2%) developed acute 
rejection after the first dose reduction (T4), but he confessed later on that he discon-
tinued his assigned medication completely. He was treated as described before with 
one course of prednisolone. His creatinine level stabilized after this treatment. Three 
patients (6%) refused to follow the study protocol after one dose reduction, because 
their fear to develop acute rejection. One patient (2%) developed biopsy proven 
chronic allograft nephropathy after the first dose reduction. One patient (2%) devel-
oped glaucoma. One patient has not yet reached the end of follow up at this mo-
ment. The mean creatinine level was 111 ± 36 µmol/l at T0 versus 117 ± 40 µmol/l at 
T12 (p=0.46) (figure 1). None of the remaining patients developed proteinuria during 
follow-up. The median proteinuria level was 0.10 g/l (0.10-0.25 g/l) at T0 versus 0.10 
g/l (0.10-0.23 g/l) at T12 (p=0.51) (figure 2).
Table 1. Baseline characteristics of the patients at time of inclusion.
Sex (female/male)
Age (years)
Median time after transplantation (years)
Living/deceased donor
MMF/AZA at inclusion (number of patients)
Serum creatinine (µmol/l)
14/31
48  ± 12.5
4.3 (range 2.0-15.5)
33/12
26/16
103 (59-243)
Conclusion
Trying to prevent long-term side effects by tapering the immunosuppressive load 
must be weighed against the risk of developing rejection and/or graft loss. Testing 
for T-cell reactivity to select a patient group in which tapering of medication is safe 
is suggested by many groups (2-8). Recently, we have shown that conversion of im-
munosuppressive medication in renal transplant recipients is safe when their donor 
specific CTLpf is low (1). In the present study, we have shown that a fifty percent 
reduction of the MMF or AZA dose in renal transplant recipients with low donor 
specific CTLpf is a safe procedure. There was a small, but clinical non-relevant in-
crease of serum creatinine levels reflecting the normal loss of glomerular filtration rate 
within one year. No acute rejection occurred in the patients who followed the study 
protocol. Further reduction of the immunosuppressive load in this patient group and 
compare them with a patient group with high donor specific CTLpf is the obvious 
next step. 
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T-lymphocyte precursor frequency (CTLpf) was low (10
per million PBMCs).1 We wondered whether further reduc-
tion of the immunosuppressive load in patients not on
calcineurin inhibitors and with a low donor-specific CTLpf
was possible, too.
PATIENTS AND METHODS
Forty-five renal transplant recipients who were at least 2 years after
transplantation with stable renal function, no proteinuria, without
acute rejection in the last 6 months, and with low (10 per million
PBMCs) donor-specific CTLpf before reduction of their immuno-
suppressive medication were included in this prospective study.
HLA identical transplantations were excluded. Donor spleen cells
of a deceased donor or living donor PBMC had to be available to
measure CTLpf. CTLpf was measured using a limiting dilution
assay as described before.1 All patients had a high CTLpf against
third-party cells.
At time of inclusion (T0), all patients were treated with AZA
2 mg/kg per day or MMF 2 g/day in combination with prednisone
10 mg/day. The AZA or MMF dose was reduced to 75% of the
original dose at 4 months (T4) and to 50% at 8 months after
inclusion, reaching maintenance treatment of AZA 1 mg/kg per
day or MMF 1 g/day combined with prednisone 10 mg/day.
Endpoints of the study were end of follow-up at 12 months after
inclusion (T12), death, graft loss, or acute rejection. The diagnose
of acute rejection was made on clinical grounds (rising creatinine,
proteinuria, oliguria, fever, or graft tenderness) and confirmed by
core needle biopsy. Acute rejection was treated with methyl
prednisolone, 1 g IV a day for 3 consecutive days.
Statistical Analysis
Numerical data were compared using paired t test or the Wilcoxon
signed rank test. The results are reported as the mean with
standard deviation or the median with range. A two-tailed P  .05
was considered to be significant.
RESULTS
The baseline characteristics of the patients at time of
inclusion are shown in Table 1. Thirty-seven patients (82%)
have reached T12. One patient (2%) developed acute
rejection after the first dose reduction (T4), but he con-
fessed later that he discontinued his assigned medication
completely. He was treated as described before with one
course of prednisolone. His creatinine level stabilized after
this treatment. Three patients (6%) refused to follow the
study protocol after one dose reduction because of their
fear of acute rejection. One patient (2%) developed biopsy-
proven chronic allograft nephropathy after the first dose
reduction. One patient (2%) developed glaucoma. One
patient has not yet reached the end of follow-up. The mean
creatinine level was 111  36 mol/L at T0 versus 117 
40 mol/L at T12 (P  .46) (Fig 1). None of the remaining
patients developed proteinuria during follow-up. The me-
dian proteinuria level was 0.10 g/L (0.10–0.25 g/L) at T0
versus 0.10 g/L (0.10–0.23 g/L) at T12 (P  .51) (Fig 2).
DISCUSSION
Trying to prevent long-term side effects by tapering the
immunosuppressive load must be weighed against the risk
of developing rejection or graft loss. Testing for T-cell
reactivity to select a patient group in which tapering of
Table 1. Baseline Characteristics of the Patients at Time
of Inclusion
Sex (female/male) 14/31
Age (years) 48  12.5
Median time after transplantation
(years)
4.3 (range 2.0–15.5)
Living/deceased donor 33/12
MMF/AZA at inclusion
(number of patients)
26/16
Serum creatinine (mol/L) 103 (59–243)
Fig 1. Serum creatine levels at time of inclusion (T0) and at the
end of follow-up (T12).
Fig 2. Proteinuria at time of inclusion (T0) and at the end of
follow-up (T12).
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Forty-five renal transplant recipients who were at least 2 years after
transplantation with stable renal function, no proteinuria, without
acute rejection in the last 6 months, and with low (10 per million
PBMCs) donor-specific CTLpf before reduction of their immuno-
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of a deceased donor or living donor PBMC had to be available to
measure CTLpf. CTLpf was measured using a limiting dilution
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At time of inclusion (T0), all patients were treated with AZA
2 mg/kg per day or MMF 2 g/day in combination with prednisone
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original dose at 4 months (T4) and to 50% at 8 months after
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day or MMF 1 g/day combined with prednisone 10 mg/day.
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proteinuria, oliguria, fever, or graft tenderness) and confirmed by
core needle biopsy. Acute rejection was treated with methyl
prednisolone, 1 g IV a day for 3 consecutive days.
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 .46) (Fig 1). None of the remaining
patients developed proteinuria during follow-up. The me-
dian proteinuria level was 0.10 g/L (0.10–0.25 g/L) at T0
versus 0.10 g/L (0.10–0.23 g/L) at T12 (P  .51) (Fig 2).
DISCUSSION
Trying to prevent long-term side effects by tapering the
immunosuppressive load must be weighed against the risk
of developing rejection or graft loss. Testing for T-cell
reactivity to select a patient group in which tapering of
Table 1. Baseline Characteristics of the Patients at Time
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Sex (female/male) 14/31
Age (years) 48  12.5
Median time after transplantation
(years)
4.3 (range 2.0–15.5)
Living/deceased donor 33/12
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Fig 2. Proteinuria at time of inclusion (T0) and at the end of
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Figure 1: Serum creatinine levels at time of inclusion (T0) and at the end of follow-up (T12).
 
Figure 2: Proteinuria at time of inclusion (T0) and at the end of follow-up (T12).
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Abstract
Background
Recently, we described a significant decrease in donor-specific cytotoxic T-lympho-
cyte precursor frequency (CTLpf) after discontinuation of CNI, while the proliferative 
capacity in mixed lymphocyte culture (MLC), and the number of IFN-γ producing 
cells (pc) in Elispot remained unchanged.
Methods
We tested T-cell reactivity in calcineurin inhibitors (CNI) free patients with stable renal 
graft function, on MMF or AZA plus prednisone, who were tapered to 50% of their 
MMF or AZA dose.
Results
Furthermore, tapering of the MMF or AZA dose resulted in a decrease of donor-
reactive CTLpf in all patients with detectable CTLpf. Detectable numbers decreased 
from a median of 32 to 8 CTLp per 106 PBMC. No effect on third-party reactive 
CTLpf was found, while the T-cell reactivity to donor and third-party cells as tested in 
MLC and in IFN-γ Elispot was not affected either by tapering of immunosuppression. 
Third-party reactivity was significantly higher than donor-specific reactivity in all tests. 
A control group showed no changes in any of the in vitro assays.
Conclusion
Both withdrawal of CNI and tapering of MMF or AZA dose decreases the donor-
specific CTLpf. Our data suggest that reduction of immunosuppression results in a 
specific decrease of donor-directed cytotoxic capacity of immunocompetent cells, 
while their proliferation and cytokine production capacity remained unchanged. Im-
munosuppression hinders development of cytotoxic nonresponsiveness.
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Introduction
Advances in immunosuppression spectacularly improved the success of organ trans-
plantation. Nowadays, over-immunosuppression has emerged as the major problem 
after transplantation (1). Therefore, the focus of immunosuppression management 
has shifted from the prevention of acute rejection to minimization of the total immuno-
suppressive load.
In earlier studies, it was demonstrated that elimination of calcineurin inhibitors (CNI: 
cyclosporine A and tacrolimus) in patients treated with mycophenolate mofetil (MMF) 
and prednisone at 3 or 6 months after transplantation (2, 3) or in patients converted 
to MMF or azathioprine (AZA) (4) resulted in an improvement of renal function and 
hypertension. In these studies, CNI were withdrawn within 1 year after transplanta-
tion, and the incidence of acute rejection was between 15 and 25%. Recently, we 
performed a study in which CNI were withdrawn in 51 renal transplant recipients who 
were at least 2 years after transplantation. Thereafter, patients received only MMF or 
AZA in combination with prednisone. Only one reversible acute rejection occurred 
(5). In that study we observed a significant decrease in the number of donor-specific 
cytotoxic T-lymphocyte precursors (CTLp) after CNI withdrawal, while no difference 
was found in third-party reactive CTLp frequency (CTLpf), donor and third-party 
mixed lymphocyte culture (MLC), and the number of IFN-γ pc directed to donor or 
third-party cells.
Apart from the side-effects of immunosuppression per se, e.g. infections and malig-
nancies, MMF and AZA also have their own agent-specific side-effects, like anaemia, 
leukopenia, gastrointestinal and liver problems (1, 6). As we had observed no in-
crease in T-cell reactivity after discontinuation of CNI in our patients, the immunosup-
pression was reduced further to approximately 50% of the MMF or AZA dose in an 
attempt to reduce the risk for side-effects (7). 
In the present study, we questioned whether 50% reduction of the MMF or AZA 
dose has an effect on immune reactivity in CNI-free patients with stable renal func-
tion more than 2 years after transplantation, on MMF or AZA plus prednisone. T-cell 
reactivity of patients’ PBMC against donor and third-party cells was tested in limiting 
dilution assay to determine the number of CTLp, in MLC to determine the proliferative 
capacity, and in Elispot-assay to determine the number of IFN-γ producing cells. The 
results of the assays were compared before and after tapering immunosuppression, 
and with a control group in which the MMF and AZA dose remained unchanged. 
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Patients and Methods
Patients
Recently, we described a prospective study, in which CNI were withdrawn more than 
2 years after kidney transplantation (5). Thereafter the patients received MMF or AZA 
plus corticosteroids. After informed consent, a number of patients agreed to a further 
dose reduction of MMF or AZA to approximately 50%.
All patients were recipients of a first kidney graft, had stable graft function without 
proteinuria (<0.5 g/L), and were free from rejection for at least 1 year. The patient 
characteristics are presented in Table 1.
At inclusion, patients (n=19) received a median dose of 2000 mg/day MMF (n=13: 
range: 1000 - 2000) or 150 mg/day AZA (n=6: range: 100 - 175). The MMF or AZA 
dose was tapered in two steps of 4 months to a median dose of 1000 mg/day MMF 
(range: 500 - 1000) or 62.5 mg/day AZA (range: 50 - 75) (Table 1). The T-cell reactiv-
ity was analysed at inclusion and at 4 months after the last dose reduction (one year 
after inclusion). A group of 8 patients (MMF: n=5, AZA: n=3), not tapered in immu-
nosuppression, served as control. T-cell reactivity was analysed at time of inclusion 
and one year later. 
Table 1:
Patients characteristics of kidney transplant recipients who were tapered in their 
MMF or AZA dose.
Patient LR
*
or PM#
Time after
KTx^ (in years)
Immunosuppression
before tapering
Immunosuppression
after tapering
MMF or AZA
(mg/d)
Pred
(mg/d)
MMF or AZA
(mg/d)
Pred
(mg/d)
1 LR 6.92 150 AZA 10 50 AZA 10
2 LR 3.43 2000 MMF 7.5 1000 MMF 7.5
3 PM 3.56 1000 MMF 7.5 500 MMF 7.5
4 LR 6.62 175 AZA 10 75 AZA 10
5 LR 3.16 2000 MMF 10 1000 MMF 10
6 PM 2.44 2000 MMF 10 1000 MMF 10
7 PM 5.49 100 AZA 10 50 AZA 10
8 PM 3.65 2000 MMF 10 1000 MMF 10
9 PM 4.15 2000 MMF 10 1000 MMF 10
10 LR 5.91 2000 MMF 10 1000 MMF 10
11 PM 3.67 2000 MMF 10 1000 MMF 10
12 LR 4.28 150 AZA 10 75 AZA 10
13 PM 2.56 2000 MMF 7.5 1000 MMF 7.5
14 LR 2.92 2000 MMF 10 1000 MMF 10
15 LR 4.22 2000 MMF 10 1000 MMF 5
16 LR 2.01 2000 MMF 10 1000 MMF 10
17 LR 2.86 2000 MMF 10 1000 MMF 10
18 LR 2.94 150 AZA 10 75 AZA 10
19 LR 11.19 100 AZA 10 50 AZA 10
* LR : kidney donation from a living-related donor
# PM: kidney donation from a deceased donor
^ KTx: kidney transplantation
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PBMC and spleen cell sampling
Heparinised blood samples (35 ml) from patients and living-related donors were 
drawn. PBMC were isolated from heparinised blood as described before (8) and 
stored at -140ºC until use. Spleen cells were obtained by mechanical dissociation 
of small pieces of spleen derived from the organ donor (8). Subsequently, the cell 
suspension was filtrated through a 70 µm cell strainer (BD Falcon, Bedford, MA) and 
washed. Thereafter, the cells were centrifuged over a Ficoll-Paque (Amersham  
Biosciences, Uppsala, Sweden) density gradient, collected, washed and stored at 
-140°c. MLC and tetanus toxoid (TET) stimulation
MLC were set up as described earlier (5) with 100 µl of a 5x104 responder PBMC in 
triplicate wells and 100 µl of (a) 5x104 irradiated (40 Gy) PBMC or spleen cells from 
the donor; (b) 5x104 irradiated (40 Gy) PBMC from a third-party; (c) tetanus toxoid 
(TET: RIVM, Bilthoven, The Netherlands) at 7.5 lf/well final concentration as nominal 
antigen to test the memory immune response; (d) PHA (2 µg/ml of purified PHA (Mu-
rex Biotech Ltd) to check the viability of the cells; and (e) culture medium. After  
7 days (for PHA 3 days), proliferation was measured by incorporation of 3H-thymidine 
added during the last 8 hours of culture. The stimulation index (SI) was calculated by 
the ratio of the cpm obtained in the presence of antigen to the cpm in the absence of 
antigen.
Only the results of viable cells (SI ³ 50) from patient, donor and third-party were  
analyzed in the described results. For some patients not enough cells were available 
to perform all tests.
Elispot assay
One hundred ml containing 105 patient PBMC in complete culture medium was 
added to 100 ml 105 irradiated (40 Gy) PBMC or spleen cells derived from the donor 
or third-party in round-bottomed wells (6-fold) of a 96-well plate (Nunc, Roskilde, 
Denmark) as described earlier (9). To control the influence of irradiation on cytokine 
production, PBMC were incubated with irradiated PBMC of the same patient (autolo-
gous control). We also stimulated the cells with TET as recall antigen and PHA as 
positive control. After 40 hours of incubation the non-adherent cells were harvested 
and transferred in triplicate to a flat-bottom 96-well Elispot plate (U-CyTech B.V. 
Diagnostics, Utrecht, The Netherlands) pre-coated with a mouse anti-human IFN-γ 
monoclonal Ab and post-coated with PBS containing 1% BSA. Cells were incubated 
in the Elispot plate for 5 hours to allow spot formation. The spots were counted 
automatically by using a Bioreader 3000 Elispot-reader (BioSys GmbH, Karben, 
Germany).
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Limiting dilution assay (LDA)
Limiting dilution cultures were set up as described previously (5). In brief, 24 repli-
cates of graded number responder PBMC were titrated in 7-step double dilutions 
starting from 5x104 to 781 PBMC/well and stimulated with irradiated (40 Gy) donor 
or third-party PBMC/spleen cells (5x104 cells/well) in 200 µl culture medium [RPMI-
1640-DM (GibcoBRL, Scotland, United Kingdom) supplemented with 100 IU/ml of 
penicillin (Cambrex, Verviers, Belgium) and 100 mg/ml of streptomycin (Cambrex) 
and 10% pooled heat-inactivated and filtered (0.20 µm sterile syringe filter, Corning 
Incorporated, Corning, NY, USA) human serum, that was tested for adequate cell 
growth support in mixed lymphocyte cultures] containing recombinant IL-2 (200 U/
ml, 12.2 ng/ml IL-2; proleukin: Chiron BV, Amsterdam, The Netherlands). Addition-
ally, 24 wells contained stimulator cells alone. After 7 days of culture, each well was 
individually tested for cytolytic activity against 5x103 Europium-DTPA labelled target 
cells [T-cell blasts, cultured with PHA (Murex Biotech Ltd, Kent, England) and rIL-2 
(Chiron)]. After 4 hours of incubation, the plates were centrifuged and 20 µl of the 
supernatant was harvested. Fluorescence of the released Europium was measured 
and was expressed in counts per second (cps). The mean cps of the wells in which 
only stimulator cells were present, were considered as background. Experimental 
wells were scored positive, if the counts in that well exceeded the mean + 3 x SD of 
the wells in which only stimulator cells were present. For each cell concentration the 
number of negative wells was determined and used to calculate the frequency with 
a computer program designed by Strijbosch et al. (10). The CTLpf was expressed as 
the number of CTL per 106 PBMC.
Statistical analysis
The significance of differences between the tests before and after tapering immuno-
suppression was analyzed using the paired Wilcoxon signed rank test. Data concern-
ing the presence of detectable donor-specific CTLpf of the patients before or after 
tapering were analyzed with Fischer’s Exact Test.
Results
Clinical results
After tapering the immunosuppressive dose to 50% of the original MMF or AZA dose 
the serum creatinine level remained unchanged [100%: median 103 µmol/l (range: 
59-175) vs. 50%: 113 µmol/l (range: 55-182)], and was comparable with the control 
group [T=0 months: 119 µmol/l (range: 79-156) vs. T=12 months 115 µmol/l (range: 
65-182)]. One year after dose reduction the serum creatinine levels remained still 
unchanged (median: 107 µmol/l (range: 53-174). None of the patients developed 
rejection or proteinuria (>0.5 g/l).
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Figure 1
Number of IFN-γ producing cells directed to donor cells (A) or to third-party cells (B) in PBMC from pa-
tients before (100%) and after (50%) tapering the immunosuppressive dose to 50% of the original dose.
One yr after dose reduction the serum creatinine
levels remained still unchanged (median:
107 lmol/L (range: 53–174). None of the patients
developed rejection or proteinuria (>0.5 g/L).
The mycophenolic acid (MPA) levels decreased
significantly from a median of 2.42 mg/L (range:
1.54–8.22) to 1.40 (0.50–3.07) after tapering the
MMF dose (p = 0.0002). From all patients
(tapered n = 19, controls n = 8) we isolated
PBMC before and after dose reduction of the
immunosuppressive load to perform in each
sample the T-cell reactivity against donor and
third-party reactivity in MLC, Elispot and LDA
to determine the number of CTLp. In addition,
TET-reactivity was used to test the general
immune response. Only data are presented of
viable cells (SI ‡ 50) from patient, donor and
third-party. For some patients not enough cells
were available to perform all tests.
Mixed lymphocyte culture
The donor-specific MLC did not change as a
consequence of tapering the immunosuppressive
load [100% immunosuppression (T = 0): median
SI 13 (range: 1–570) vs. 50% immunosuppression
(T = 12) SI 11 (1–559)]. Furthermore in the
control group, the donor-specific MLC remains
unchanged [T = 0 months: SI 2 (range: 1–4) vs.
T = 12 months SI 3 (1–35)]. Third-party reactivity
in both tapered and control group was significantly
higher than the donor-specific MLC (p = 0.001 vs.
p = 0.008 respectively). The third-party specific
MLC was not different before and after tapering
immunosuppression [T = 0 months: median SI
107 (range: 14–685) vs. T = 12 months: SI 157
(25–846)]. The third-party MLC did not change in
time in the control group [T = 0 months: SI 152
(range: 62–185) vs. T = 12 months: SI 112 (23–
204)].
Frequency of IFN-c producing cells
Neither the number of IFN-c pc directed to donor
antigens (Fig. 1A) nor directed to third-party
antigens (Fig. 1B) was different in the period
before and after tapering immunosuppression.
The response to third-party cells was significantly
higher than to donor antigens (p < 0.0001). In the
control group, no difference in time was found in
donor [T = 0 months: 40 IFN-c pc/106 PBMC
(range: 0–170) vs. T = 12 months: 40 IFN-c pc/
106 PBMC (0–150)] and third-party
[T = 0 months: 140 IFN-c pc/106 PBMC (range:
0–270) vs. T = 12 months: 80 IFN-c pc/106
PBMC (0–450)] reactivity.
Tetanus toxoid reactivity
The reactivity to TET measured in a proliferation
assay did not change after tapering immunosup-
pression [before tapering: median SI 4 (range: 1–
142) vs. after tapering: SI 4 (1–270)]. The TET
reactivity in the control group remained stable
in time [T = 0 months: SI 3 (1–22) vs. T =
12 months: 12 (1–559)]. Furthermore, the number
of IFN-c pc specific for TET was comparable
before and after tapering immunosuppression
[before: 40 IFN-c pc/106 (0–620) vs. after: 15
IFN-c pc/106 (0–395)], and in the control group
[T = 0 months, 25 IFN-c pc/106 (0–255) vs.
T = 12 months, 78 IFN-c pc/106 (0–595)].
100% 50% 
0 
25 
50 
75 
100 
100 
600 
n = 18 n = 17 
# 
IF
N
-γ
 
pc
/1
06
 
PB
M
C 
100% 50% 
0 
50 
100 
150 
200 
n = 18 n = 17 
200 
600 
# 
IF
N
-γ
 
pc
/1
06
 
PB
M
C 
A
B
Fig. 1. Number of IFN-c producing cells directed to donor
cells (A) or to third-party cells (B) in PBMC from patients
before (100%) and after (50%) tapering the immunosuppres-
sive dose to 50% of the original dose.
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One yr after dose reduction the serum creatinine
levels remained still unchanged (median:
107 lmol/L (range: 53–174). None of the patients
developed rejection or proteinuria (>0.5 g/L).
The mycophenolic acid (MPA) levels decreased
significantly from a median of 2.42 mg/L (range:
1.54–8.22) to 1.40 (0.50–3.07) after tapering the
MMF dose (p = 0.0002). From all patients
(tapered n = 19, controls n = 8) we isolated
PBMC before and after dose reduction of the
immunosuppressive load to perform in each
sample the T-cell reactivity against donor and
third-party reactivity in MLC, Elispot and LDA
to determine the number of CTLp. In addition,
TET-reactivity was used to test the general
immune response. Only data are presented of
viable cells (SI ‡ 50) from patient, donor and
third-party. For some patients not enough cells
were available to perform all tests.
Mixed lymphocyte culture
The donor-specific MLC did not change as a
consequence of tapering the immunosuppressive
load [100% immunosuppression (T = 0): median
SI 13 (range: 1–570) vs. 50% immunosuppression
(T = 12) SI 11 (1–559)]. Furthermore in the
control group, the donor-specific MLC remains
unchanged [T = 0 months: SI 2 (range: 1–4) vs.
T = 12 months SI 3 (1–35)]. Third-party reactivity
in both tapered and control group was significantly
higher than the donor-specific MLC (p = 0.001 vs.
p = 0.008 respectively). The third-party specific
MLC was not different before and after tapering
immunosuppression [T = 0 months: median SI
107 (range: 14–685) vs. T = 12 months: SI 157
(25–846)]. The third-party MLC did not change in
time in the control group [T = 0 months: SI 152
(range: 62–185) vs. T = 12 months: SI 112 (23–
204)].
Frequency of IFN-c producing cells
Neither the number of IFN-c pc directed to donor
antigens (Fig. 1A) nor directed to third-party
antigens (Fig. 1B) was different in the period
before and after tapering immunosuppression.
The response to third-party cells was significantly
higher than to donor antigens (p < 0.0001). In the
control group, no difference in time was found in
donor [T = 0 months: 40 IFN-c pc/106 PBMC
(range: 0–170) vs. T 12 months: 40 IFN-c pc/
106 PBMC (0–150)] and third-party
[T = 0 months: 140 IFN-c pc/106 PBMC (range:
0–270) vs. T = 12 months: 80 IFN-c pc/106
PBMC (0–450)] reactivity.
Tetanus toxoid reactivity
The reactivity to TET measured in a proliferation
assay did not change after tapering immunosup-
pression [before tapering: median SI 4 (range: 1–
142) vs. after tapering: SI 4 (1–270)]. The TET
reactivity in the control group remained stable
in time [T = 0 months: SI 3 (1–22) vs. T =
12 months: 12 (1–559)]. Furthermore, the number
of IFN-c pc specific for TET was comparable
before and after tapering immunosuppression
[before: 40 IFN-c pc/106 (0–620) vs. after: 15
IFN-c pc/106 (0–395)], and in the control group
[T = 0 months, 25 IFN-c pc/106 (0–255) vs.
T = 12 months, 78 IFN-c pc/106 (0–595)].
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cells (A) or to third-party cells (B) in PBMC from patients
before (100%) and after (50%) tapering the immunosuppres-
sive dose to 50% of the original dose.
van Besouw et al.
132
A B
The MPA levels decreased significantly from a median of 2.42 mg/l (range: 1.54-8.22) 
to 1.40 (0.50-3.07) after tapering the MMF dose (p=0.0002).
From all patients (tapered n=19, controls n=8) we isolated PBMC before and after 
dose reduction of the immunosuppressive load to perform in each sample the T-cell 
reactivity against donor and third-party reactivity in MLC, Elispot, and limiting dilution 
assay to determine the number of CTLp. In addition, TET-reactivity was used to test 
the general immune response. Only data are presented of viable cells (SI ³ 50) from 
patient, donor and third-party. For some patients not enough cells were available to 
perform all tests.
Mixed lymphocyte culture (MLC)
The donor-specific MLC did not change as a consequence of tapering the immuno-
suppressive load [100% immunosuppression (T=0): median SI 13 (range: 1-570) vs. 
50% immunosuppression (T=12) SI 11 (1-559)]. Also in the control group, the donor-
specific MLC remains unchanged [T=0 months: SI 2 (range: 1-4) vs. T=12 months SI 
3 (1-35)].
Third-party re tivity in both tap red and control group was significantly higher than 
the donor-specific MLC (p=0.001 vs. p=0.008, respectively).
The third- arty specific MLC was not different before and after tapering immunosup-
pression [T=0 months: median SI 107 (range: 14-685) vs. T=12 months: SI 157 (25-
846)]. The third-party MLC did not change in time in the control group [T=0 months: 
SI 152 (range: 62-185) vs. T=12 months: SI 112 (23-204)]. 
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Frequency of IFN-γ producing cells (pc)
Neither the number of IFN-γ pc directed to donor antigens (Figure 1A) nor directed to 
third-party antigens (Figure 1B) was different in the period before and after tapering 
immunosuppression. The response to third-party cells was significantly higher than 
to donor antigens (p<0.0001). 
In the control group, no difference in time was found in donor [T=0 months: 40 IFN-γ 
pc/106 PBMC (range: 0-170) vs. T=12 months: 40 IFN-γ pc/106 PBMC (0-150)] and 
third-party [T=0 months: 140 IFN-γ pc/106 PBMC (range: 0-270) vs. T=12 months: 
80 IFN-γ pc/106 PBMC (0-450)] reactivity.
Tetanus toxoid (TET) reactivity
The reactivity to TET measured in a proliferation assay did not change after tapering 
immunosuppression [before tapering: median SI 4 (range: 1-142) vs. after tapering: 
SI 4 (1-270)]. The TET reactivity in the control group remained stable in time [T=0 
months: SI 3 (1-22) vs. T=12 months: 12 (1-559)].
Also the number of IFN-γ producing cells specific for TET was comparable before 
and after tapering immunosuppression [before: 40 IFN-γ pc/106 (0-620) vs. after: 15 
IFN-γ pc/106 (0-395)], and in the control group [T=0 months, 25 IFN-γ pc/106 (0-
255) vs. T=12 months, 78 IFN-γ pc/106 (0-595)].
Cytotoxic T-lymphocyte precursor frequency (CTLpf)
Before tapering the immunosuppressive load, the donor-specific CTLpf was detect-
able (≥10/106 PBMC) in 44% (7/16) of the patients tested in CTLpf (Figure 2A). In the 
control group 43% (3/7) of the patients had detectable donor-specific CTLpf. The 
donor-specific CTLpf of the 7 patients with detectable CTLpf (n=6 MMF, n=1 AZA) 
Figure 2
CTLpf determined against donor cells (A) or against third-party cells (B) in patients before (100%) and 
after (50%) tapering the immunosuppressive dose to 50% of the original dose. 
Cytotoxic T-lymphocyte precursor frequency
Before tapering the immunosuppressive load, the
donor-specific CTLpf was detectable (‡10/106
PBMC) in 44% (seven of 16) of the patients tested
in CTLpf (Fig. 2A). In the control group 43%
(three out of seven) of the patients had detectable
donor-specific CTLpf. The donor-specific CTLpf
of the seven patients with detectable CTLpf (n = 6
MMF, n = 1 AZA) decreased in all cases after
tapering the immunosuppressive load from median
of 32/106 PBMC (range: 10–69) to 8/106 PBMC
(range: 4–14). This pattern was not seen in the
control group. Third-party reactivity in both the
tapered and control group was significantly higher
than the donor-specific CTLpf (p < 0.0001), but
tapering immunosuppression had no effect on
third-party CTLpf (Fig. 2B).
Discussion
After clinical transplantation life-long immuno-
suppression is deemed necessary. As minimizing
immunosuppression is presumed to be beneficial,
avoiding or tapering of one of the immunosup-
pressive drugs is recommended (1, 11). In our
transplant centre, all patients with stable kidney
function and two yr after transplantation were
withdrawn from CNI to receive MMF or AZA
in combination with low dose prednisone (5).
Thereafter, the MMF and AZA dose were tapered
to half of the original dose (7).
In the present study, we investigated T-cell
reactivity during tapering the MMF or AZA dose.
Comparable with our results after withdrawal
of CNI (5), we found a decrease in donor-reactive
CTLpf and no change in third-party reactive
CTLpf, donor and third-party MLC, frequency
of IFN-c pc directed to donor or third-party
antigens and TET reactivity after tapering the
immunosuppression. After tapering the immuno-
suppressive dose, the hyporesponsiveness of donor-
specific CTLp became even more evident.
Although our data have to be confirmed in a
larger group of transplant patients who will be
reduced in their immunosuppressive load vs. those
who are not, we suggest that a specific downregu-
lation of CTLp directed to donor antigens pre-
sented by the direct presentation pathway occurred
during tapering the MMF or AZA dose. This
downregulation might be caused by anergy, dele-
tion or regulation. Because IL-2 reverses the
anergic state of cells (12), and we added exogenous
IL-2 to the LDA cultures to determine CTLpf,
anergy of donor-specific CTLp is an unlikely cause
of the low numbers of donor-specific CTLp.
Mycophenolic acid was shown to increase apop-
tosis of human T-cell lines (13) and deletion of
in vivo activated T-cells (14). If deletion of donor-
activated CTLp occurs during MMF treatment, we
expect that after tapering the MMF dose an
increase in number of CTLp should be detected.
In contrast, we found a decrease in CTLpf.
Therefore, we assume that suppression of regula-
tory T-cells (Treg) by MMF or AZA is a more
convenient explanation of the low number of
donor-specific CTL after tapering the MMF or
AZA dose.
Regulatory T-cell suppressor function has been
demonstrated to be dependent on the presence of
IL-2 (15, 16). Recently, IL-2 signalling has been
shown to be necessary for the survival of FoxP3+
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Fig. 2. CTLpf determined against donor cells (A) or against
third-party cells (B) in patients before (100%) and after
(50%) tapering the immunosuppressive dose to 50% of the
original dose.
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Cytotoxic T-lymphocyte precursor frequency
Before tapering the immunosuppressive load, the
donor-specific CTLpf was detectable (‡10/106
PBMC) in 44% (seven of 16) of the patients tested
in CTLpf (Fig. 2A). In the control group 43%
(three out of seven) of the patients had detectable
donor-specific CTLpf. The donor-specific CTLpf
of the seven patients with detectable CTLpf (n = 6
MMF, n = 1 AZA) decreased in all cases after
tapering the immunosuppressive load from median
of 32/106 PBMC (range: 10–69) to 8/106 PBMC
(range: 4–14). This pattern was not seen in the
control group. Third-party reactivity in both the
tapered and control group was significantly higher
than the donor-specific CTLpf (p < 0.0001), but
tapering immunosuppression had no effect on
third-party CTLpf (Fig. 2B).
Discussion
After clinical transplantation life-long immuno-
suppression is deemed necessary. As minimizing
immunosuppression is presumed to be beneficial,
avoiding or tapering of one of the immunosup-
pressive drugs is recommended (1, 11). In our
transplant centre, all patients with stable kidney
function and two yr after transplantation were
withdrawn from CNI to receive MMF or AZA
in combination with low dose prednisone (5).
Thereafter, the MMF and AZA dose were tapered
to half of the original dose (7).
In the present study, we investigated T-cell
reactivity during tapering the MMF or AZA dose.
Comparable with our results after withdrawal
of CNI (5), we found a decrease in donor-reactive
CTLpf and no change in third-party reactive
CTLpf, donor and third-party MLC, frequency
of IFN-c pc directed to donor or third-party
antigens and TET reactivity after tapering the
immunosuppression. After tapering the immuno-
suppressive dose, the hyporesponsiveness of donor-
specific CTLp became even more evident.
Although our data have to be confirmed in a
larger group of transplant patients who will be
reduced in their immunosuppressive load vs. those
who are not, we suggest that a specific downregu-
lation of CTLp directed to donor antigens pre-
sented by the direct presentation pathway occurred
during tapering the MMF or AZA dose. This
downregulation might be caused by anergy, dele-
tion or regulation. Because IL-2 reverses the
anergic state of cells (12), and we added exogenous
IL-2 to the LDA c ltures to de ermine CTLpf,
anergy of donor-specific CTLp is an unlikely cause
of the low numbers of donor-specific CTLp.
Mycophenolic acid was shown to increase apop-
tosis of human T-cell lines (13) and deletion of
in vivo activated T-cells (14). If deletion of donor-
activated CTLp occurs during MMF treatment, we
expect that after tapering the MMF dose an
increase in number of CTLp should be detected.
In contrast, we found a decrease in CTLpf.
Therefore, we assume that suppression of regula-
tory T-cells (Treg) by MMF or AZA is a more
convenient explanation of the low number of
donor-specific CTL after tapering the MMF or
AZA dose.
Regulatory T-cell suppressor function has been
demonstrated to be dependent on the presence of
IL-2 (15, 16). Recently, IL-2 signalling has been
shown to be necessary for the survival of FoxP3+
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decreased in all cases after tapering the immunosuppressive load from median of 
32/106 PBMC (range: 10-69) to 8/106 PBMC (range: 4-14). This pattern was not seen 
in the control group. Third-party reactivity in both the tapered and control group was 
significantly higher than the donor-specific CTLpf (p<0.0001), but tapering immuno-
suppression had no effect on third-party CTLpf (Figure 2B).
Discussion
After clinical transplantation life-long immunosuppression is deemed necessary. As 
minimizing immunosuppression is presumed to be beneficial, avoiding or tapering 
of one of the immunosuppressive drugs is recommended (1, 11). In our transplant 
center, all patients with stable kidney function and 2 years after transplantation were 
withdrawn from CNI to receive MMF or AZA in combination with low dosed Pred (5). 
Thereafter, the MMF and AZA dose were tapered to half of the original dose (7).
In the present study, we investigated T-cell reactivity during tapering the MMF or AZA 
dose. Comparable with our results after withdrawal of CNI (5), we found a decrease in 
donor-reactive CTLpf and no change in third-party reactive CTLpf, donor and third-
party MLC, frequency of IFN-γ pc directed to donor or third-party antigens, and TET 
reactivity after tapering the immunosuppression. After tapering the immunosuppres-
sive dose, the hyporesponsiveness of donor-specific CTLp became even more evi-
dent. Although, our data have to be confirmed in a larger group of transplant patients 
who will be reduced in their immunosuppressive load versus those who are not, we 
suggest that a specific down-regulation of CTLp directed to donor antigens presented 
by the direct presentation pathways occurred during tapering the MMF or AZA dose. 
This downregulation might be due to anergy, deletion or regulation. Because IL-2 
reverses the anergic state of cells (12), and we added exogenous IL-2 to the LDA 
cultures to determine CTLpf, anergy of donor-specific CTLp is an unlikely cause of the 
low numbers of donor-specific CTLp.
Mycophenolic acid (MPA) was shown to increase apoptosis of human T-cell lines (13) 
and deletion of in vivo activated T-cells (14). If deletion of donor-activated CTLp oc-
curs during MMF treatment, we expect that after tapering the MMF dose an increase 
in number of CTLp should be detected. In contrast, we found a decrease in CTLpf. 
Therefore, we assume that suppression of regulatory T-cells (Treg) by MMF or AZA is 
a more convenient explanation of the low number of donor-specific CTL after tapering 
the MMF or AZA dose.
Regulatory T-cell suppressor function has been demonstrated to be dependent on the 
presence of IL-2 (15, 16). Recently, IL-2 signalling has been shown to be necessary for 
the survival of FoxP3+ Treg in vivo (17). Before, we have shown that CNI discontinua-
tion led to increased numbers of Treg (5), probably as the result of the reducing effect 
of CNI on IL-2 production. We also have shown that CNI reduces FoxP3 expression 
in human cells (18). In mice it was demonstrated that exogenous IL-2 can overcome 
reduced FoxP3 expression and the functional defect in Treg induced by CsA (19).
70
Chapter 5
Less is known about the relevance of MMF and AZA on Treg function. The antipro-
liferative agents MMF and AZA prevent expansion of alloactivated T and B-cells. 
Recently, it was shown in a mice model that MMF and AZA showed opposite effect 
on induction of regulatory cells after intratracheal delivery of donor splenocytes. AZA 
abrogated such induction, whereas MMF could promote the generation of Treg (20). 
In contrast to CNI, MMF did result in reduced FoxP3 gene expression when murine 
Tregs were exposed in vitro to immununosuppressive medication, while MMF inter-
fered with Treg related protection in an acute graft-versus-host disease mice model 
(19). Thus, MMF could have an effect on Tregs in vivo.
The nature of dendritic cells (DC) has a major impact on the ability to induce Treg. 
DC mediated induction of Tregs includes, next to cell-cell contact and IL-2, CD80/
CD86 interactions (21). Preferential expansion of FoxP3+ T-cells was found in the 
presence of  mature DC compared to immature DC (21). The active metabolite of 
MMF, MPA, affects the phenotype and function of DC by reducing the expression 
of costimulatory molecules (22). Therefore, the suppressive effect of Treg exposed 
to MPA could be hindered by an indirect effect of MPA on DC. This may explain that 
after reducing the MMF dose, the donor-specifc CTLpf decreases, because of higher 
Treg activity.
Waldmann et al. (23) reported that mechanisms ranging from anergy and deletion to 
regulation should not be seen as distinctive mechanisms, but these may all interact 
with each other. This interaction is also suggested by a recent study of our group. 
Tregs of patients with positive MLC to donor-antigens could prevent rejection and 
allow stable graft function, while in other patients donor responder cells are no longer 
present in periphery, and therefore there are no cells to suppress (24).
In summary, we conclude that in kidney transplant recipients reduction of immuno-
suppressive load leads to lower CTLp activity.
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Abstract
This study investigated specific gene expression profiles in patients with donor-
specific cytotoxic-hyporesponsiveness, reflected by cytotoxic T-lymphocyte pre-
cursors frequency (CTLp). The effect of calcineurin inhibitor (CNI) withdrawal was 
studied on markers for cytotoxicity(perforin, granzyme B), apoptosis(Fas,FasL), Th1 
and Th2 cytokines(IL-2, IL-10), Th1 and Th2 transcription factors(T-bet, GATA 3), 
Th17 transcription factor and cytokine(RORγt, IL-17), and for immune regulation/
activation(CD25, FOXP3). Peripheral blood samples from renal allograft recipients 
(n=18), more than 2 years after transplantation with stable renal function were ana-
lyzed before and 4 months after CNI withdrawal. Additionally, systolic and diastolic 
blood pressure, cholesterol, serum creatinine and proteinuria were evaluated and 
no significant differences were measured before and after CNI withdrawal. How-
ever, CNIs’ discontinuation influenced peripheral gene expression profiles. After CNI 
withdrawal the mRNA expression of Granzyme-B, Perforin, Fas, FasL, T-bet, GATA3, 
CD25 were significantly lower than during CNI treatment. After CNI discontinuation, 
donor specific CTLp frequency decreased, while FOXP3 expression discriminated 
between detectable and non-detectable donor-specific cytolysis reactivity; FOXP3 
transcript values were highest in absence of donor-specific cytotoxicity (p<0.01). 
Our study shows, CNI withdrawal in stable kidney transplant recipients 2 years after 
transplantation, is safe. Moreover, discontinuation of CNIs’ treatment allows FOXP3+ 
regulatory T-cells development, resulting in a significant decrease of anti-donor im-
mune reactivity.
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Introduction
Over the past years there has been a remarkable decline in acute rejection and early 
graft loss rates after kidney transplantation [1, 2]. Unfortunately, this positive outcome 
is accompanied by specific side effects such as nephrotoxicity, hypertension, lipid 
disorders, diabetes mellitus and an increased incidence of infections and malignan-
cies [3]. Therefore, dose reduction or withdrawal of CNI (e.g., cyclosporine, tacroli-
mus) is advisable, provided that no rejection or graft loss will occur. Previous studies, 
in which CNI were replaced by mycophenolate mofetil (MMF) or azathioprine (AZA), 
reported improved renal function with low rates of hypertension [4] though a rela-
tive high acute rejection rate did occur (15-25%) [5-7]. However, these studies were 
performed within the first year after transplantation. Whether CNI withdrawal at later 
time points after transplantation also is associated with acute rejection and reduced 
CNI related side effects is still unknown. To assess at what time after transplantation 
CNI can be safely stopped, the use of a proper biomarker that measures anti-donor 
reactivity is helpful [8, 9]. For instance, we have shown that conversion from CNI to 
MMF or AZA is a safe procedure when their donor-specific cytotoxic T lymphocyte 
precursor frequency (CTLpf) is low [9]. 
Nowadays, it is evident from in vitro and animal studies that immunosuppressive 
agents interfere in both immune activation cascades as in the immunosuppressive 
counter mechanisms. For instance, CNI inhibit the gene transcription of IL-2, a cy-
tokine with immunostimulatory as well as essential immunosuppressive actions [10]. 
IL-2 downregulates immune responses by both its pro-apoptotic actions and directs 
the function of CD4+CD25+CD127-/lowFOXP3+ suppressor T-cells [11]. 
In the present study, the effects of CNI withdrawal in patients > 2 year after kidney 
transplantation on both clinical and immunological parameters were studied. Param-
eters for kidney function, blood pressure and cholesterol were studied in concert with 
the biomarkers: CTLp frequencies, markers for cytotoxicity (perforin, granzyme B), 
apoptosis (Fas, FasL), Th1 and Th2 transcription factors and cytokines (T-bet, IL-2, 
GATA-3, IL-10), Th17 cells (RORγt, IL-17), and immune regulation (FOXP3).
Material and Methods
Patients
Stable renal transplant recipients (N=18) who were at least 2 years after transplanta-
tion (range 28-69 months) and rejection free in the last 6 months were withdrawn 
from the CNI tacrolimus or cyclosporine. At time of inclusion the patients were treated 
with tacrolimus or cyclosporine and AZA 2 mg/kg/day or MMF 2 g/day combined 
with prednisone 10 mg/day. Four weeks after inclusion, the patients were CNI free 
and used 2 g MMF (N=17) or 2 mg/kg AZA (N=1) combined with 10 mg prednisone 
a day (figure 1) [12]. Patients were removed from the study after developing graft loss 
or acute rejection. HLA identical living related transplantations were excluded. 
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The immune parameters CTLp frequencies, and mRNA expression levels of per-
forin, granzyme B, Fas, FasL, T-bet, IL-2, GATA-3, IL-10, RORγt, IL-17, and FOXP3 
were measured before and 4 months after CNI withdrawal. From these patients, in 
the following part of our study, kidney function, blood pressure and cholesterol were 
studied before and after CNI withdrawal at 4 months. In addition, these clinical  
parameters were analyzed in the CNI free patients after further MMF dosage reduc-
tion (2 times 25%) at 24 months (figure 1) [12].
CTL precursors frequency
To determine the number of donor-specific cytotoxic T-lymphocytes, donor spleen 
cells in case of a deceased donor or living donor PBMC had to be available. Periph-
eral blood mononuclear cell (PBMC) samples of patients and living unrelated donors 
were isolated as described before, and stored at -140°c until use. 
Cytotoxic T-lymphocyte precursor frequency (CTLpf) was measured using a limiting 
dilution assay as described previously [8] In brief, 24 replicates of graded number 
responder PBMC were titrated in 7-step double dilutions starting from 5x104 to 781 
PBMC/well and stimulated with irradiated (40Gy) donor or third party PBMC/spleen 
cells (5x104 cells/well) in 200 µl culture medium containing recombinant IL-2 (20 U/
well, 12.2 ng/ml IL-2; proleukin: Chiron BV, Amsterdam, The Netherlands). Addition-
ally, 24 wells contained stimulator cells alone. After 7 days of culture, each well was 
individually tested for cytolysis activity against 5x103 Europium-DTPA labeled target 
cells (T-cell blasts, cultured with PHA and recombinant IL-2 (Chiron). After 4 hours of 
incubation, the plates were centrifuged and 20 µl of the supernatant was harvested. 
FIGURE 1. Study design. At the time of the conversion, the CNI medication was withdrawn. Blood 
samples were taken from 18 patients. Further tapering was made at 4 and at 8 months after withdrawal. 
At 24 months after CNI withdrawal blood samples were taken from patients for the needs of the clinical 
evaluation.
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Fluorescence of the released Europium was measured in a time-resolved fluorometer 
and was expressed in counts per second (cps). The mean cps of the wells in which 
only stimulator cells were present, were considered as background. Experimental 
wells were scored positive, if the counts in that well exceeded the mean three times 
the standard deviation of the wells in which only stimulator cells were present. For 
each cell concentration the number of negative wells was determined and used to 
calculate the frequency with computer program designed by Strijbosch et al [13] The 
CTLpf was expressed as the number per 106 PBMC.
Quantitative Real Time-PCR  
Messenger RNA extraction from the PBMC, cDNA transcription and amplification 
was performed as described before [10]. In brief, total RNA was isolated using the 
High Pure RNA Isolation kit (Roche Applied Science, Penzberg, Germany), accord-
ing to the manufacturer’s instructions. RNA concentrations were measured using the 
RiboGreen® RNA Quantification Reagent And Kit (Molecular Probes, Eugene, OR,), 
and cDNA was synthesized from 500 ng RNA with random primers.
For the quantitative real time PCR analysis, the TaqMan technology (7700 Sequence 
Detector; Applied Biosystems, Foster City, CA) was applied according to the manu-
facturer’s instructions. Messenger RNA expression levels of Granzyme B, Perforin, 
Fas, FasL, T-bet, IL-2, GATA3, IL-10, RORγt, IL17, FOXP3 and CD25 were quantified. 
The choice of primer and probe (IL-2, Granzyme B, Perforin, T-bet, GATA3) was de-
fined using the primer express software (Applied Biosystems) and are listed in Table 
1. FOXP3 (Hs00203958_m1) IL-10 (Hs00174086_m1) RORγt (Hs 00172858_m1) and 
IL-17A (Hs 00174383_m1) mRNA measurements were performed using Assay on 
Demand and pre-developed Taqman® PDAR assays to measure CD25 (4328847F), 
Fas (4318333F) and FasL (4319441F) concentrations (Applied Biosystems). 
TABLE 1. Primer and probe sequences
Forward primer IL-2 5’-TTT-GAA-TGG-AAT-TAA-TTA-CAA-GAA-TCC-3’
Reverse primer IL-2 5’-TTC-TAG-ACA-CTG-AAG-CTG-TTT-CAG-TTC-3’
Probe IL-2 5’FAM-CCA-GGA-TGC-TCA-CAT-TTA-AGT-TTT-ACA-TGC-CC-TAMRA3’
Forward primer Perforin-1 5’-GTG-CCG-CTT-CTA-CAG-TTT-CCA-3’
Reverse primer Perforin-1 5’-CGT-AGT-TGG-AGA-TAA-GCC-TGA-GGT-A-3’
Probe Perforin-1 5’FAM-TGG-TAC-ACA-CTC-CCC-CGC-TGC-AC-TAMRA3’
Forward primer Granzyme-B 5’-CCC-TAC-ATG-GCT-TAT-CTT-ATG-ATC-TG-3’
Reverse primer Granzyme-B 5’-GAC-ATT-TAT-GGA-GCT-TCC-CCA-A-3’
Probe Granzyme-B 5’FAM-TGA-GCA-GCT-GTC-AGC-ACG-AAG-TCG-T-TAMRA3’
Forward primer T-bet 5’-AAT-GTG-ACC-CAG-ATG-ATT-GTG-CT-3’
Reverse primer T-bet 5’-TTC-AGC-TGA-GTA-ATC-TCG-GCA-TT-3’
Probe T-bet 5’FAM-TGG-TAG-GCA-GTC-ACG-GCA-ATG-AAC-TG-3’
Forward primer GATA-3 5’-CGG-TCC-AGC-ACA-GGC-AG-3’
Reverse primer GATA-3 5’-GGC-TGC-AGA-CAG-CCT-TCG-3’
Probe GATA-3 5’FAM-TGT-GTG-AAC-TGT-GGG-GCA-ACC-TCG-TAMRA3’
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To quantify IL-2, Granzyme B, Perforin, T-bet and GATA3 transcript levels 5 ml cDNA 
was added to 20 µl PCR mixture containing 12,5 µl Universal PCR Master Mix  
(Applied Biosystems), 0,5 µl of sense primer (25 pmol), 0,5 µl anti-sense primer  
(25 pmol), 0,5 µl of FAM labeled probe (5 pmol) and 6 µl H2O. To determine FOXP3, 
CD25, IL-10, Fas and FasL mRNA expression levels, we added 5 ml cDNA to 20 µl 
PCR mixture containing 12,5 µl Universal PCR Master Mix, 0.625 µl primer/probe mix 
and 6.875 µl H2O. The PCR was performed after a first step of 2-min 50°C and 10-
min 95°C by 40 cycles of 15 seconds at 95°C and 1 minute at 58°C (IL-2, Granzyme 
B, GATA3) or 59°C (Perforin, T-bet) or 60°c (FOXP3, CD25, Fas, FasL and IL-10). 
Each run contained several negative controls (no template), and two positive refer-
ence samples. For the quantification of mRNA expression levels we used the 2^(40-Ct) 
procedure as described by Bustin et al., and denoted target expression levels as 
copy number/500 ng RNA[14].
Statistical analysis 
Statistical analysis was conducted using the Mann-Whitney test to compare the 
two groups, the one with the patients before the withdrawal of the CNI drug and the 
other, after the conversion. Results are reported as medians with range. A two-tailed 
P-value of <0.05 was considered to be significant. 
Results
Clinical results
The clinical data are summarized in table 2a and table 2b and are in accordance 
with our previous published data [12]. After CNI discontinuation, and reduction of the 
immunosuppressive load 1 out of 18 patients developed proteinuria of 0,5 g/l, while 
the creatinine levels remained stable during time of observation (table 2). Further-
more, during the study period there were no significant differences between systolic 
and diastolic blood pressure (ps =0.59 and pd =0.13, table 2) and cholesterol levels 
(p=0.06).    
TABLE 2a
CNI+ CNI- P value
Serum creatinine (µmol/l)
108.0 
(61.0-238.0)
96.0
(59.0-221.0)
0.19
Proteinuria (g/l)
0.10
(0.10-0.17)
0.10
(0.10-0.54)
0.16
Systolic pressure (mmHg)
142
(125-200)
137
(120-180)
0.59
Diastolic pressure (mmHg)
80
(75.0-90.0)
80
(70.0-90.0)
0.13
Cholesterol (mmol/l)
6.10
(4.9-8.1)
6.00
(4.4-7.7)
0.06
81
Discontinuation of CNI and FOXP3+ regulatory T cells
6
TABLE 2b
CNI+ CNI-
(24 months)
P value
Serum creatinine (µmol/l)
108.0
(61.00-238.0)
106.0
(53.00-251.0)
0.71
Proteinuria (g/l)
0.10
(0.10-0.17)
0.10
(0.06-0.84)
0.55
Systolic pressure (mmHg)
142
(125-200)
140
(110-170)
0.34
Diastolic pressure (mmHg)
80
(75-90)
80
(65-90)
0.41
Cholesterol (mmol/l)
6.10
(4.9-8.1)
6.00
(4.2-7.2)
0.35
TABLES 2a and 2b. Clinical data as medians with a range, before, during, and two years following the 
conversion. Patients have been submitted to a further tapering of the new medication’s dose at the 4th 
and 8th month after the medication’s switch.
CTLp frequencies before and after withdrawal of CNI
CTLp frequencies (CTLpf) were studied before CNI withdrawal and at 4 months after 
its discontinuation. During CNI treatment, PBMC samples from 13/18 patients were 
available, and after CNI discontinuation from all patients samples were present for 
CTLpf analysis. At inclusion 8/13 patients had detectable numbers of donor specific 
CTL (≥10/106 PBMC) and after stopping CNI treatment donor specific CTLs were 
measurable in the peripheral blood of 5/13 patients. The donor specific CTL numbers 
decreased after withdrawal of CNI in each patient. The median CTLpf of all patients 
at the time of the inclusion was 19/106  (range 0-548/106 PBMC) and after CNI with-
drawal 7/106  (range 0-208/106 PBMC, p=0.03, figure 2A). All patients had detect-
able CTLpf against third-party antigens before CNI discontinuation (figure 2B).
FIGURE 2 A and B. Analysis of cytotoxic T-lymphocyte precursor frequency (CTLpf/106 PBMC) 
against donor-specific and HLA 2-2-2 mismatched third-party cells, respectively, before (CNI +) and 4 
months after (CNI -) withdrawal of CNI. The statistical difference, the median and the range between the 
groups are also evidenced.
with the patients before the withdrawal of the CNI
drug and the other, after the conversion. Results
are reported as medians with range. A two-tailed
p-value of <0.05 was considered to be significant.
Results
Clinical results
The clinical data are summarized in Table 2 and
are in accordance with our previous published data
(12). After CNI discontinuation, and reduction of
the immunosuppressive load, one of 18 patients
developed proteinuria of 0.5 g/L, while th creat-
inine levels remained stable during time of obser-
vation (Table 2). Furthermore, during the study
period, there were no significant differences be-
tween systolic and diastolic blood pressure
(ps = 0.59 and pd = 0.13, Table 2) and choles-
terol levels (p = 0.06).
CTLpf before and after withdrawal of CNI
CTLpf were studied before CNI withdrawal and at
four months after its discontinuation. During CNI
treatment, PBMC samples from 13/18 patients
were available, and after CNI discontinuation from
all patients samples were present for CTLpf
analysis. At inclusion, 8/13 patients had detectable
numbers of donor-specific cytotoxic T-lymphocyte
(CTL) (‡10/106 PBMC) and after stopping CNI
treatment donor-specific CTLs were measurable in
the peripheral blood of 5/13 patients. The donor-
specific CTL numbers decreased after withdrawal
of CNI in each patient. The median CTLpf of all
patients at the time of the inclusion was 19/106
(range 0–548/106 PBMC) and after CNI with-
drawal 7/106 (range 0–208/106 PBMC, p = 0.03,
Fig. 2A). All patients had detectable CTLpf
against third-party antigens before CNI discontin-
uation (F g. 2B).
Relative RNA expression levels before and after CNI
withdrawal
Fig. 3 shows significantly lower mRNA levels of
granzyme B, perforin, Fas, FasL, T-bet and
GATA3 in PBMC patients after CNI discontinu-
ation. This effect was also seen for the CD25
mRNA expression levels.
No effect of CNI withdrawal was found for the
mRNA expression levels of FOXP3 (p = 0.10,
Fig. 4A), IL-10, RORct and IL-17 (data not
shown).
Table 2. Clinical data as medians with a range, before, during and two yr following the conversion
CNI+ CNI) p-Value CNI) (24 months)
p-Value
(24 months)
Serum creatinine (lmol/L) 108.0 (61.0–238.0) 96.0 (59.0–221.0) 0.19 106.0 (53.00–251.0) 0.71
Proteinuria (g/L) 0.10 (0.10–0.17) 0.10 (0.10–0.54) 0.16 0.10 (0.06–0.84) 0.55
Systolic pressure (mmHg) 142 (125–200) 137 (120–180) 0.59 140 (110–170) 0.34
Diastolic pressure (mmHg) 80 (75.0–90.0) 80 (70.0–90.0) 0.13 80 (65–90) 0.41
Cholesterol (mmol/L) 6.10 (4.9–8.1) 6.00 (4.4–7.7) 0.06 6.00 (4.2–7.2) 0.35
CNI, calcineurin inhibitor.
Patients have been submitted to a further tapering of the new medications dose at the fourth and eighth month after the medications switch.
Fig. 2. (A) and (B) Analysis of
cytotoxic T-lymphocyte precursor
frequency (CTLpf/106 PBMC
[peripheral blood mononuclear cell])
against donor-specific and HLA 2-2-2
mismatched third-party cells, respec-
tively, before (CNI+) and four months
after (CNI)) withdrawal of CNI. The
statistical difference, the median and
the range between the groups are also
evidenced.
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mRNA expression levels vs. donor-specific cytotoxicity
To define the relationship between donor-specific
cytotoxicity and gene expression profiles, we
compared the mRNA expression levels of PBMC
from patients with and without a detectable
donor-specific CTLpf (‡10/106 vs. <10/106 PBMC).
Before CNI discontinuation, no significant differ-
ence in mRNA expression level of granzyme B,
perforin, Fas, FasL, T-bet, IL-2, GATA3, IL-10,
RORct, IL-17, FOXP3 and CD25 was found
between patients with and without detectable
donor-specific CTLpf. After CNI withdrawal, a
significant difference between FOXP3 mRNA
transcription levels in patients with (N = 5) and
without (N = 13) donor-specific CTLpf was
found. This transcription factor for regulatory
T-cells discriminated between detectable and
non-detectable donor-specific cytolytic reactivity.
The highest FOXP3 mRNA levels were measured
when donor-specific cytotoxic reactivity was not
measurable (Fig. 4B, p < 0.01).
Fig. 3. Analysis of relative mRNA
expression levels before (CNI+) and
four months after (CNI)) withdrawal.
The values are log transformed. Figures
A and B are represent the markers of
cytotoxicity (Perforin I, Granzyme B),
figures C and D the apoptotic markers
(Fas and FasL), figure E and F the Th1
(T-bet) and Th2 (GATA 3) transcrip-
tion factors, and figure G the IL-2
receptor CD25.
Wetering et al.
44
FIGURE 3. Analysis of relative mRNA expression levels before (CNI+) and 4 months after (CNI-) 
withdrawal. The values are log transformed. Figures A and B are represent the markers of cytotoxicity 
(Perforin I, Granzyme B), figures C and D the apoptotic markers (Fas and FasL), figure E and F the Th1 
(T-bet) and Th2 (GATA 3) transcription factors, and figure G the IL-2 receptor CD25.
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Relative mRNA expression levels before and after CNI withdrawal
Figure 3 shows significantly lower mRNA levels of granzyme B, perforin, Fas, FasL,  
T-bet and GATA3 in PBMC patients after CNI discontinuation. This effect was also 
seen for the CD25 mRNA expression levels. 
No effect of CNI withdrawal was found for the mRNA expression levels of FOXP3 
(p=0.10, figure 4A), IL-10, RORγt and IL-17 (data not shown).
mRNA expression levels vs donor-specific cytotoxicity
To define the relationship between donor-specific cytotoxicity and gene expression 
profiles, we compared the mRNA expression levels of PBMC from patients with and 
without a detectable donor specific CTLpf (> 10/106 vs <10/106 PBMC). Before CNI 
discontinuation, no significant difference in mRNA expression level of granzyme B, 
perforin, Fas, FasL, T-bet, IL-2, GATA3, IL-10, RORγt, IL-17, FOXP3 and CD25 was 
found between patients with and without detectable donor-specific CTLpf. After 
CNI withdrawal, a significant difference between FOXP3 mRNA transcription levels 
in patients with (N=5) and without (N=13) donor specific CTLpf was found. This 
transcription factor for regulatory T-cells discriminated between detectable and non-
detectable donor-specific cytolytic reactivity. The highest FOXP3 mRNA levels were 
measured when donor-specific cytotoxic reactivity was not measurable (Figure 4B, 
p<0.01).
Discussion
This study shows that stable kidney transplant
patients on CNI, MMF and steroids >2 years
after transplantation can be safely withdrawn from
CNI. The avoidance of rejection and the achieve-
ment of clinical stability in renal function were
ascertained even with further tapering of MMF of
25% at the 4th and at the 8th month. In contrast to
studies showing an effect on CNI withdrawal
shortly after transplantation in our patients, in
whom the CNI was stopped later after transplan-
tation, no effect of CNI withdrawal was observed
on kidney function parameters, blood pressure and
cholesterol (12). These findings suggest that long-
term treatment with CNI affects the mechanisms
and cells in CNI-treated patients in such a way that
damage occurred, and as a result no beneficial
effect of CNI withdrawal can be found. The
mechanisms by which CNI treatment induces side
effects are not completely understood, but it is
known that for instance the CNI CsA increases
mRNA levels of a number of genes involved in
cholesterol biosynthesis and hypertension (15, 16).
Apart from the parameters for kidney function,
blood pressure and cholesterol, we studied the
effect of CNI withdrawal on several immune
biomarkers. The patients material available al-
lowed us to perform assays only four months after
the CNI withdrawal and not during the period of
the further MMFs tapering. CNI withdrawal
significantly decreased the mRNA expression levels
in unstimulated PBMC for granzyme B, perforin,
Fas, FasL, T-bet, GATA3 and CD25. Further-
more, a decrease in donor-specific and not
anti-third-party CTLpf was measured. The latter
findings in combination with the decreased gran-
zyme/perforin levels imply a direct and specific
downregulation or deletion of anti-donor CD8+
cytotoxic T-cells after withdrawal of CNI. It
has been demonstrated that FOXP3+ regulatory
T-cells control antigen-activated CD8+ effector
T-cells. In a mouse model, depletion of
CD4+FOXP3+ regulatory T-cells before viral
infection significantly enhanced the magnitude of
virus-specific CD8+ T-cell effector function (17).
Moreover, data from human regulatory T-cells
show that CD4+FOXP3+ cells also modulate the
number, activation and function of CD8 T-cells
(18). This mechanism of action of FOXP3+
T-cells could be the explanation our findings.
Circulating activated donor-specific CD8+ T-cells
are not properly controlled by CD4+FOXP3+
T-cells in CNI-treated patients. CNIs interfere in
the mechanisms that contribute in diminishing the
anti-donor repertoire (19). CNI block the phos-
phatase activity of calcineurin, which is then
unable to dephosphorylate NFAT, remains in the
cytoplasm and therefore prevents the transcription
of IL-2 (20–23). IL-2 is well known for its ability to
promote T-cell proliferation, to inhibit apoptosis
and to induce cytokines like IFN-c. Moreover,
IL-2 regulates granzyme B and perforin expression
(24). The importance of IL-2 in the function of cells
that control immune reactivity, the FOXP3+
regulatory T-cells, is well recognized (11, 25).
Furthermore, others and we have shown that
CNI prevent the transcription of FOXP3 and a
loss of the highly suppressive CD27+ regulatory
T-cell population has been reported (10, 26). Here,
we confirm that in vivo, in kidney transplant
patients indeed CNI interfere in the cascades
leading to donor-specific hyporesponsiveness. In
the absence of CNI, cytotoxic-hyporesponsiveness
was associated with high FOXP3 mRNA expres-
sion levels and suggests that donor-specific reac-
tivity is the result of impaired regulation by
FOXP3+ T-cells. After withdrawal of CNI, these
regulatory mechanisms emerge.
Our study shows that CNI withdrawal in stable
kidney transplant recipients who are at least two yr
after transplantation is safe but in contrast to
Fig. 4. (A) Analysis of FOXP3 mRNA
expression levels before (CNI+) and
four months after (CNI)) withdrawal.
(B). Relative FOXP3 mRNA expres-
sion in patients with high donor-specific
cytotoxic T-lymphocyte precursor
frequency (CTLpf) (‡10/106 PBMC
[peripheral blood mononuclear cell]) vs.
low donor-specific CTLpf (<10/106
PBMC) after CNI withdrawal.
Immunosuppression and FOXP3+ T cells
45
FIGURE 4. (A) Analysis of FOXP3 mRNA expression levels before (CNI+) and 4 months after (CNI-) 
withdrawal . (B). Relative FOXP3 mRNA expression in patients with high donor specific CTLpf ( ≥10/106 
PBMC) vs low donor-specific CTLpf (< 10/106 PBMC) after CNI withdrawal.
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Discussion
The present study shows that stable kidney transplant patients on CNI, MMF and 
steroids > 2 years after transplantation can be safely withdrawn from CNI. The avoid-
ance of rejection and the achievement of clinical stability in renal function were ascer-
tained even with further tapering of MMF of 25% at the 4th and at the 8th month. In 
contrast to studies showing an effect on CNI withdrawal shortly after transplantation 
in our patients, in whom the CNI was stopped later after transplantation, no effect of 
CNI withdrawal was observed on kidney function parameters, blood pressure and 
cholesterol [12]. These findings suggest that long-term treatment with CNI, affect the 
mechanisms and cells in CNI treated patients in such a way that damage occurred 
and as a result no beneficial effect of CNI withdrawal can be found. The mechanisms 
by which CNI treatment induces side effects are not completely understood but it is 
known that for instance the CNI CsA increases mRNA levels of a number of genes 
involved in cholesterol biosynthesis and hypertension [15, 16]. 
Apart from the parameters for kidney function, blood pressure and cholesterol, we 
studied the effect of CNI withdrawal on several immune biomarkers. The patients’ 
material available allowed us to perform assays only 4 months after the CNI with-
drawal and not during the period of the further MMF’s tapering. CNI withdrawal 
significantly decreased the mRNA expression levels in unstimulated PBMC for 
granzyme B, perforin, Fas, FasL, T-bet, GATA3 and CD25. Furthermore, a decrease 
in donor-specific and not anti-third party CTLpf was measured. The latter findings in 
combination with the decreased granzyme/perforin levels imply a direct and specific 
down-regulation or deletion of anti-donor CD8+ cytotoxic T cells after withdrawal of 
CNI. It has been demonstrated that FoxP3+ regulatory T cells control antigen acti-
vated CD8+ effector T cells. In a mouse model, depletion of CD4+FoxP3+ regulatory 
T cells before viral infection significantly enhanced the magnitude of virus-specific 
CD8+ T cell effector function [17]. Moreover, data from human regulatory T cells 
show that CD4+FoxP3+ cells also modulate the number, activation and function of 
CD8 T cells [18]. This mechanism of action of FoxP3+ T cells could be the explana-
tion our findings. Circulating activated donor-specific CD8+ T cells are not properly 
controlled by CD4+FoxP3+ T cells in CNI treated patients. CNIs interfere in the 
mechanisms that contribute in diminishing the anti-donor repertoire [19]. CNI block 
the phosphatase activity of calcineurin, which is then unable to dephosphorylate 
NFAT, remains in the cytoplasm and therefore prevents the transcription of IL-2 [20-
23]. IL-2 is well known for its ability to promote T-cell proliferation, to inhibit apoptosis 
and to induce cytokines like IFN-γ. Moreover IL-2 regulates granzyme B and perforin 
expression [24]. The importance of IL-2 in the function of cells that control immune 
reactivity, the FoxP3+ regulatory T-cells, is well recognized [11, 25]. Furthermore, 
others and we have shown that CNI prevent the transcription of FoxP3 and a loss 
of the highly suppressive CD27+ regulatory T cell population has been reported [10, 
26]. Here we confirm that in vivo, in kidney transplant patients indeed CNI interfere in 
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the cascades leading to donor –specific hyporesponsiveness. In the absence of CNI, 
cytotoxic hyporesponsiveness was associated with high FOXP3 mRNA expression 
levels and suggests that donor-specific reactivity is the result of impaired regulation 
by FOXP3+ T-cells. After withdrawal of CNI, these regulatory mechanisms emerge. 
Our study shows that CNI withdrawal in stable kidney transplant recipients who are 
at least 2 years after transplantation is safe but in contrast to withdrawal at earlier 
time point after transplantation, not associated with reduction in CNI related side 
effects. In addition, discontinuation of CNI treatment allows the development of 
FOXP3+ regulatory T-cells resulting in a significant decrease of anti-donor immune 
reactivity. 
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Abstract
Introduction
Living-related HLA-identical renal transplant (RTx) recipients often receive standard 
immunosuppression, despite the absence of mismatched major HLA-antigens and 
the known complications of long-term use of immunosuppression. No data are avail-
able on the need for immunosuppression for these specific patients. We wondered 
whether their immunosuppressive load could be radically reduced.
Method
Between November 1982 and November 2005, 83 living-related HLA-identical RTx 
were performed in our center. Their unadjusted graft survival was 74% at 10 years. In 
29 patients (median time after transplantation 5.6 (range 1.0-21.4) years) with stable 
uncompromised renal function, we tapered their immunosuppression from triple or 
dual therapy to prednisolone 5 mg/day.  Follow up on prednisolone monotherapy 
was at least 24 months. 
Results 
In 27 of 29 patients reduction of immunosuppression to prednisolone monotherapy 
was uneventful. One patient, using dual therapy, developed JC-virus nephropathy 
resulting in graft loss. One refused further discontinuation of his medication. Four 
(15%) of the 27 patients on monotherapy developed biopsy proven recurrence of 
their original disease. Only one of them showed a transient decline in renal function. 
One additional patient developed minor proteinuria and a rise in serum creatinine 
level, due to chronic urinary tract infections. The remaining 23/27 (85%) patients had 
an uneventful follow up during 24 months prednisolone monotherapy. 
Conclusion
We conclude that HLA-identical living-related RTx recipients who are at least one 
year after transplantation might be treated with low dose steroid monotherapy. Close 
surveillance of patients for recurrence of their original disease is recommended to 
allow for potential early therapeutic intervention.
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Introduction
After Human Leucocyte Antigen (HLA)-identical living-related (LR) renal transplan-
tation (RTx) there is less acute rejection and better graft survival compared with 
non-identical renal transplant recipients. These superior results are due to the fact 
that HLA-identical LR transplants are less immunogenic than non-identical renal 
transplants, because in HLA-identical LR RTx all major (class I and II) HLA molecules 
are identical and only mismatches in minor histocompatibility antigens (mHAgs) or 
non-HLA antigens may exist. In animal models, the importance of mHAgs has been 
shown after cardiac transplantation and allogeneic bone marrow transplantation(1-5). 
In humans, mismatches in mHAgs have been shown to induce graft versus host 
disease (GVHD) after HLA-identical bone marrow transplantation, but minor HLA 
mismatches had no influence on 5-year graft outcome after RTx (6, 7).
Nevertheless, recipients of HLA-identical LR donor kidney generally receive the same 
immunosuppressive regime as HLA-mismatched renal transplant recipients. There-
fore they remain at risk for cardiovascular disease, metabolic complications, infec-
tions and malignancies, all known side effects of immunosuppressive medication and 
familiar risk factors for poor patient and graft survival after RTx(8). 
Insufficient data are available about immunosuppression after HLA-identical LR RTx 
(9-13). Even less data are available of the possibility to reduce or discontinue their 
immunosuppressive medication(14). Considering this, we designed a study to reduce 
the immunosuppressive load dramatically in this specific patient group.
Materials and methods
Patients
Between November 1982 and November 2005, 83 LR HLA-identical RTx were 
performed in our center. Molecular HLA typing was performed on DNA obtained 
from blood by polymerase chain reaction/sequence-specific oligonucleotide us-
ing a reverse dot-blot method. (20) Al study patients who were transplanted before 
this technique was available were retyped with this PCR technique to be sure they 
were really HLA-identical with their donor. A transplant was classed as HLA-identical 
if donor and recipient were reported to have identical HLA A, B, Cw, DR and DQ 
antigens. All patients had negative cross matches with their donor prior to transplan-
tation. Of these 83 patients, 43 (52%) were male and 40 (48%) were female. Their 
median age was 50 yrs (range 21-78 yrs)(Table 1). At time of observation (n=83), the 
median time after transplantation was 7.0 years (range 0.8-23.8 yrs). Their unadjust-
ed graft survival was 74% at 10 years, compared to 61% after LR HLA-mismatched 
renal transplantation (Figure 1). 
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Total HLA- identical RTx Not enrolled Study Group
Number of patients 83 54 29
Male: female 43:40 28:26 15:14
Age 
(median in yrs, range)
50 (21-78) 50 (26-78) 51 (21-66)
Male recipient, female donor
Female recipient, male donor
28/43 (65%)
17/40 (43%)
18/28 (64%)
11/26 (42%)
10/15 (67%)
6/14 (43%)
Time after RTx 
(median in yrs, range)
7.0 (0.8-23.8) 8.8 (0.8-23.8) 5.6 (1.0-21.4)
Original disease with potential  
to recur
42 (51%) 26 (49%) 16 (55%)
Table 1: baseline characteristics of the living-related HLA-identical renal transplant recipients  
transplanted between November 1982 and November 2005. 
Figure 1: Unadjusted graft survival after living-related HLA-identical (solid line) and  
HLA-mismatched (dotted line) renal transplantation 
Out of 83 HLA-identical LR RTx recipients, 54 patients could not be enrolled in our 
study (demographics see Table 1). Seven (13%) patients died before with a function-
ing kidney (median time after RTx was 9.6 yrs, range 0.9-15.6 yrs), due to cardio-
vascular disease (n=4), infection (n=1), malignancy (n=1) and suicide (n=1).
In 6 (11%) patients graft loss was observed, due to recurrence of the original disease 
(n=1), chronic rejection (n=2), tubular interstitial nephritis due to medication (n=1), 
surgical complication (n=1) and infection (n=1).
Figure 1: Unadjusted graft survival after living-related HLA-identical (green line) and HLA-mismatched (red line) 
renal transplantation 	
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Two (4%) patients were less then 1 year after transplantation, 3 (6%) patients re-
ceived a kidney from their identical twin sister, 1 (2%) patient already used mono-
therapy, in 1 (2%) patient was transplanted for the 4th time, 11 (20%) patients were 
excluded for logistic reasons and 7 (13%) refused to participate in the present study. 
Seventeen (31%) patients could not be included because of proteinuria. Of these 
17 patients, 6 patients had a biopsy proved recurrence of their original disease, 5 
patients had a chronic allograft nephropathy (CAN), in 1 patient the proteinuria disap-
peared after nephrectomy of his native kidneys and in 5 patients the cause of their 
proteinuria remained unknown. 
The ethical review committee of our center approved the protocol that was con-
ducted according to local requirements. After informed consent, 29 LR HLA-identical 
renal transplant recipients who were more then 1 year after RTx, with stable renal 
function, without proteinuria (<0.2 g/l) and on triple or dual immunosuppression were 
enrolled in our immunosuppression reduction study. Their demographics are shown 
in table 1. The median time after transplantation was 5.6 years. Only 5 patients were 
more than 10 years after transplantation.
Depending on the medication patients used at time of inclusion, we started tapering 
their calcineurin inhibitor (CNI), followed by mycophenolate mofetil (MMF) or azathio-
prine (AZA) and prednisolone dose with 2 months regular intervals to prednisolone 
monotherapy of 5 mg/day. Serum creatinine levels and proteinuria were monitored. 
A renal biopsy was taken if patients developed a clinically relevant rise of serum cre-
atinine or proteinuria (defined as >0.5 g/l). Blood was obtained for monotoring T-cell 
reactivity (results described by Gerrits et al, submitted to Transplantation)
Statistical methods
Data for this study were obtained by patient chart analysis. Survival curves were 
made using the Kaplan-Meier method and the log-rank test was used to compare 
the survival rates. Continuous variables are reported as means ± SD and tested by 
paired Student’s t-test. Data that did not follow a normal distribution are presented as 
medians and tested by Wilcoxon signed rank test. Qualitative variables are reported 
as percentages and were tested by the Pearson’s chi-squared test.
The SSPS statistical package version 12.0.1 was used. P-values <0.05 were consid-
ered significant
Results
Twenty-nine HLA-identical LR RTx recipients were included in our immunosuppres-
sion reduction study. In 27 patients this was their first, for 1 patient it was his second 
and for 1 it was her third RTx. Their median PRA was 2% (range 0-98%) before 
transplantation.
The majority of the patients used dual immunosuppressive therapy at inclusion. Nine-
teen (66%) used AZA combined with prednisolone, 4 (14%) patients used tacrolimus 
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(Tacro) combined with mycophenolate mofetil (MMF), 3 (10%) patients used MMF 
combined with prednisolone and 1 (3%) patient used cyclosporine (CyA) combined 
with prednisolone. Two patients (7%) used triple immunosuppression consisting of 
Tacro, MMF and prednisolone. Figure 2 shows the results of serum creatinine levels 
and proteinuria at time of inclusion (using different combinations of immunosuppres-
sive medication), at the moment patients started with prednisolone monotherapy 
5 mg/day and after they had been on prednisolone monotherapy for 12 and 24 
months. 
Figure 2: Serum creatinine levels and proteinuria at time of inclusion (using different  
combinations of immunosuppressive medication), at the moment patients started with prednisolone 
monotherapy 5 mg/day and after they had been on prednisolone  
monotherapy for 12 and 24 months.
Figure 2: Serum creatinine levels and proteinuria at time of inclusion (using different combinations of 
immunosuppressive medication), at the moment patients started with prednisolone monotherapy 5 mg/day and after 
they had been on prednisolone monotherapy for 12 and 24 months. 	
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■Patient 7: recurrence Membranous GN, 4.6 yrs after RTx
▲ Patient 11: Chronic Pyelonephritis, 3.3 yrs after RTx
∗ Patient 13: JC-virus infection, 1.1 yrs after RTx
Ο Patient 21: recurrence DM, 10.7 yrs after RTx
●Patient 24: recurrence Membranous GN, 7 yrs after RTx
♦ Patient 29: recurrence IgA nephropathy, 7.8 yrs after RTx
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One patient refused further discontinuation of his immunosuppressive medication 
after inclusion in the study. Another patient, still on dual therapy, developed a biopsy 
proved JC-virus nephropathy 13.3 months after transplantation. Despite reducing her 
immunosuppressive medication to prednisolone 10 mg/day, combined with lefluno-
mide 30 mg/day, she had a progressive decline of her creatinine clearance resulting 
in graft loss 25.3 months after RTx. 
Four (15%) of the 27 patients showed a recurrence of their original disease in their 
renal biopsy, after being on monotherapy prednisolone 5 mg/day for 2, 13, 17 and 22 
months and 11, 8, 5 and 7 years after RTx respectively. Despite proteinuria, serum 
creatinine levels remained stable in 3 of them. The other showed a transient rise in 
serum creatinine level, due to IgA nephropathy, which stabilized after reintroduc-
tion of MMF 2 gram a day and raising the prednisolone dose to 10 mg/day. Another 
patient showed a rise in serum creatinine level due to a chronic urinary tract infection, 
after several urological procedures (Table 2).
Patient Serum
Creatinine
(µmol/l)
Protein-
uria
(g/l)
Medication Years 
after 
RTx
Diagnose
7 Stable
(102→103)
+
(1.5)
Pred mono for 
16.8 months
4.6 Recurrence membranous 
nephropathy
11 ↑
(108→126)
+
(0.74)
Pred mono for 2 
months
3.3 Chronic urinary tract  
infection 
13 ↑
(87→213)
-
(0.02)
MMF 500 mg + 
Pred 5 mg 
1.1 JC-virus infection
24 Stable
(58→64)
+
(1.73)
Pred mono for 21.7 
months
7.0 Recurrence membranous 
nephropathy
21 Stable  
(133→107)
+
(2.96)
Pred mono for 2.1 
months 
10.7 Recurrence diabetes  
nephropathy 
29 ↑
(111→203)
-
(0.09)
Pred mono for 
13.3 months
7.8 Recurrence IgA  
nephropathy
Table 2: Characteristics of patients who developed proteinuria or a rise in their serum creatinine dur-
ing tapering of their immunosuppressive medication. Clinical relevant proteinuria is defined as > 0.5g/l. 
“Medication” is defined as the medication patients used at the moment their serum creatinine rise and/
or they developed proteinuria. Diagnose is made on clinical grounds and confirmed by renal biopsy. 
“Pred”=prednisolone, “MMF”=mycophenolate mofetil, “RTx”=renal transplantation
In 23 (85%) of the 27 patients the immunosuppression could be successfully re-
duced to prednisolone monotherapy 5 mg/day. No significant changes in serum 
creatinine levels, 99 µmol/l (range 66-196) vs. 93 µmol/l (range 68-196), or protein 
excretion, 0.08 (range 0.02-0.19) vs. 0.10 (range 0.04-0.38) g/l, were observed be-
tween time of inclusion and after 24 months of prednisolone monotherapy 5 mg/day. 
There were no significant changes in systolic-, diastolic blood pressure, the number 
of antihypertensive drugs taken, serum total-, LDL- or HDL cholesterol levels, haemo-
globulin, thrombocytes or leucocytes between time of inclusion and after 24 months 
of prednisolone monotherapy. 
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Discussion
With the current results of patient and graft survival after RTx we are confronted 
with the inherited complications of long-term use of immunosuppressive medica-
tion. Therefore, we have the obligation to investigate the possibilities of tapering this 
medication without reducing the short and long-term graft and patient survival. A 
lot of our study patients were treated with azathioprine and prednisolone, by many 
classified as “light immunosuppression”. These patients were probably at low risk 
for rejection after tapering immunosuppression and this is exactly what we showed. 
More over we should keep in mind that even maintenance therapy with so-called 
“light immunosuppression” is accompanied with serious side effects. 
 In our opinion, in living-related HLA-identical RTx recipients monotherapy with low 
dose steroids, although not devoid from all side effects, is preferred above mono-
therapy with low dose AZA, MMF or CNI, with regard to infections and malignancies. 
This also holds true for recently described protocols with antithymocyte globulin, total 
lymphoid irradiation and hematopoietic-cell transplantation (15). In our LR HLA-iden-
tical RTx study group, dramatically tapering of their immunosuppressive medication 
to low dose prednisolone monotherapy is well tolerated, without the occurrence of 
acute rejections during a follow up of 2 years. Acute rejection episodes after identi-
cal sibling RTx have been reported. However, the majority of them were described in 
the AZA era in a time class II match was not perfect and BK-virus nephropathy was 
an unrecognized entity. Nevertheless, mismatches in minor HLA-antigens has been 
found relevant in the context of bone marrow transplantation and might theoretical 
induce immunological reactivity against minor mismatched solid organs. Recently, 
Gerrits et al described in vitro reactivity against donor cells after HLA-identical living-
related RTx, but could not prove that this was the result of mismatches in minor 
HLA-antigens(16). Thus, acute rejection after tapering immunosuppression could be 
immunologically explained. However, it did not occur in our study, which is in line with 
the observation of Heinold et al, who did not find a clinical relevant role of minor HLA 
mismatches after solid organ transplantation (7). Differences in non-HLA antigens 
could be an alternative explanation for donor reactivity after HLA-identical RTx (18,19)
After tapering their immunosuppressive medication, recurrence of original disease 
occurred in 15% (4 out of 27) of the patients of the total study group, or otherwise 
specified, in 25% (4 out of 16) of the group of patients who had an original disease 
with potential to recur. After 2 years follow up, none of their renal grafts had failed. 
It should be mentioned that 1 of these 4 patients had a diabetes nephropathy. We 
wondered whether the recurrence of primary glomerulonefritis in the other 3 patients 
could be related to the tapering of their immunosuppressive load or that this just 
reflects the natural course of recurrence of a primary glomerulonephritis after RTx. 
In 1999, Andresdottir et al described a biopsy proven prevalence of recurrence of 
original disease after LR HLA-identical RTx of at least 27%, with a graft failure due to 
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recurrence of 15%, with a mean time after transplantation of 7.7 ±6.1 years (17). 
Before we embarked on the present study, we screened our LR HLA-identical popu-
lation under full dose immunosuppression. There was a prevalence of 17% (7 out 
of 42) of biopsy proven recurrence of original disease, in the group of patients who 
had that potential. In 5 patients with proteinuria, no histology was available, so the 
true incidence of recurrence could have been as high as 35%. This suggest that the 
prevalence of recurrence after tapering immunosuppressive medication in our study 
group was comparable to that described before in LR HLA-identical RTx recipients 
who used full dose immunosuppression and is in line with earlier observation. 
In conclusion, the immunosuppressive medication can be safely reduced to low 
dose steroid monotherapy of 5 mg/day in HLA-identical living-related renal transplant 
recipients provided that they have stable renal function, without proteinuria and they 
are at least one year after transplantation. Close surveillance of patients for recur-
rence of their original disease is recommended to allow for potential early therapeutic 
intervention. 
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Abstract
Background
In many transplant centers, HLA-identical living-related (LR) renal transplant recipi-
ents receive standard maintenance immunosuppression from one year after trans-
plantation. We questioned whether discontinuation of AZA or MMF influenced T-cell 
reactivity, circulating DC subsets numbers and their maturation status.
Methods
Twenty-nine HLA-identical LR renal transplant recipients were withdrawn from AZA 
or MMF. Thereafter, the patients received only prednisolone. T-cell reactivity was de-
termined by IFN-γ (n=23), IL-10 (n=16) and granzyme B (GrB; n=10) Elispot assays. 
Circulating DC subset numbers and their maturation status determined by CCR2, 
CCR5, CCR7 and CD83 expression were measured by flow cytometry (n=12).
Results
The number of donor, 3rd-party, and TET-reactive IFN-γ and GrB producing cells 
was not affected after withdrawal of immunosuppression. Discontinuation of AZA or 
MMF resulted in significant increased numbers of 3rd-party (p=0.003) and TET-reac-
tive (p=0.008) IL-10 producing cells, and a trend in higher numbers of donor-reactive 
IL-10 producing cells (p=0.06). No effect was found on the number of circulating DC 
subsets, but DC were shifted towards a more mature phenotype. 
Conclusions
In HLA-identical LR renal transplant recipients, therapy with AZA and MMF suppress 
the IL-10 production and the maturation of DC. This suggests that these immunosup-
pressants may hinder downregulation of immune responses in general, including 
allogeneic responses.
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Introduction
After HLA-identical LR renal transplantation, mismatches only in minor histocompat-
ibility antigens (mHAgs) and other non-HLA antigens may exist between donor and 
recipient (1, 2). mHAgs are genetic inherited peptides derived from polymorphic intra-
cellular proteins presented in the context of HLA class I and II molecules and can be 
recognized by T cells. In humans, the clinical relevance of mHAgs has been reported 
after bone marrow transplantation (2), and even after solid organ transplantation a 
role of mHAgs and non-HLA antigens has been suggested (3-5). Theoretically, both 
mismatches in mHAgs and other non-HLA antigens between donor and recipient 
might induce graft rejection. Consequently, HLA-identical LR renal transplant re-
cipients still receive immunosuppression. However, the necessity for long-term use 
of immunosuppression in this patient group is yet unknown. We wondered whether 
HLA-identical LR renal transplant recipients should be exposed to the severe side-
effects of immunosuppression such as nephrotoxicity, malignancies, cardiovascular 
disease and diabetes mellitus (6, 7). 
Previously, we demonstrated that donor-reactive cytokine responses can be found 
after HLA-identical LR renal transplantation (8). Additionally, we showed that HLA-
identical LR renal transplant recipients, who received azathioprine (AZA) in combi-
nation with prednisone, could be tapered to 50% of their original AZA dose without 
the occurrence of acute rejection. Furthermore, renal function and donor-reactive 
responses remained unaffected after tapering the AZA dose (9, 10). Therefore, we 
speculate that those patients are still over-immunosuppressed and that the immuno-
suppressive dose could be reduced further.
Increased donor-reactivity could occur after discontinuation of immunosuppression 
in transplant recipients after HLA-mismatched renal transplantation (11-14). Complete 
discontinuation of immunosuppression has been reported in a minority of renal trans-
plant recipients long after transplantation with stable graft function and without clini-
cal signs of rejection (15-20). In general, a decreased T-cell response was reported 
in those studies compared to patients with chronic allograft nephropathy (15, 16, 19, 
20).
In addition to immunological monitoring of donor-reactive T-cell responses in trans-
plant recipients, it has been suggested that monitoring of circulating myeloid dendrit-
ic cells (CD11c+CD123lowBDCA-1+ mDC) and plasmacytoid DC (CD11c-CD123highB-
DCA-2+ pDC) (21) numbers in peripheral blood might be an useful tool for identifying 
transplant recipients in whom the immunosuppressive load can be safely tapered 
(22, 23). mDC produce high levels of IL-12 and induce T-helper 1 (Th1) and cytotoxic 
T-cell  (CTL) responses, while pDC produce IFN-a in response to viruses and induce 
T-helper 2 (Th2) responses (24). Furthermore, it has been suggested that pDC are 
involved in the induction of peripheral T-cell tolerance after organ transplantation (23, 
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25). According to their surface immunophenotype, DC subsets can be identified as 
immature DC and mature DC (24, 26). In peripheral blood and tissues, DC reside 
as immature DC where they may internalize antigens. Upon antigen capture, imma-
ture DC differentiates into mature DC that are highly specialised to stimulate T cells 
efficiently (27). Several studies reported the influence of immunosuppressive drugs 
on DC subset numbers, differentiation and their maturation status (23, 28-33). Fur-
thermore, Mazariegos et al. reported that the proportion of pDC in peripheral blood 
mononuclear cells (PBMC) was higher in stable liver transplant recipients who could 
be successfully weaned from their immunosuppressive load (23). 
In the present study, we discontinued the AZA and mycophenolate mofetil (MMF) 
dose. Thereafter, all patients received at least one-year steroid monotherapy. We 
questioned whether discontinuation of AZA or MMF influenced T-cell reactivity 
determined by Elispot assays. This assay was used to determine the frequency 
of pro-inflammatory cytokine IFN-γ and anti-inflammatory cytokine IL-10 that have 
been associated with allograft rejection or downregulation of the immune response, 
respectively (34, 35). Granzyme B (GrB) was used as a marker of activity of cyto-
toxic T-lymphocytes (CTL) (10, 36). CTL plays a crucial role in allograft rejection (37). 
Additionally, we wondered whether discontinuation of immunosuppression affected 
the circulating DC subsets numbers and their maturation status determined by flow 
cytometry.
Materials and Methods
HLA-identical LR renal transplant recipients
The ethical review committee of our center approved the protocol that was con-
ducted according to local requirements. Between November 1982 and November 
2005, 83 living-related HLA-identical renal transplants were performed in our center. 
Out of those 83 patients, 54 patients could not be enrolled in our study: 7 patients 
died with a functioning kidney (n=4: cardio-vascular disease; n=1: infection; n=1: 
malignancy; n=1: suicide), in 6 patients graft loss was observed (n=1: recurrence of 
original disease; n=2: chronic rejection; n=1: tubular intestinal nephritis due to medi-
cation; n=1: surgical complication; n=1: infection), 2 patients were less than 1 year 
after transplantation, 3 patients received a kidney from their HLA-identical twin sister, 
1 patient already used monotherapy, 1 patient was transplanted for the 4th time, 11 
patients were excluded for logistic reasons, 7 patients refused to participate in the 
present study, and 17 patients could not be included because of proteinuria (n=6: re-
currence of their original disease; n=5: chronic allograft nephropathy; n=1 proteinuria 
disappeared after nephrectomy of his native kidneys, n=5: cause of proteinuria is 
unknown)(57). After informed consent, 29 HLA-identical LR renal transplant recipi-
ents agreed to participate in this study. Characteristics of the patients are described 
in Table 1. 
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The patients were more than one year after transplantation with stable serum creati-
nine levels and no proteinuria (<0.5 g/L), and on triple or dual immunosuppressive 
therapy. From the 29 patients, 19 patients used AZA in combination with predniso-
lone and 3 patients used MMF in combination with prednisolone. The other 7 pa-
tients (n=4, Tacro+MMF; n=1, CsA+prednisolone; n=2, Tacro+MMF+prednisolone) 
were converted to 500 mg/day MMF in combination with 5 mg/day prednisolone. 
Then, the AZA or MMF dose was gradually discontinued over a period of 4 months 
and patients were kept on 5 mg/day prednisolone monotherapy. The follow-up of the 
patients on prednisolone monotherapy was one year (Figure 1). Our laboratory analy-
sis on T-cell reactivity started at dual therapy and 1-year monotherapy (Figure 1).
Detection of spots was performed as described before (39).
The spots were counted automatically by using a Bioreader
3000 Elispot reader (BioSys, GmbH, Karben, Germany).
Antibodies for mDC and pDC Staining
Fluorescence-activated cell sorter analysis was per-
formed using the following mouse anti-human monoclonal
antibodies: allophycocyanin-conjugated BDCA-1 (clone:
AD5-8E7) and allophycocyanin-conjugated BDCA-2 (clone:
AC144) (Miltenyi Biotec, GmbH, Germany), peridinin
chlorophyll protein-conjugated CD14 (clone: mP9) and
peridinin chlorophyll protein-conjugated CD19 (clone:
4G7; Becton Dickinson Biosciences, San Jose, CA), fluo-
rescein isothiocyanate (FITC)-conjugated CD83 (clone:
HB15A17.11; DPC, Serotec, Oxford, UK), phycoerythrin
(PE)-conjugated CCR2 (clone: 48607.211) and PE-conjugated
CCR7 (clone: 150503; R&DSystems Europe, Abingdon,UK),
FITC-conjugated CCR5 (clone: 2d7; Becton Dickinson), and
FITC-conjugated IgG2a (clone: X39) and PE-conjugated
IgG2b (clone: X39) isotype control monoclonal antibodies
(Becton Dickinson).
Immunofluorescence Staining and Flow
Cytometric Analysis of Dendritic Cell Subsets
and Their Maturation Status
Analysis of DC numbers and maturation status was
performed as described before (40). Briefly, 2 mL fresh hep-
arinized blood was obtained from 12 HLA-identical LR renal
transplant recipients (patient: 2, 5, 6, 7, 8, 9, 10, 14, 17, 19, 22,
and 28; Table 1) and processed within 4 hr. Whole blood
samples were incubated with the abovementioned monoclo-
nal antibodies for 30 min in the dark at room temperature.
Cells that stained negative for CD14 and CD19 were gated
and analyzed for BDCA-1 andBDCA-2 expression.mDCand
pDC were identified as CD14CD19BDCA-1 cells and
CD14CD19BDCA-2 cells, respectively. Immature mDC
were defined as CD83CCR7CCR5CCR2, and mature
mDC as CD83CCR7CCR5CCR2. Immature pDCwere
defined as CD83CCR7CCR5CCR2, and mature pDC
as CD83CCR7CCR5CCR2. The proportion of mDC
and pDC positive for CD83, CCR7, CCR5, and CCR2 was
determined by comparison with their respective isotype con-
trol antibodies. Fromeach tube, 500,000 eventswere acquired
on a FACScalibur flow cytometer using CELLQUEST PRO
software (Becton Dickinson).
The absolute counts for each DC subset was calculated
by multiplying the proportion of mDC and pDC within the
total leukocyte population by the absolute number of white
blood cells determined on an automatically cell counter (Ca-
sey, Scha¨rfe System, GmbH, Rentlingen, Germany). The ab-
solute count for total DC was calculated by the sum of the
absolute counts of mDC and pDC. The pDC/mDC ratio was
determined by dividing the absolute number of pDCwith the
absolute number of mDC.
Statistical Analysis
TheWilcoxon signed rank test was used to compare the
frequency of cytokine-producing cells, the absolute number
of total DC (mDCpDC), mDC and pDC numbers, and the
pDC/mDC ratio at dual therapy andmonotherapy. The same
test was used to compare the percentage positive of CD83,
CCR7, CCR2, and CCR5 on DC subsets before and after dis-
continuation of AZA or MMF. The Fischer’s exact test was
used to compare the number of patients who responded to
TET antigens before and after withdrawal of AZA or MMF.
Two-sided P values less than or equal to 0.05 were considered
significant. For statistical analysis, SPSS 11.5 for Windows
was used (SPSS, Inc., Chicago, IL).
RESULTS
Clinical Results
After inclusion (dual therapy), 2 of 29 (7%)HLA-iden-
tical LR renal transplant recipients did not reach steroid
monotherapy because of JC-virus infection (patient 13) and
one patient (patient 1) refused to discontinue his immuno-
suppressive medication after inclusion in the study (Table 1).
None of the patients had an acute rejection episode. A de-
tailed description of the clinical results of this study is de-
scribed by Van de Wetering et al. (38).
Patient 11, 21, 26, and 29 (n4) were not tested in the
cellular assays, because we were unable to receive patient and
donor PBMC, respectively (Table 1).
We received 35mLheparinized bloodduring dual ther-
apy and during monotherapy. The PBMC yield is variable
after transplantation. From all patients described below,
FIGURE 1. Schematic overview
of discontinuation of immunosup-
pressive medication in human
leukocyte antigen-identical living-
related renal transplant recipients
and time of blood sampling
(dual therapy and 1-year steroid
monotherapy).
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Figure 1: 
Schematic overview of discontinuation of immunosuppressive medication in HLA-identical living-related 
renal transplant recipients and time of blood sampling (dual therapy and 1-year steroid monotherapy).
Blood sampling
We received 35 ml heparinized peripheral blood at dual therapy and monotherapy to 
perform Elispot assays (33 ml peripheral blood), and to measure DC subset num-
bers and their maturation tatus (2 ml peripheral blood). PBMC from recipient and 
donor were isolated from heparinized blood by density gradient centrifugation using 
Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden) and stored at –140°C as 
described before (9).
IFN-γ, IL-10 and GrB Elispot assays
The phytohemagglutinin (PHA; Murex Biotech, Kent, UK) proliferation assay was per-
formed to control the viability of the PBMC as described before (9). The mean counts 
per minute (cpm) were determined, and the stimulation index (SI) was calculated by 
the ratio of the cpm obtain d in the presen e of PHA to the cpm in the absence of 
PHA. Only results of viable cells (SI ≥ 50) were analyzed in the described results.
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The IFN-γ, IL-10 and GrB Elispot assays (U-CyTech Biosciences, Utrecht, The Neth-
erlands) were used to determine the number of cytokine producing cells reactive to 
donor, 3rd-party and tetanus toxoid (TET) antigens (38). Briefly, in a 96-wells round 
bottom plate (Nunc, Roskilde, Denmark), patients’ PBMC were stimulated with donor 
PBMC, 3rd-party PBMC and TET. The 3rd-party PBMC did not share HLA antigens 
with donor and patient, and the same 3rd-party PBMC was used at dual therapy 
and steroid monotherapy. TET stimulation (RIVM, Bilthoven, The Netherlands) was 
used to determine the memory immune response to nominal antigens. As negative 
controls, we used patients’ PBMC stimulated with irradiated patients’ PBMC (autolo-
gous response; to control the influence of irradiation), and patients’ PBMC in culture 
media alone (unstimulated patients’ PBMC). The autologous response was subtract-
ed from the donor and 3rd-party reactive response. The response of unstimulated 
patients’ PBMC was subtracted from the TET response. After 40 hours of incubation, 
non-adherent cells were harvested and transferred in triplicate to a flat-bottom plate 
(Nunc, Roskilde, Denmark) precoated with IFN-γ, IL-10 or GrB monoclonal antibod-
ies (U-CyTech Biosciences) and post-coated with phosphate-buffered saline (PBS) 
supplemented with 1x Blocking stock solution B (U-CyTech Biosciences). Cells were 
incubated for 5 hours at 37°C for IFN-γ and GrB Elispot assays, and overnight for 
IL-10 Elispot assay. Detection of spots was performed as described before (38). The 
spots were counted automatically by using a Bioreader 3000 Elispot reader (BioSys, 
GmbH, Karben, Germany).
Antibodies for mDC and pDC staining
Fluorescence-activated cell sorter (FACS) analysis was performed using the follow-
ing mouse anti-human monoclonal antibodies: allophycocyanin (APC)-conjugated 
BDCA-1 (clone: AD5-8E7) and APC-conjugated BDCA-2 (clone: AC144) (Miltenyi 
Biotec, GmbH, Germany), peridinin chlorophyll protein (PerCP)-conjugated CD14 
(clone: mfP9) and PerCP-conjugated CD19 (clone: 4G7; Becton Dickinson Bio-
sciences, San Jose, CA, USA), fluorescein isothiocyanate (FITC)-conjugated CD83 
(clone: HB15A17.11; DPC, Serotec, Oxford, UK), phycoerythrin (PE)-conjugated 
CCR2 (clone: 48607.211) and PE-conjugated CCR7 (clone: 150503; R&D Systems 
Europe, Abingdon, UK), FITC-conjugated CCR5 (clone: 2d7; Becton Dickinson), and 
FITC-conjugated IgG2a (clone: X39) and PE-conjugated IgG2b (clone: X39) isotype 
control monoclonal antibodies (Becton Dickinson).
Immunofluorescence staining and flow cytometric analysis of den-
dritic cell subsets and their maturation status
Analysis of DC numbers and maturation status was performed as described before 
(39). Briefly, 2 ml fresh heparinized blood was obtained from 12 HLA-identical LR 
renal transplant recipients (patient: 2, 5, 6, 7, 8, 9, 10, 14, 17, 19, 22, 28; Table 1) and 
processed within 4 hours. Whole blood samples were incubated with the above-
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mentioned monoclonal antibodies for 30 minutes in the dark at room temperature. 
Cells that stained negative for CD14 and CD19 were gated and analysed for BDCA-1 
and BDCA-2 expression. mDC and pDC were identified as CD14-CD19-BDCA-1+ 
cells and CD14-CD19-BDCA-2+ cells, respectively. Immature mDC were defined 
as CD83-CCR7 -CCR5+CCR2+, and mature mDC as CD83+CCR7+CCR5-CCR2-. 
Immature pDC were defined as CD83-CCR7+CCR5+CCR2+, and mature pDC as 
CD83+CCR7++CCR5-CCR2-. The proportion of mDC and pDC positive for CD83, 
CCR7, CCR5 and CCR2 was determined by comparison to their respective isotype 
control antibodies. From each tube, 500,000 events were acquired on a FACScalibur 
flow cytometer using CELLQUEST PRO software (Becton Dickinson). 
The absolute counts for each DC subset was calculated by multiplying the propor-
tion of mDC and pDC within the total leucocyte population by the absolute number of 
white blood cells determined on an automatically cell counter (Casey®, Schärfe Sys-
tem, GmbH, Rentlingen, Germany). The absolute counts for total DC were calculated 
by the sum of the absolute counts of mDC and pDC. The pDC/mDC ratio was deter-
mined by dividing the absolute number of pDC with the absolute number of mDC.
Statistical analysis
The Wilcoxon signed rank test was used to compare the frequency of cytokine pro-
ducing cells, the absolute number of total DC (mDC+pDC), mDC and pDC numbers, 
and the pDC/mDC ratio at dual therapy and monotherapy. The same test was used 
to compare the percentage positive of CD83, CCR7, CCR2 and CCR5 on DC sub-
sets before and after discontinuation of AZA or MMF. The Fischer’s Exact test was 
used to compare the number of patients that responded to TET antigens before and 
after withdrawal of AZA or MMF. Two sided P-values ≤0.05 were considered signifi-
cant. For statistical analysis, SPSS 11.5 for Windows was used (SPSS, Inc., Chicago, 
IL, USA).
Results
Clinical results
After inclusion (dual therapy), 2 out of 29 (7%) HLA-identical LR renal transplant 
recipients did not reach steroid monotherapy due to JC-virus infection (patient 13) 
and one patient (patient 1) refused to discontinue his immunosuppressive medica-
tion after inclusion in the study (Table 1). None of the patients had an acute rejection 
episode. A detailed description of the clinical results of this study is described by Van 
de Wetering et al. (57).
Patient 11, 21, 26 and 29 (n=4) were not tested in the cellular assays, because we 
were unable to receive patient and donor PBMC, respectively (Table 1).
We received 35 ml heparinized blood during dual therapy and during monotherapy. 
The PBMC yield is variable after transplantation. From all patients described below, 
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PBMC samples were tested during dual and after one year on monotherapy. We 
could perform an IFN-γ Elispot assay in 23 patients, from 16 patients enough cells 
were available to perform the IL-10 Elispot, and even from 10 patients we also could 
perform a GrB Elispot.
In 2003 it was reported that monitoring of circulating DC would be a good tool to 
identify transplant recipients in whom the immunosuppressive medication can be 
safely discontinued (23). Then, we observed that cryopreservation of PBMC signifi-
cantly effects chemokine receptor markers on DC (39). In other words, we could only 
determine the DC subsets and their chemokine receptors in fresh whole blood. Our 
inclusion of patients was from the beginning of 2003. Therefore, we have monitored 
the DC in 12 patients before and after withdrawal of AZA or MMF.
    
The frequency of IFN-γ, IL-10 and GrB producing cells
The frequency of donor-reactive IFN-γ producing cells did not increase after discon-
tinuation of AZA or MMF [dual therapy: median, 2 IFN-γ producing cells/2x105 PBMC 
(range, 0-13); monotherapy: median, 0 IFN-γ producing cells/2x105 PBMC (0-16); 
p=0.21; Figure 2A]. The donor response was significantly lower than the 3rd-party 
response (dual therapy, p<0.001; monotherapy, p<0.001). The 3rd-party reactiv-
ity was comparable between dual therapy [median, 33 IFN-γ producing cells/2x105 
PBMC (5-333)] and monotherapy [median, 31 IFN-γ producing cells/2x105 (4-322); 
p=0.59; Figure 2B]. 
 
From 16 patients we were able to perform IL-10 Elispot assays. The number of donor-
reactive IL-10 producing cells was low on dual therapy [median, 1 IL-10 producing 
cells/2x105 PBMC (range, 0-4)] and tended to be higher after discontinuation of 
AZA or MMF [median, 1 IL-10 producing cells/2x105 (0-80); p=0.06; Figure 2C]. No 
significant difference was found in donor and 3rd-party reactive IL-10 producing cells 
(dual therapy, p=0.18; monotherapy, p=0.06). The frequency of 3rd-party reactive 
IL-10 producing cells was significantly higher during monotherapy [median, 13 IL-10 
producing cells/2x105 PBMC (0-208); p=0.003; Figure 2D] than during dual therapy 
[median, 2 IL-10 producing cells/2x105 PBMC (0-8)].
We were able to perform GrB Elispot assays from 10 patients. No difference was 
observed between the number of donor-reactive GrB producing cells at dual therapy 
[median, 2 GrB producing cells/2x105 PBMC (range, 0-40)] and at monotherapy 
[median, 0 GrB producing cells/2x105 (0-6); p=0.18; Figure 2E]. The donor-reactive 
GrB producing cells was significantly lower than the 3rd-party reactive GrB pro-
ducing cells (dual therapy, p=0.008; monotherapy, p=0.007). At dual therapy, the 
frequency of 3rd-party reactive GrB producing cells [median, 17 GrB producing 
cells/2x105 PBMC (0-49)] was comparable with monotherapy [median, 16 GrB pro-
ducing cells/2x105 PBMC [(0-47); p=0.84; Figure 2F].
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Figure 2: Number of IFN-γ, IL-10 and granzyme B (GrB) producing cells reactive to donor cells (A, C, E) 
and 3rd-party cells (B, D, F) before (dual therapy) and after (1-year monotherapy) discontinuation of AZA 
or MMF in PBMC from HLA-identical living-related renal transplants determined by IFN-γ, IL-10 and GrB 
Elispot assays.
Tetanus toxoid reactivity
The TET reactivity was not affected after withdrawal of AZA or MMF in IFN-γ Elispot 
assays [dual therapy: median, 6 IFN-γ producing cells/2x105 PBMC (0-217) vs. mon-
otherapy: median, 4 IFN-γ producing cells/2x105 PBMC (0-179); p=0.74], and GrB 
Elispot assays [dual therapy: median, 5 GrB producing cells/2x105 PBMC (0-112) vs. 
monotherapy: median, 8 GrB producing cells/2x105 PBMC (0-115); p=0.44].
The total number of TET-reactive IL-10 producing cells was comparable during dual 
and monotherapy [dual therapy: median, 3 IL-10 producing cells/2x105 PBMC (0-77) 
vs. monotherapy: median, 10 IL-10 producing cells/2x105 PBMC (0-102); p=0.32]. 
PBMC samples were tested during dual and after 1 year on
monotherapy.We could performan IFN-Elispot assay in 23
patients, from 16 patients enough cells were available to per-
form the IL-10 Elispot, and even from 10 patients we also
could perform a GrB Elispot.
In 2003, it was reported that monitoring of circulating
DC would be a good tool to identify transplant recipients in
whom the immunosuppressive medication can be safely dis-
continued (23). Then, we observed that cryopreservatio of
PBMC significantly effects chemokine receptor markers on
DC (40). In other words, we could only determine the DC
subsets and their chemokine receptors in fresh whole blood.
Our inclusion of patients was from the beginning of 2003.
Therefore, we have monitored the DC in 12 patients before
and after withdrawal of AZA or MMF.
The Frequency of IFN-, IL-10, and
GrB-Producing Cells
The frequency of donor-reactive IFN- producing cells
did not increase after discontinuation of AZA or MMF (dual
therapy: median, two IFN- producing cells/2105 PBMC
[range, 0–13]; monotherapy: median, 0 IFN- producing
cells/2105 PBMC [0–16]; P0.21; Fig. 2A). The donor re-
sponse was significantly lower than the third-party response
(dual therapy, P0.001; monotherapy, P0.001). The third-
party reactivity was comparable between dual therapy (me-
dian, 33 IFN- producing cells/2105 PBMC [5–333]) and
monotherapy (median, 31 IFN- producing cells/2105
[4–322]; P0.59; Fig. 2B).
From16patients, wewere able to perform IL-10 Elispot
assays. The number of donor-reactive IL-10 producing cells
was low on dual therapy (median, 1 IL-10 producing cells/
2105 PBMC [range, 0–4]) and tended to be higher after
discontinuation of AZA orMMF (median, 1 IL-10 producing
cells/2105 [0–80]; P0.06; Fig. 2C). No significant differ-
ence was found in don r and third-party reactive IL-10 pro-
ducing cells (dual therapy, P0.18; monotherapy, P0.06).
The frequency of third-party reactive IL-10 producing cells
was significantly higher during monotherapy (median, 13
IL-10 producing cells/2105 PBMC [0–208]; P0.003; Fig.
2D) than during dual therapy (median, 2 IL-10 roducing
cells/2105 PBMC [0–8]).
We were able to perform GrB Elispot assays from 10
patients. No difference was observed between the number of
donor-reactive GrB-producing cells at dual therapy (median,
twoGrB-producing cells/2105 PBMC[range, 0–40]) and at
monotherapy (median, zero GrB-producing cells/2105
[0–6]; P0.18; Fig. 2E). The donor-reactive GrB-producing
cells was significantly lower than the third-party reactive
GrB-producing cells (dual therapy, P0.008; monotherapy,
P0.007). At dual therapy, the frequency of third-party reac-
tive GrB-producing cells (median, 17 GrB-producing cells/
FIGURE 2. Number of interfer-
on-, interleukin-10 and gran-
zyme-B producing cells reactive to
donor cells (A, C, and E) and third-
party cells (B, D, and F) before
(dual therapy) and after (1-year
monotherapy) discontinuation of
azathioprine or mycophenolate
mofetil in peripheral blood mono-
nuclear cell from human leukocyte
antigen-identical living-related
renal transplants determined by
interferon-, interleukin-10 and
granzyme B Elispot assays.
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PBMC samples were tested during dual and after 1 year on
monotherapy.We could performan IFN-Elispot assay in 23
patients, from 16 patients enough cel were available to per-
form the IL-10 Elispot, and even from 10 patients we also
could perform a GrB Elispot.
In 2003, it was reported that monitoring of circulating
DC would be a good tool to identify transplant recipients in
whom the immunosuppressive medication can be safely dis-
continued (23). Then, we observed that cryopreservation of
PBMC significantly effects chemokine receptor markers on
DC (40). In other words, we could only determine the DC
subsets and their chemokine receptors in fresh whole blood.
Our inclusion of patients was from the begi ning of 2003.
Therefore, we have monitored the DC in 12 patients before
and after withdrawal of AZA or MMF.
The Frequency of IFN-, IL-10, and
GrB-Producing Cells
The frequency of donor-reactive IFN- producing cells
did not increase after discontinuation of AZA or MMF (dual
therapy: median, two IFN- producing cells/2105 PBMC
[range, 0–13]; monotherapy: median, 0 IFN- producing
cells/2105 PBMC [0–16]; P0.21; Fig. 2A). The donor re-
sponse was significantly lower than the third-party response
(dual therapy, P0.001; monotherapy, P0.001). The third-
party reactivity was comparable between dual therapy (me-
dian, 33 IFN- producing cells/2105 PBMC [5–333]) and
monotherapy (median, 31 IFN- producing cells/2105
[4–322]; P0.59; Fig. 2B).
From16patients, wewere able to perform IL-10 Elispot
assays. The number of donor-reactive IL-10 producing cells
was low on dual therapy (median, 1 IL-10 producing cells/
2105 PBMC [range, 0–4]) and tended to be higher after
discontinuati n of AZA orMMF (median, 1 IL-10 producing
cells/2105 [0–80]; P0.06; Fig. 2C). No significant differ-
ence was found in donor and third-party reactive IL-10 pro-
ducing cells (dual therapy, P0.18; monotherapy, P0.06).
The frequency of third-party reactive IL-10 producing cells
was significantly higher during monotherapy (median, 13
IL-10 producing cells/2105 PBMC [0–208]; P0.003; Fig.
2D) than during dual therapy (median, 2 IL-10 producing
cells/2105 PBMC [0–8]).
We were able to perform GrB Elispot assays from 10
patients. No difference was observed between the number of
donor-reactive GrB-producing cells at dual therapy (median,
twoGrB-producing cells/2105 PBMC[range, 0–40]) and at
monotherapy (median, zero GrB-producing cells/2105
[0–6]; P0.18; Fig. 2E). The donor-reactive GrB-producing
cells was significantly lower than the third-party reactive
GrB-producing cells (dual therapy, P0.008; monotherapy,
P0.007). At dual therapy, the frequency of third-party reac-
tive GrB-producing cells (median, 17 GrB-producing cells/
FIGURE 2. Number of interfer-
on-, interleukin-10 and gran-
zyme-B producing cells reactive to
donor cells (A, C, and E) and third-
party cells (B, D, and F) before
(dual therapy) and after (1-year
monotherapy) discontinuation of
azathioprine or mycophenolate
mofetil in peripheral blood mono-
nuclear cell from human leukocyte
antigen-identical living-related
renal transplants determined by
interferon-, interleukin-10 and
granzyme B Elispot assays.
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However, the number of patients that could respond to TET antigens (≥5 cytokine 
producing cells/2x105 PBMC) in the IL-10 Elispot assay was significantly higher at 
monotherapy than at dual therapy (dual therapy, 5/20 (25%) vs. monotherapy, 13/18 
(72%); p=0.008; Fisher’s Exact test). No differences were found in IFN-γ (p=0.57) 
and GrB (p=0.43) Elispot assays.
2105 PBMC [0–49]) was comparable with monotherapy
(median, 16 GrB-producing cells/2105 PBMC [0–47];
P0.84; Figure 2F).
Tetanus Toxoid Reactivity
The TET reactivity was not affected after withdrawal of
AZA or MMF in IFN- Elispot assays (dual therapy: median,
six IFN- producing cells/2105 PBMC [0–217] vs. mono-
therapy: median, four IFN- producing cells/2105 PBMC
[0–179]; P0.74), and GrB Elispot assays (dual therapy: me-
dian, five GrB-producing cells/2105 PBMC [0–112] vs.
monotherapy: median, eight GrB-producing cells/2105
PBMC [0–115]; P0.44).
The total number of TET-reactive IL-10 producing
cells was comparable during dual and monotherapy (dual
therapy: median, three IL-10 producing cells/2105 PBMC
[0–77] vs. monotherapy: median, 10 IL-10 producing cells/
2105 PBMC [0–102]; P0.32). However, the number of
patients who could respond to TET antigens (5 cytokine-
producing cells/2105 peripheral bloodmononuclear cell) in
the IL-10 Elispot assay was significantly higher at mono-
therapy than at dual therapy (dual therapy, 5/20 (25%) vs.
monotherapy, 13/18 (72%); P0.008; Fisher’s exact test). No
differences were found in IFN- (P0.57) andGrB (P0.43)
Elispot assays.
Dendritic Cell Subsets and Maturation Status
Discontinuation of AZA or MMF had no effect on the
total DC numbers (dual therapy: median, 14.6 DC/L [range
5.5–31.1]; monotherapy: median, 14.4 DC/L [3.5–26.2];
P0.52), the number ofmDC (dual therapy:median, 10.7L
mDC [4.0–23.7];monotherapy:median, 10.0LmDC [2.6–
20.8]; P0.62, Fig. 3A) and pDC (dual therapy: median, 4.7
L pDC [1.6–8.8]; monotherapy; median, 3.0 L pDC
(0.93–11.3); P0.62, Fig. 3E), nor on the pDC/mDC ratio
(dual therapy: median, 0.37 [0.23–0.82]; monotherapy: me-
dian, 0.33 [0.16–0.96]; P0.49).
The percentage of CD83 mDC was not affected after
discontinuation of AZA or MMF (dual therapy: median,
0.49% [0–2.8]; monotherapy: median: 0.65% [0.08–1.45];
P0.47). During monotherapy, the percentage of CCR7
mDC (median, 22.3% [10.2–28.6]; P0.007) was signifi-
cantly higher than during dual therapy (median, 10.3% [5.3–
20.9]; Fig. 3B). During monotherapy, the percentage CCR2
mDC (dual therapy: median, 87.6% [49.5–95.9]; mono-
therapy: median, 69.5% [50.3–91.4]; P0.01; Fig. 3C) and
CCR5 mDC (dual therapy: median, 91.2% [56.1–97.3];
monotherapy: median, 80.1% [53.4–94.6]; P0.04; Fig. 3D)
was significantly lower than during dual therapy.
A similar pattern was found for pDC. No differences
were observed in the percentage CD83 pDC (dual therapy:
median, 0% [0–0.6]; monotherapy: median, 0% [0–0.9];
P0.31) during dual and monotherapy. The percentage
CCR7 pDC increased after discontinuation of AZAorMMF
(dual therapy: median, 86.8% [81.3–94.7]; monotherapy:
median, 91.1% [86.6–96.9];P0.12; Fig. 3F). The percentage
CCR2 pDC (dual therapy: median, 96.8% [92.5–98.5];
monotherapy: median, 94.2% [90.4–98.2]; P0.04; Fig. 3G)
and CCR5 pDC (dual therapy: median, 99.4% [98.3–100];
monotherapy: median, 98.9% [95.9–100]; P0.02; Fig. 3H)
decreased after discontinuation of AZA or MMF.
DISCUSSION
After solid organ transplantation, life-long use of im-
munosuppression is deemed necessary to prevent graft rejec-
tion. However, after HLA-identical LR renal transplantation,
the necessity for long term use of immunosuppression is yet
unknown. Considering the severe side effects of immunosup-
pression,minimizingof immunosuppression in these transplant
recipients might be beneficial. Theoretically, discontinuation
of immunosuppression in organ transplant recipients might
result into an increased donor-reactive T-cell response (12-14,
41). This study showed that the number of donor, third-party,
FIGURE 3. Absolute numbers and theirmaturation status ofmDC (A–D) andpDC (E–H)determinedbefore (dual therapy)
and after (1-year monotherapy) discontinuation of azathioprine or mycophenolate mofetil in peripheral blood from recip-
ients of an human leukocyte antigen-identical living-related renal transplant (n12) by flow cytometry.
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2105 PBMC [0–49]) was comparable with monotherapy
(median, 16 GrB-producing cells/2105 PBMC [0–47];
P0.84; Figure 2F).
Tetanus Toxoid Reactivity
The TET reactivity was not affected after withdrawal of
AZA or MMF in IFN- Elispot assays (dual therapy: median,
six IFN- producing cells/2105 PBMC [0–217] vs. mono-
therapy: median, four IFN- producing cells/2105 PBMC
[0–179]; P0.74), and GrB Elispot assays (dual therapy: me-
dian, five GrB-producing cells/2105 PBMC [0–112] vs.
monotherapy: median, eight GrB-producing cells/2105
PBMC [0–115]; P0.44).
The total number of TET-reactive IL-10 producing
cells was comparable during dual and monotherapy (dual
therapy: median, three IL-10 producing cells/2105 PBMC
[0–77] vs. monotherapy: median, 10 IL-10 producing cells/
2105 PBMC [0–102]; P0.32). However, the number of
patients who could respond to TET antigens (5 cytokine-
producing cells/2105 peripheral bloodmononuclear cell) in
the IL-10 Elispot assay was significantly higher at mono-
therapy than at dual therapy (dual therapy, 5/20 (25%) vs.
monotherapy, 13/18 (72%); P0.008; Fisher’s exact test). No
differences were found in IFN- (P0.57) andGrB (P0.43)
Elispot assays.
Dendritic Cell Subsets and Maturation Status
Discontinuation of AZA or MMF had no effect on the
total DC numbers (dual therapy: median, 14.6 DC/L [range
5.5–31.1]; monotherapy: median, 14.4 DC/L [3.5–26.2];
P0.52), the number ofmDC (dual therapy:median, 10.7L
mDC [4.0–23.7];monotherapy:median, 10.0LmDC [2.6–
20.8]; P0.62, Fig. 3A) and pDC (dual therapy: median, 4.7
L pDC [1.6–8.8]; monotherapy; median, 3.0 L pDC
(0.93–11.3); P0.62, Fig. 3E), nor on the pDC/mDC ratio
(dual therapy: median, 0.37 [0.23–0.82]; monotherapy: me-
dian, 0.33 [0.16–0.96]; P0.49).
The percentage of CD83 mDC was not affected after
discontinuation of AZA or MMF (dual therapy: median,
0.49% [0–2.8]; monotherapy: median: 0.65% [0.08–1.45];
P0.47). During monotherapy, the percentage of CCR7
mDC (median, 22.3% [10.2–28.6]; P0.007) was signifi-
cantly higher than during dual therapy (median, 10.3% [5.3–
20.9]; Fig. 3B). During monotherapy, the percentage CCR2
mDC (dual therapy: median, 87.6% [49.5–95.9]; mono-
therapy: median, 69.5% [50.3–91.4]; P0.01; Fig. 3C) and
CCR5 mDC (dual therapy: median, 91.2% [56.1–97.3];
monotherapy: median, 80.1% [53.4–94.6]; P0.04; Fig. 3D)
was significantly lower than during dual therapy.
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were observed in the percentage CD83 pDC (dual therapy:
median, 0% [0–0.6]; monotherapy: median, 0% [0–0.9];
P0.31) during dual and monotherapy. The percentage
CCR7 pDC increased after discontinuation of AZAorMMF
(dual therapy: median, 86.8% [81.3–94.7]; monotherapy:
median, 91.1% [86.6–96.9];P0.12; Fig. 3F). The percentage
CCR2 pDC (dual therapy: median, 96.8% [92.5–98.5];
monotherapy: median, 94.2% [90.4–98.2]; P0.04; Fig. 3G)
and CCR5 pDC (dual therapy: median, 99.4% [98.3–100];
monotherapy: median, 98.9% [95.9–100]; P0.02; Fig. 3H)
decreased after discontinuation of AZA or MMF.
DISCUSSION
After solid organ transplantation, life-long use of im-
munosuppression is deemed necessary to prevent graft rejec-
tion. However, after HLA-identical LR renal transplantation,
the necessity for long term use of immunosuppression is yet
unknown. Considering the severe side effects of immunosup-
pression,minimizingof immunosuppression in these transplant
recipients might be beneficial. Theoretically, discontinuation
of immunosuppression in organ transplant recipients might
result into an increased donor-reactive T-cell response (12-14,
41). This study showed that the number of donor, third-party,
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(median, 16 GrB-producing cells/2105 PBMC [0–47];
P0.84; Figure 2F).
Tetanus Toxoid Reactivity
The TET reactivity was not affected after withdrawal of
AZA or MMF in IFN- Elispot assays (dual therapy: median,
six IFN- producing cells/2105 PBMC [0–217] vs. mono-
therapy: median, four IFN- producing cells/2105 PBMC
[0–179]; P0.74), and GrB Elispot assays (dual therapy: me-
dian, five GrB-producing cells/2105 PBMC [0–112] vs.
monotherapy: median, eight GrB-producing cells/2105
PBMC [0–115]; P0.44).
The total number of TET-reactive IL-10 producing
cells was comparable during dual and monotherapy (dual
therapy: median, three IL-10 producing cells/2105 PBMC
[0–77] vs. monotherapy: median, 10 IL-10 producing cells/
2105 PBMC [0–102]; P0.32). However, the number of
patients who could respond to TET antigens (5 cytokine-
producing cells/2105 peripheral bloodmononuclear cell) in
the IL-10 Elispot assay was significantly higher at mono-
therapy than at dual therapy (dual therapy, 5/20 (25%) vs.
monotherapy, 13/18 (72%); P0.008; Fisher’s exact test). No
differences were found in IFN- (P0.57) andGrB (P0.43)
Elispot assays.
Dendritic Cell Subsets and Maturation Status
Discontinuation of AZA or MMF had no effect on the
total DC numbers (dual therapy: median, 14.6 DC/L [range
5.5–31.1]; monotherapy: median, 14.4 DC/L [3.5–26.2];
P0.52), the number ofmDC (dual therapy:median, 10.7L
mDC [4.0–23.7];monotherapy:median, 10.0LmDC [2.6–
20.8]; P0.62, Fig. 3A) and pDC (dual therapy: median, 4.7
L pDC [1.6–8.8]; monotherapy; median, 3.0 L pDC
(0.93–11.3); P0.62, Fig. 3E), nor on the pDC/mDC ratio
(dual therapy: median, 0.37 [0.23–0.82]; monotherapy: me-
dian, 0.33 [0.16–0.96]; P0.49).
The percentage of CD83 mDC was not affected after
discontinuation of AZA or MMF (dual therapy: median,
0.49% [0–2.8]; monotherapy: median: 0.65% [0.08–1.45];
P0.47). During monotherapy, the perce tag of CCR7
mDC (median, 22.3% [10. –28.6]; P0.007) was signifi-
cantly higher than during dual herapy (median, 10.3% [5.3–
20.9]; Fig. 3B). During monotherapy, the percentage CCR2
mDC (dual therapy: median, 87.6% [49.5–95.9]; mono-
therapy: median, 69.5% [50.3–91.4]; P0.01; Fig. 3C) and
CCR5 mDC (dual therapy: median, 91.2% [56.1–97.3];
monotherapy: median, 80.1% [53.4–94.6]; P0.04; Fig. 3D)
was significantly lower than during dual therapy.
A similar pattern was found for pDC. No differences
were observed in the percentage CD83 pDC (dual ther py:
median, 0% [0–0.6]; monotherapy: median, 0% [0–0.9];
P0.31) during dual and monotherapy. The percentage
CCR7 pDC increased after discontinuati f AZAorMMF
(dual therapy: median, 86.8% [81.3–94.7]; monotherapy:
median, 91.1% [86.6–96.9];P0.12; Fig. F). The perc ntage
CCR2 pDC (dual therapy: median, 96.8% [92.5–98.5];
monotherapy: median, 94.2% [90.4–98.2]; P0.04; Fig. 3G)
and CCR5 pDC (dual therapy: median, 99.4% [98.3–100];
monotherapy: median, 98.9% [95.9–100]; P0.02; Fig. 3H)
decreased after discontinuation of AZA or MMF.
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munosuppression is deemed necessary to prevent graft rejec-
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the necessity for long term use of immunosuppression is yet
unknown. Considering the severe side effects of immunosup-
pression,minimizingof immunosuppression in these transplant
recipients might be beneficial. Theoretically, discontinuation
of immunosuppression in organ transplant recipients might
result into an increased donor-reactive T-cell response (12-14,
41). This study showed that the number of donor, third-party,
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2105 PBMC [0–49]) was comparable with monotherapy
(median, 16 GrB-producing cells/2105 PBMC [0–47];
P0.84; Figure 2F).
Tetanus Toxoid Reactivity
The TET reactivity was not affected after withdrawal of
AZA or MMF in IFN- Elispot assays (dual therapy: median,
six IFN- producing cells/2105 PBMC [0–217] vs. mono-
therapy: median, four IFN- producing cells/2105 PBMC
[0–179]; P0.74), and GrB Elispot assays (dual therapy: me-
dian, five GrB-producing cells/2105 PBMC [0–112] vs.
monotherapy: median, eight GrB-producing cells/2105
PBMC [0–115]; P0.44).
The total number of TET-reactive IL-10 producing
cells was comparable during dual and monotherapy (dual
therapy: median, three IL-10 producing cells/2105 PBMC
[0–77] vs. monotherapy: median, 10 IL-10 producing cells/
2105 PBMC [0–102]; P0.32). However, the number of
patients who could respond to TET antigens (5 cytokine-
producing cells/2105 peripheral bloodmononuclear cell) in
the IL-10 Elispot assay was significantly higher at mono-
therapy than at dual therapy (dual therapy, 5/20 (25%) vs.
monotherapy, 13/18 (72%); P0.008; Fisher’s exact test). No
differences were found in IFN- (P0.57) andGrB (P0.43)
Elispot assays.
Dendritic Cell Subsets and Maturation Status
Discontinuation of AZA or MMF had no effect on the
total DC numbers (dual therapy: median, 14.6 DC/L [range
5.5–31.1]; monotherapy: median, 14.4 DC/L [3.5–26.2];
P0.52), the number ofmDC (dual therapy:median, 10.7L
mDC [4.0–23.7];monotherapy:median, 10.0LmDC [2.6–
20.8]; P0.62, Fig. 3A) and pDC (dual therapy: median, 4.7
L pDC [1.6–8.8]; monotherapy; median, 3.0 L pDC
(0.93–11.3); P0.62, Fig. 3E), nor on the pDC/mDC ratio
(dual therapy: median, 0.37 [0.23–0.82]; monotherapy: me-
dian, 0.33 [0.16–0.96]; P0.49).
The percentage of CD83 mDC was not affected after
discontinuation of AZA or MMF (dual therapy: median,
0.49% [0–2.8]; monotherapy: median: 0.65% [0.08–1.45];
P0.47). During monotherapy, the percentage of CCR7
mDC (median, 22.3% [10.2–28.6]; P0.007) was signifi-
cantly higher than during dual therapy (median, 10.3% [5.3–
20.9]; Fig. 3B). During monotherapy, the percentage CCR2
mDC (dual therapy: median, 87.6% [49.5–95.9]; mono-
therapy: median, 69.5% [50.3–91.4]; P0.01; Fig. 3C) and
CCR5 mDC (dual therapy: median, 91.2% [56.1–97.3];
monotherapy: median, 80.1% [53.4–94.6]; P0.04; Fig. 3D)
was significantly lower than during dual therapy.
A similar pattern was found for pDC. No differences
were observed in the percentage CD83 pDC (dual therapy:
median, 0% [0–0.6]; monotherapy: median, 0% [0–0.9];
P0.31) during dual and monotherapy. The percentage
CCR7 pDC increased after discontinuation of AZAorMMF
(dual therapy: median, 86.8% [81.3–94.7]; monotherapy:
median, 91.1% [86.6–96.9];P0.12; Fig. 3F). The percentage
CCR2 pDC (dual therapy: median, 96.8% [92.5–98.5];
monotherapy: median, 94.2% [90.4–98.2]; P0.04; Fig. 3G)
and CCR5 pDC (dual therapy: median, 99.4% [98.3–100];
monotherapy: median, 98.9% [95.9–100]; P0.02; Fig. 3H)
decreased after discontinuation of AZA or MMF.
DISCUSSION
After solid organ transplantation, life-long use of im-
munosuppression is deemed necessary to prevent graft rejec-
tion. However, after HLA-identical LR renal transplantation,
the necessity for long term use of immunosuppression is yet
unknown. Considering the severe side effects of immunosup-
pression,minimizingof immunosuppression in these transplant
recipients might be beneficial. Theoretically, discontinuation
of immunosuppression in organ transplant recipients might
result into an increased donor-reactive T-cell response (12-14,
41). This study showed that the number of donor, third-party,
FIGURE 3. Absolute numbers and theirmaturation status ofmDC (A–D) andpDC (E–H)determinedbefore (dual therapy)
and after (1-year monotherapy) discontinuation of azathioprine or mycophenolate mofetil in peripheral blood from recip-
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Figure 3: Absolute numbers 
and their maturation status of 
mDC (A-D) and pDC (E-H)  
determined before (dual 
therapy) and after (1-year 
monotherapy) discontinuation 
of AZA or MMF in peripheral 
blood from recipients of an 
HLA-identical living-related 
renal transplant (n=12) by  
flow cytometry.
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Dendritic cell subsets and maturation status
Discontinuation of AZA or MMF had no effect on the total DC numbers [dual therapy: 
median, 14.6 DC/ml (range, 5.5-31.1); monotherapy: median, 14.4 DC/ml (3.5-26.2); 
p=0.52], the number of mDC [dual therapy: median, 10.7 ml mDC (4.0-23.7); mono-
therapy: median, 10.0 ml mDC (2.6-20.8); p=0.62, Figure 3A] and pDC [dual therapy: 
median, 4.7 ml pDC (1.6-8.8); monotherapy; median, 3.0 ml pDC (0.93-11.3); p=0.62, 
Figure 3E], nor on the pDC/mDC ratio [dual therapy: median, 0.37 (0.23-0.82); 
monotherapy: median, 0.33 (0.16-0.96); p=0.49].
The percentage of CD83+ mDC was not affected after discontinuation of AZA or 
MMF [dual therapy: median, 0.49% (0-2.8); monotherapy: median: 0.65% (0.08-
1.45); p=0.47]. During monotherapy, the percentage of CCR7+ mDC [median, 22.3% 
(10.2-28.6); p=0.007] was significantly higher than during dual therapy [median, 
10.29% (5.29-20.96); Figure 3B]. The percentage CCR2+ mDC [dual therapy: me-
dian, 87.6% (49.5-95.9); monotherapy: median, 69.5% (50.3-91.4); p=0.01; Figure 
3C] and CCR5+ mDC [dual therapy: median, 91.2% (56.1-97.3); monotherapy: 
median, 80.1% (53.4-94.6); p=0.04; Figure 3D] was significantly lower during AZA 
or MMF.A similar pattern was found for pDC. No differences were observed in the 
percentage CD83+ pDC [dual therapy: median, 0% (0-0.6); monotherapy: median, 
0% (0-0.9); p=0.31] during dual and monotherapy. The percentage CCR7+ pDC 
increased after discontinuation of AZA or MMF [dual therapy: median, 86.8% (81.3-
94.7); monotherapy: median, 91.1% (86.6-96.9); p=0.12; Figure 3F]. The percentage 
CCR2+ pDC [dual therapy: median, 96.8% (92.5-98.5); monotherapy: median, 94.2% 
(90.4-98.2); p=0.04; Figure 3G] and CCR5+ pDC [dual therapy: median, 99.4% 
(98.3-100); monotherapy: median, 98.9% (95.9-100); p=0.02; Figure 3H] decreased 
after discontinuation of AZA or MMF.
Discussion
After solid organ transplantation, life-long use of immunosuppression is deemed  
necessary to prevent graft rejection. However, after HLA-identical LR renal trans-
plantation, the necessity for long-term use of immunosuppression is yet unknown. 
Considering the severe side-effects of immunosuppression, minimizing of immuno-
suppression in these transplant recipients might be beneficial. Theoretically, discon-
tinuation of immunosuppression in organ transplant recipients might result into an in-
creased donor-reactive T-cell response (12-14, 40). In this study, we showed that the 
number of donor, 3rd-party and TET-reactive IFN-γ producing cells or GrB producing 
cells did not increase after discontinuation of AZA or MMF. However, significantly in-
creased numbers of 3rd-party (p=0.003) and TET-reactive (p=0.008) IL-10 producing 
cells and a trend in more donor-reactive IL-10 producing cells (p=0.06) were found 
in HLA-identical LR renal transplant recipients. Additionally, no acute rejections oc-
curred (57). We suggest that the suppressive function of IL-10 was hindered by AZA 
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and MMF. AZA and MMF are anti-proliferative agents, and may also have an effect 
on cytokine production of lymphocytes (41-43).
IL-10 is an anti-inflammatory cytokine that have been associated with down regulation 
of the immune response (44). Several cells can secrete IL-10, such as B cells, mono-
cytes, DC, activated Th2 cells, and regulatory T cells (44). In our assay, we assume 
that monocytes and DC did not produce IL-10, because only non-adherent cells were 
transferred to the IL-10 Elispot plate. Upon activation by donor cells, both Th2 cells 
and regulatory T cells mainly produce IL-10 (45). In the present study, we observed 
higher numbers of donor, 3rd-party and TET reactive IL-10 producing cells after with-
drawal of AZA or MMF, while the number of IFN-γ and GrB producing cells remained 
stable. In agreement with our results, also other studies reported in HLA-identical LR 
renal transplant recipients the presence of donor-reactive IL-10 in HLA-identical LR 
renal transplant recipients that could reflect allograft tolerance (20, 46).
Renal transplant recipients who receive long-term immunosuppression are suscep-
tible for infections (6). Therefore, tapering of immunosuppression may reduce the 
chance for infections in those patients. In our study, we observed that more patients 
could respond to TET antigens in IL-10 Elispot assays after discontinuation of AZA 
and MMF, suggesting an improvement of reactivity directed to nominal antigens.
Mismatches in mHAgs between donor and recipient in combination with the pres-
ence of the correct HLA-restriction molecule may trigger T-cell reactivity (2). We 
analysed whether donor-reactive T-cell responses could be a result of known mHAg 
disparities between donor and recipient. In the present study, we again found no 
relation between mHAg mismatches and the number of donor-reactive cytokine 
producing cells, which is in agreement with our previous studies (9, 38). Further-
more, Heinold et al. showed after cadaveric and living-related renal transplantation 
that mHAgs mismatches between donor and recipients had no significant effect on 
death-censored 5-year graft survival (5).
DC could play an important role in determining the balance between transplant toler-
ance and immunity (47). It has been suggested that immunological monitoring of pe-
ripheral blood DC subset numbers and their ratio might identify transplant recipients 
in whom the immunosuppressive load can be safely tapered (23). It is assumed that 
blood DC in healthy individuals display an immature phenotype and induce T cell un-
responsiveness (48, 49). Immature DC are specialised in the capture of antigens, and 
transport them from peripheral tissues to secondary lymph nodes. Both donor and 
recipient DC could play a role in allograft rejection. Donor DC are transferred with 
the graft and can directly interact with recipient T-cells. Recipient DC in peripheral 
lymphoid organs can take up soluble donor antigens, infiltrate the graft, and present 
the antigens to T-cells (50). Little is known about circulating DC after withdrawal of 
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immunosuppression in kidney transplant recipients. Several studies reported interfer-
ence of immunosuppressive drugs with DC numbers, differentiation and maturation 
of DC (23, 29-31, 33). Our study showed that withdrawal of AZA or MMF had no 
effect on the absolute numbers of total DC, mDC and pDC and their ratio. Although, 
several problems related to monitoring DC phenotype and subsets in peripheral 
blood were reported, e.g. variability in technique, absence of reference standards, 
incomplete data regarding the influence of disease, medication, and patient-related 
factors on blood DC subsets (51). Additionally, some patients had mDC and pDC 
numbers that differed from the majority of patients. Nevertheless, interestingly, DC 
subsets shifted towards more mature DC phenotype after discontinuation of AZA 
or MMF, suggesting that AZA or MMF hinders the phenotypic maturation status of 
DC. In agreement with our data, it has been reported that MMF effects phenotypic 
DC maturation in both mice and in vitro models (52, 53). In MMF-treated DC a lower 
expression of CD40, CD80, CD86, CD83, and CD54 was observed, suggesting an 
inhibitory effect of MMF on DC maturation (52). Also a dose-dependent inhibition 
of MLR with AZA treated DC was reported (54). MMF is an inhibitor of the enzyme 
IMPDH, which is involved in the novo synthesis of guanosine nucleotides.  
The inhibitory effect of MMF on DC maturation could be caused by an imbalance 
between cyclic guanosine monophosphate and cyclic adenosine monophosphate 
(cAMP) in DC (55). Because both mDC and pDC circulate in peripheral blood (56), 
those data support our results that after discontinuation of AZA and MMF DC shifted 
towards a more mature phenotype. 
In conclusion, recipients of an HLA-identical LR renal transplant can be safely with-
drawn from AZA or MMF. The number of donor, 3rd-party and TET-reactive IL-10 
producing cells and maturation of DC was suppressed by AZA and MMF, suggesting 
that these immunosuppressive drugs may hinder down regulation of the general im-
mune reactivity, including allogeneic responses.
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Summary
In this thesis we first describe the incidence of two important long term side ef-
fects, namely calcineurine inhibitor (CNI) induced nephrotoxicity and malignancies 
in a Dutch heart- and renal transplant population respectively, and its influence on 
patient- and graft survival. Knowing the negative influence of immunosuppression on 
these complications, we then explored the possibilities to reduce the immunosup-
pressive load long after transplantation in our HLA-mismatched- and a HLA-identical 
renal transplant population. Furthermore, we studied the influence of reducing the 
immunosuppressive load on clinical and immunological parameters.
Chapter 1 is a general introduction to the background and the aim of this thesis 
and describes three well known (long-term) complications after solid organ trans-
plantation, i.e. cardiovascular disease, malignancy and CNI induced nephrotoxicity. 
The incidence and possible underlying mechanisms behind these complications after 
transplantation form the rationale to explore the possibilities of reducing the immuno-
suppressive load in a selected group of transplanted recipients.
In Chapter 2  we evaluated the development of end stage renal failure (ESRF) in 
heart transplant recipients after 21 years of heart transplantation in our clinic, and 
studied its influence on patient survival. Since an increased expression of the profi-
brotic transforming growth factor-ß (TGF-ß) is considered an important etiologic 
factor for CNI induced nephrotoxicity, we studied the impact of gene polymorphisms 
in codon 10 and 25 of the promoter region of TGF-ß on the risk of developing ESRF 
in these heart transplant recipients. In this observation period, the prevalence of 
ESRF after heart transplantation was high; almost one fifth of them had developed 
ESRF. Developing ESRF after heart transplantation results in very high mortality rates. 
We found a highly significant association between TGF- ß polymorphisms and CNI 
induced ESRF after heart transplantation. In the univariable Cox proportional haz-
ards analysis we found a highly significant association between Pro carriers of either 
codon 10 or 25 and developing ESRF. In the multivariable analysis, the influence of 
TGF-ß codon 10 gene polymorphism remained significant. The implications of our 
findings are that maintenance immunosuppressive
regimens of cardiac allograft recipients with a TGF-ß codon 10 and probably also 25 
gene polymorphism should no longer contain CNI, particularly because ESRF after 
heart transplantation results in an extremely high mortality rate.
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Apart from chronic CNI induced nephrotoxicity, we have studied another long term 
complication after solid organ transplantation, namely the development of cancer.
In all reports from different transplant centres all over the world, the incidence of 
almost all tumour types, skin and non-skin, is increased after solid organ transplanta-
tion compared with the general population. 
In Chapter 3 we described the incidence of cancer in the Dutch renal transplant 
population, transplanted between March 1966 and May 2008, and performed an 
analysis of patient and graft survival both from the day of transplantation and the 
diagnosis of cancer in recipients with invasive cancer in a nested case-controlled 
analysis. After 42 years of renal transplantation in the Netherlands, a significant pro-
portion of patients have developed cancer. This feared complication of organ trans-
plantation and treatment with immunosuppressive agents, comes at a significant 
later time point than other well known complications like, for example, infections and 
cardiovascular disease. Almost all patients who had developed cancer after trans-
plantation die due to this complication, with a very short median survival after the 
diagnosis of cancer.
Our study shows that even compared with other renal transplant recipients, matched 
for gender, age, time after transplantation, and year of transplantation, developing 
cancer after renal transplantation significantly affects life expectancy and carries a 
poor prognosis with a limited patient survival after the diagnosis.
Tapering of immunosuppressive medication is indicated to prevent these long term 
side effects. In 2000, van Besouw et al had already shown that stable renal trans-
plant recipients in our transplant population can be safely converted from calcineurin 
inhibitors to mycophenolate mofetil or azathioprine when their T-cell mediated donor 
reactivity, represented by donor-specific cytotoxic T-lymphocyte precursor frequen-
cies (CTLpf), are low. In sequel to these results we wondered whether a low donor 
specific CTLpf had also predictive value for further reducing the immunosuppressive 
load in human leucocyte antigen (HLA) mismatched renal transplant recipients treat-
ed with duo therapy immunosuppression, consisting of prednisolone combined with 
mycophenolate mofetil (MMF) or azathioprine (AZA). In chapter 4 we describe that 
gradually decrease the dose of AZA or MMF to 50% of the original dose at inclusion, 
is safe in these selected patients, without developing acute rejection or deterioration 
of renal function in the observation time. 
In chapter 5 the T-cell reactivity in these transplant patients after tapering of AZA or 
MMF is described. Tapering of the AZA or MMF dose resulted in a decrease of donor 
specific CTLpf in all patients with detectable donor specific CTLpf before reduction of 
their immunosuppression, while no effect on third-party reactive CTLpf were found. 
The T-cell reactivity to donor and third party cells as tested in mixed lymphocyte cul-
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ture and in IFN-γ Elispot was not affected either by tapering of immunosuppression. 
It is concluded that reduction of immunosuppression results in a specific decrease of 
donor-directed cytotoxic capacity of immunocompetent cells, while their proliferation 
and cytokine production capacity remained unchanged. These results suggest that 
immunosuppression hinders development of cytotoxic non-responsiveness.
Chapter 6 describes a study of CNI withdrawal in stable renal transplant recipients, 
with donor-specific cytotoxic hyporesponsiveness, who were originally treated with a 
triple immunosuppressive regimen, consisting of the CNIs tacrolimus or cyclosporine 
and AZA or MMF combined with prednisone. Four months after CNI withdrawal, 
the mRNA expression of Granzyme B (GrB) and Perforin as markers for cytotoxicity, 
Fas and FasL as markers for apoptosis, T-bet and GATA3 as Th1 and Th2 transcrip-
tion factors, and CD25 were significantly lower than during CNI treatment. After CNI 
discontinuation, donor-specific CTLpf decreased, while FOXP3 expression discrimi-
nated between detectable and non-detectable donor-specific cytolysis reactivity; 
FOXP3 transcript values were highest in absence of donor-specific cytotoxicity. It is 
discussed that, in kidney transplant patients indeed CNI interfere in the cascades 
leading to donor-specific hyporesponsiveness. In the absence of CNI, cytotoxic 
hyporesponsiveness was associated with high FOXP3 mRNA expression levels and 
suggests that donor-specific reactivity is the result of impaired regulation by FOXP3+ 
T-cells. After withdrawal of CNI, these regulatory mechanisms emerge.
Renal function, blood pressure and cholesterol were studied before and after CNI 
withdrawal at four months. In addition, these clinical parameters were analyzed in the 
CNI-free patients after further dosage reduction of AZA or MMF (two times 25%) at 
24 months. No significant changes in renal function, blood pressure or serum choles-
terol occurred after CNI withdrawal or dose reduction of AZA or MMF. These findings 
suggest that long-term treatment with CNI affects the mechanisms and cells in CNI-
treated patients in such a way that damage occurred, and as a result no beneficial 
effect of CNI withdrawal on this clinical parameters can be found.
Although an immune respons to a renal allograft is mainly driven by HLA differences 
between the donor and the recipient, HLA-identical living-related transplant recipi-
ents are usually treated following the same immunosuppressive protocols as for non-
identical pairs. Wondering whether this is correct, we conducted a study in stable 
HLA-identical living-related renal transplant recipients, in which the immunosuppres-
sive medication is reduced dramatically. The results of this study are described in 
chapter 7. In our HLA-identical study group, dramatically tapering of their immu-
nosuppressive medication to low-dose prednisolone monotherapy of 5 mg a day 
is well tolerated, without the occurrence of acute rejections during a follow up of 2 
years. The role of tapering immunosuppression and the risk of recurrence of original 
disease is discussed. After studying our HLA-identical living-related renal transplant 
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recipients under full dose immunosuppression and screening literature, we conclud-
ed that the prevalence of recurrence after tapering immunosuppressive medication in 
our study group was comparable with that described before in living-related HLA-
identical renal transplant recipients who used full-dose immunosuppression and is in 
line with earlier observation.
Furthermore we questioned whether discontinuation of AZA or MMF influenced T-cell 
reactivity, determined by Elispot assays, in these HLA-identical patients. This Elis-
pot assay determine the frequency of pro-inflammatory cytokine interferon-gamma 
(IFN-γ) and anti-inflammatory cytokine IL-10 that have been associated with allo-
graft rejection or suppression of the immune response, respectively. Granzyme B 
(GrB) was used as a marker of activity of cytotoxic T-lymphocytes. Additionally, we 
wondered whether discontinuation of immunosuppression affected the circulating 
dendritic cell (DC) subsets numbers and their maturation status determined by flow 
cytometry, knowing that dendritic cells could play an important role in determining 
the balance between transplant tolerance and immunity. The results of this study 
are described in chapter 8. We showed that the number of donor, third-party, and 
tetanus (TET)-reactive IFN-γ producing cells or GrB-producing cells did not increase 
after discontinuation of AZA or MMF. However, significantly increased numbers of 
third-party and TET-reactive IL-10 producing cells and a trend in more donor-reactive 
IL-10 producing cells were found in HLA-identical LR renal transplant recipients, sug-
gesting that the suppressive function of IL-10 was hindered by AZA and MMF. With-
drawal of AZA or MMF had no effect on the absolute numbers of total DC, myeloid 
DC and plasmacytoid DC or their ratio. Nevertheless, DC subsets shifted toward 
more mature DC phenotype after discontinuation of AZA or MMF, suggesting that 
AZA or MMF hinders the phenotypic maturation status of DC.
Conclusion and comment of recommendation
Long-term complications after transplantation are responsible for a decrease in 
patient and graft survival. This is illustrated by cardiovascular disease and malignan-
cies being the first and second most frequent causes of death after transplantation 
and “death with a functioning graft” is still the most common cause of graft loss after 
solid organ transplantation. With the current patient and graft survival, the prevalence 
of these long-term complications is increasing and thus we have to explore the pos-
sibilities to reduce these problems in our transplant population. Causal factors like 
gender, race, age at transplantation, environment and lifestyle play an important role, 
but, on top of this, these long term complications are adversely affected by the use 
of a variety immunosuppressive drugs. Because, there are huge differences between 
various transplant centers in different countries concerning composition of popula-
tion, acceptance criteria for recipients and donors and preferences for the immuno-
suppressive regimens, the complication rates are also different between individual 
centers and countries. So, results of different transplant centers as described in 
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literature can not be adopted indiscriminately by each individual transplant center or 
country and individual inventory of complications is indicated. In our retrospective 
analysis of the Dutch renal transplant population, we showed that cancer manifests 
rather late after transplantation and the prognosis is unfavorable. So, in prospective 
studies on this long term complication rate, patient follow-up time has to be at least 
ten years. The cause of the poor prognosis after being diagnosed with cancer after 
transplantation has to be annalysed in the near future. Although, long term studies on 
the complication rate of immunosuppression are difficult to perform and the results 
are influenced by many confounders these studies are indispensible. 
Although all transplant recipients are at risk, there is an individual variable suscep-
tibility for developing immunosuppression related complications, as we showed for 
TGF- ß gene polymorphism and CNI induced nephrotoxicity. On the other hand, we 
demonstrated that reduction of the immunosuppressive load after transplantation 
is possible in a selected group of patients and that long-term, high dose immuno-
suppression even seems to hinder the development of (partial) operational clinical 
tolerance.  In the future, we have to focus on how we can identify patients who are at 
risk for developing these immunosuppression related complications and in whom the 
immunosuppression can be reduced without developing acute or chronic rejection 
of the graft. New techniques, like microarrays, make it possible to simultaneously 
screen lots of genes or proteins to identify new potential biomarkers for tolerance 
or rejection after transplantation. Prospective clinical trails are needed to assess the 
clinical relevance and usefulness of these biomarkers, so that finally the ultimate goal 
of tailor made immunosuppression for the individual patient can be reached. 
Meanwhile, based on the studies described in this thesis, we can make the following 
recommendations: 
1. the immunosuppressive load after solid organ transplantation should be re-
duced, because it is associated with unwanted complications and hinders the  
development of tolerance
2. The use of CNI’s in patients with a TGF- ß gene polymorphism of codon 10 
leads to renal insufficiency and should therefore be avoided.
3. the use of triple immunosuppression in stable renal transplant recipients long  
after transplantation is not useful and can be safely reduced.
4. Immunological monitoring should be used in adapting immunosuppressive 
treatment
5. treatment of HLA-identical living-related kidney transplant patients with  
prednisone monotherapy 5 mg per day as maintenance immunosuppressive 
therapy is sufficient.
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Samenvatting en conclusies
In het eerste gedeelte van dit proefschrift beschrijven we de incidentie van twee 
belangrijke lange termijn complicaties na orgaantransplantatie, namelijk calcineurine 
geïnduceerde nefrotoxiciteit en maligniteiten, in respectievelijk een Nederlandse hart- 
en een niertransplantatiepopulatie en de invloed hiervan op patient- en graft survival. 
Aangezien het gebruik van immuunsuppressieve medicatie deze complicaties in de 
hand werkt, hebben we in het tweede gedeelte van dit proefschrift de mogelijkheden 
van afbouw van deze medicatie bestudeerd in een HLA gemismatchte en een HLA 
identieke niertransplantatiepopulatie. Daarbij hebben we de invloed van het afbouw-
en van immuunsuppressie bestudeerd op klinische en immunologische parameters. 
Hoofdstuk 1 is een algemene inleiding over de achtergrond en het doel van dit 
proefschrift. Drie bekende en belangrijke lange termijn complicaties na orgaantrans-
plantatie worden hierin beschreven, namelijk hart- en vaat ziekten, maligniteiten 
en calcineurine (CNI) geïnduceerde nefrotoxiciteit.  De incidentie en de mogelijke 
onderliggende mechanismen van deze complicaties na orgaantransplantaie vormen 
de onderliggende reden om de mogelijkheden tot het verminderen van immuunsup-
pressie bij een vooraf geselecteerde groep transplantatiepatiënten te onderzoeken.
In hoofdstuk 2, beschrijven we het voorkomen van eind stadium nierfalen (ESRF) 
na hart transplantatie en bestuderen we de invloed van nierfalen op de patiëntover-
leving. Aangezien een verhoogde expressie van de profibrotische transforming 
growth factor-β (TGF-β) als een belangrijke etiologische factor voor CNI geïndu-
ceerde nefrotoxiciteit wordt beschouwd, bestudeerden we daarnaast de impact van 
gen-polymorfismen in codon 10 en 25 van de promotor regio van TGF-β op het risico 
van het ontwikkelen van ESRF in deze harttransplantatie ontvangers. De prevalentie 
van ESRF na harttransplantatie was in bovengenoemde observatieperiode hoog. Bi-
jna een vijfde van de harttransplantatieontvangers had ESRF ontwikkeld. Het ontwik-
kelen van ESRF na harttransplantatie resulteert in zeer hoge mortaliteitcijfers. We 
vonden een sterk verband tussen TGF-β polymorfismen en CNI geïnduceerde ESRF 
na harttransplantatie. In de univariate Cox proportional hazards analyse vonden 
we een sterk significante relatie tussen Pro dragers van een codon 10 of 25 en het 
ontwikkelen van ESRF. In de multivariate analyse bleef alleen de relatie tussen 
TGF-β genpolymorfisme van codon 10 en het risico op ESRF na harttransplantatie 
sterk significant aanwezig. De implicaties van onze bevindingen zijn dat de lange ter-
mijn immunosuppressieve regimes van harttransplantaatontvangers met een TGF-β 
codon 10 en waarschijnlijk ook 25 gen polymorfisme geen calcineurine remmers 
moeten bevatten, vooral omdat ESRF na harttransplantatie resulteert in een zeer 
hoog sterftecijfer.
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Naast chronische CNI geïnduceerde nefrotoxiciteit, hebben we ook een andere lange 
termijn complicatie na een orgaantransplantatie onderzocht, namelijk de ontwik-
keling van kanker. In alle rapportages vanuit verschillende transplantatie centra in de 
wereld, wordt er een verhoogde incidentie van bijna alle soorten kanker beschreven 
na orgaantransplantatie. Dit geldt zowel voor huid- als solide tumoren. 
In hoofdstuk 3 beschrijven we de incidentie van kanker in de Nederlandse  
niertransplantatiepopulatie, getransplanteerd tussen maart 1966 en mei 2008, en 
hebben we een analyse uitgevoerd van de patiënt- en transplantaatoverleving. Deze 
survival analyse is zowel uitgevoerd vanaf de dag van transplantatie als vanaf het 
moment dat bij een transplantatie patiënt de diagnose maligniteit gesteld is. Een 
gematchte populatie patiënten uit dezelfde transplantatieperiode zonder maligniteit 
vormde de controle groep. Na 42 jaar niertransplantatie in Nederland is duidelijk 
dat een aanzienlijk deel van de patiënten kanker ontwikkelt. Deze gevreesde 
complicatie van orgaantransplantatie ontstaat op een aanzienlijk later tijdstip dan 
de andere bekende complicaties zoals infecties en hart- en vaatziekten. Bijna alle 
patiënten die kanker hebben ontwikkeld na transplantatie overlijden ten gevolge van 
deze complicatie, met een zeer korte mediane overleving na de diagnose. Onze 
studie toont aan dat het ontwikkelen van een maligniteit na niertransplantatie de 
levensverwachting van deze patienten significant beinvloedt. Deze bevinding kwam 
uit de vergelijking met een controle groep bestaande uit niertransplatatiepatienten 
zonder maligniteit gematcht voor geslacht, leeftijd, tijd na de transplantatie, en het 
jaar van transplantatie.
Gezien de relatie tussen het gebruik van immuunsuppressie en het ontwikkelen van 
deze lange termijn complicaties, lijkt afbouwen van immuunsuppressieve medica-
tie na transplantatie geindiceerd. In het jaar 2000 hebben van Besouw et al reeds 
aangetoond dat, in stabiele niertransplantatieontvangers uit onze transplantatie 
populatie, de calcineurine remmers veilig konden worden veranderd in mycofenolaat 
mofetil (MMF) of azathioprine (AZA) indien de T-cel gemedieerde donor reactiviteit, 
gemeten m.b.v. de donor-specifieke cytotoxische T-lymfocyt voorloper frequen-
tie (CTLpf), laag was. In vervolg op deze resultaten vroegen we ons af of een lage 
donor specifieke CTLpf ook een positief voorspellende waarde had voor een verdere 
verlaging van de immunosuppressieve belasting in stabiele, HLA-gemismatche nier-
transplantatiepatiënten die werden behandeld met dubbel therapie immunosuppres-
sie, bestaande uit prednisolon in combinatie met MMF of AZA. 
In hoofdstuk 4 beschrijven we dat een geleidelijke afbouw van de dosis MMF of 
AZA tot 50% van de oorspronkelijke dosis bij inclusie veilig is bij deze geselecteerde 
patientengroep zonder dat acute afstoting van het transplantaat of een verslechtering 
van nierfunctie optrad in de observatietijd. In hoofdstuk 5 wordt de T-cel reactiviteit 
bij deze patiënten na afbouwen van AZA of MMF beschreven. Geleidelijke verminder-
ing van de AZA of MMF dosis resulteerde in een daling van donor specifieke CTLpf 
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bij alle patiënten met detecteerbare donor specifieke CTLpf vóór de reductie van hun 
immunosuppressie, terwijl er geen effect op volledig HLA-gemismatchte derde partij 
reactieve CTLpf werd gevonden. De T-cel reactiviteit tegen cellen van de donor en 
de derde partij, zoals getest in de gemengde lymfocyt cultuur (MLR) en IFN-γ Elis-
pot, werd niet beïnvloed door de geleidelijke vermindering van immunosuppressie. 
Concluderend resulteerde de vermindering van immunosuppressie in een specifieke 
daling van de donor-gerichte cytotoxische capaciteit van immunocompetente cel-
len, terwijl hun proliferatie en cytokine productiecapaciteit ongewijzigd bleef. Deze 
resultaten suggereren dat immunosuppressie de ontwikkeling van cytotoxische non-
responsiviteit belemmert. 
Hoofdstuk 6 beschrijft een studie van CNI onttrekking in stabiele niertransplanta-
tiepatiënten, met een lage donor-specifieke, cytotoxische respons, die oorspronkelijk 
werden behandeld met een drievoudige immunosuppressieve therapie, bestaande 
uit CNI’s (cyclosporine of tacrolimus), AZA of MMF in combinatie met prednison. 
Vier maanden na CNI onttrekking, bleek de mRNA expressie van Granzym B (GRB) 
en Perforine als markers voor cytotoxiciteit, Fas en FasL als markers voor apoptose, 
T-bet en GATA3 als Th1 en Th2 transcriptiefactoren, en CD25 significant lager dan 
tijdens CNI behandeling. Na CNI onttrekking was de  donor-specifieke CTLpf af-
genomen, terwijl  de Foxp3 mRNA expressie discrimineerde tussen detecteerbaar 
en niet-detecteerbare donor-specifieke cytolytische reactiviteit. De Foxp3 mRNA 
transcriptie was het hoogst in afwezigheid van donor-specifieke cytotoxiciteit. In 
de discussie wordt besproken dat CNI behandeling bij patiënten met een nier-
transplantatie inderdaad interfereert in de cascades die leiden tot donor-specifieke 
hyporesponsieviteit. In afwezigheid van CNI was cytotoxische hyporesponsieviteit 
geassocieerd met een hoge Foxp3 mRNA expressie, wat suggereert dat donor-
specifieke reactiviteit het resultaat is van een verminderde suppressie door Foxp3 + 
regulatoire T-cellen. Na het ontrekken van CNI’s zie je deze regulatoire mechanismen 
weer ontstaan. Tevens werden, voor en 4 maanden na het onttrekken van CNI’s, de 
nierfunctie, bloeddruk en serum cholesterol waarden van deze patienten vervolgd. 
Deze klinische parameters werden nog verder vervolgd in de CNI vrije patient na ver-
dere dosisreductie van de AZA of MMF (tweemaal 25% dosisreductie) op tijdstip 24 
maanden. Er hebben zich geen significante veranderingen voorgedaan in nierfunctie, 
bloeddruk of serum cholesterol waarden na CNI onttrekking of verdere dosisreductie 
van AZA of MMF. Deze bevindingen suggereren dat langdurige behandeling met CNI 
definitieve schade veroorzaakt en dat als gevolg daarvan geen gunstig effect van CNI 
onttrekking op deze klinische parameters werd gevonden. 
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Hoewel een immuunreactie tegen een donornier voornamelijk bepaald wordt door 
HLA verschillen tussen de donor en de ontvanger, worden ontvangers van een 
HLA-identiek, living-related transplantaat meestal behandeld volgens dezelfde im-
munosuppressieve protocollen als voor niet-identieke koppels. Ons afvragende of dit 
correct is, hebben we een studie uitgevoerd met stabiele HLA-identieke, living-relat-
ed niertransplantatiepatiënten, waarbij de immunosuppressieve medicatie drastisch 
werd verminderd. De resultaten van deze studie zijn beschreven in hoofdstuk 7. In 
onze HLA-identieke studiegroep werd het drastisch afbouwen van de immuunsup-
pressie tot een lage dosis prednisolon monotherapie van 5 mg per dag goed wordt 
verdragen zonder dat er acute afstoting optrad gedurende een follow-up van 2 jaar. 
De rol van het afbouwen van immunosuppressie en het risico op terugkeer van de 
oorspronkelijke ziekte in het transplantaat wordt besproken. Na het bestuderen van 
onze HLA-identieke, living-related niertransplantatiepatiënten onder volledige dosis 
immunosuppressie en screening van de literatuur, concluderen we dat de prevalentie 
van terugkeer van oorspronkelijke ziekte in het niertransplantaat na afbouw van de 
immunosuppressieve medicatie in onze studie groep, vergelijkbaar is met die eerder 
beschreven in living-related, HLA-identieke niertransplantatieontvangers behandeld 
met full-dose immunosuppressie en vergelijkbaar is met eerdere publicaties in de 
literatuur. Ook hebben we onderzocht of het staken van AZA of MMF in deze HLA-
identieke patiënten de T-cel reactiviteit, gemeten middels een Elispot assay, beïnv-
loed. Deze Elispot assay bepaald de frequentie van het pro-inflammatoire cytokine 
interferon-gamma (IFN-β) en het anti-inflammatoire cytokine IL-10 die, respectievelijk, 
geassocieerd zijn met rejectie van het transplantaat of onderdrukking van de im-
muunrespons. Granzym B (GrB) werd gebruikt als een marker van de activiteit van 
cytotoxische T-lymfocyten. Daarnaast vroegen we ons af of het stoppen van AZA 
of MMF in deze patiënten het aantal circulerende dendritische cel (DC) subsets 
en hun maturatie status, bepaald middels flowcytometrie, beïnvloedt, wetende dat 
dendritische cellen een belangrijke rol kunnen spelen bij het bepalen van het even-
wicht tussen transplantatietolerantie en immuniteit. De resultaten van deze studie zijn 
beschreven in hoofdstuk 8. Hierin hebben we aangetoond dat het aantal donor-, 
derde-partij-, en tetanus (TET)-reactieve IFN-β producerende cellen of GrB producer-
ende cellen niet toenam na stopzetting van AZA of MMF. Er werd echter wel een sig-
nificante toename van het aantal derde partij- en TET-reactieve, IL-10 producerende 
cellen en een trend in meer donor-reactieve, IL-10 producerende cellen gevonden. 
Dit suggereert dat de onderdrukkende werking van IL-10 werd gehinderd door AZA 
en MMF. Onttrekking van AZA of MMF had geen effect op de absolute aantallen van 
de totale DC, myeloïde- en plasmacytoïde DC’s of hun verhouding. Niettemin, DC 
subsets verschoven in de richting van meer mature DC fenotype na het stoppen van 
AZA of MMF, wat suggereert dat AZA of MMF de fenotypische maturatie status van 
DC belemmert.
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Conclusie en aanbevelingen
Lange termijn complicaties na transplantatie zijn verantwoordelijk voor een vermin-
derde patiënt- en transplantaat overleving. Dit wordt geïllustreerd door het feit dat 
hart- en vaatziekten en kwaadaardige aandoeningen, respectievelijk de eerste en 
tweede meest voorkomende oorzaken van overlijden na de transplantatie zijn en 
dat ‘overlijden met een functionerend transplantaat “ nog steeds de meest voorko-
mende oorzaak van verlies van het transplantaat is na orgaantransplantatie. Met de 
huidige patiënt- en transplantaatoverleving, zal de prevalentie van deze complicaties 
in de toekomst verder stijgen. Daarom is het noodzakelijk om de mogelijkheden te 
onderzoeken om deze problemen in onze transplantatiepopulatie zoveel mogelijk 
te beperken. Oorzakelijke factoren, zoals geslacht, ras, leeftijd bij transplantatie, 
omgevingsfactoren en levensstijl spelen een belangrijke rol bij het ontwikkelen van 
deze complicaties, maar daarbij worden deze lange termijn complicaties ook in de 
hand gewerkt door het gebruik van een verscheidenheid aan immunosuppressieve 
geneesmiddelen. Doordat er enorme verschillen zijn tussen de diverse transplan-
tatie centra in de wereld met betrekking tot de samenstelling van de bevolking, de 
acceptatie criteria voor ontvangers en donoren, en de voorkeuren voor immuno-
suppressieve behandelingsstrategieën, zijn de complicatie percentages eveneens 
verschillend tussen de afzonderlijke centra en landen. Hierdoor kunnen de resultaten 
van verschillende transplantatie centra, zoals beschreven in de literatuur, niet klak-
keloos worden overgenomen door elk individueel transplantatiecentrum of land. Ieder 
centrum en/of land zal dus zijn eigen inventarisatie en evaluatie van de lange termijn 
complicaties na transplantatie moeten verrichten. In onze retrospectieve analyse van 
de Nederlandse niertransplantatiepopulatie, hebben we laten zien dat kanker zich vrij 
laat na transplantatie manifesteert en dat de prognose zeer ongunstig is. De follow-
up periode in toekomstige prospectieve studies naar deze lange termijn complicaties 
zal dan ook minstens tien jaar moeten zijn. Verder onderzoek naar de achterliggende 
oorzaak van de slechte prognose na de diagnose kanker na transplantatie moet in 
de nabije toekomst plaatsvinden. Hoewel, lange termijn studies naar de complicaties 
van immunosuppressie bemoeilijkt wordt door deze noodzakelijke lange follow-up tijd 
en de resultaten beïnvloed worden door tal van confounders, zijn deze studies zijn 
onmisbaar voor onze transplantatiepatiënten.
Inmiddels kunnen we op grond van wat er in de studies die er in dit proefschrift be-
schreven staan al tot de volgende aanbevelingen komen:
1. de immuunsuppressieve druk na orgaan transplantatie zou i.h.a. moeten 
worden verminderd aangezien het gepaard gaat met ongewenste complicaties 
en het ontstaan van tolerantie hindert.
2. het gebruik van CNI’s bij patienten met een TGF-β genpolymorfisme van codon 
10, leidt tot nierinsufficientie en zou dus moeten worden beperkt.
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3. drievoudige immuunsuppressie lang na nier transplantatie is niet zinvol en kan, 
in een stabiele patiëntengroep, veilig worden afgebouwd.
4. Immunologische monitoring zou moeten worden gebruikt bij het aanpassen 
van immunosuppressieve behandeling
5. HLA-identieke living-related niertransplantatiepatiënten hebben als onderhoud 
immuunsuppressive therapie voldoende aan 5 mg prednison monotherapie 
per dag.
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Abbreviations:
Arg =  arginine
AZA =  azathioprine
BCC =  basal cell carcinoma 
CNI =  calcineurin inhibitor
CMP =  cardiomyopathy
CMV =  cytomegalovirus
CsA =  cyclosporine A
CYP3A = Cytochrome P450, family 3, subfamily A
Dx = diagnosis
EBV = Epstein-Barr virus
ESKD = end stage kidney disease
ESRD = end stage renal disease
GFR = glomerular filtration rate
HLA = human leucocyte antigen
HTx = heart transplantation
IHD = ischemic heart disease
Leu = leucine
mHAgs = minor histocompatibility antigens
MMF = mycophenolate mofetil
NHL = non-Hodgkin’s lymphoma
NMSC = non-melanoma skin cancer
NOTR = Netherlands Organ Transplant Registry
NTS = Netherlands Transplant Society 
PCR = polymerase chain reaction
Pro = proline
PTLD = post-transplant lymphoproliferative disorders
PVD =  primary valvular disease
RR =  relative risk 
RTx =  renal transplantation 
SCC =  squamous cell carcinoma
SIR =  standardized incidence ratio
Tac =  tacrolimus
TET =  tetanus toxoid
TGF-ß1 =  transforming growth factor- ß1
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